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91. Diet-associated cardiovascular disease
The current society is shifting towards a nutritional pattern characterized by increased
consumption of energy-dense food that is high in fat and sugar content, contrasted by a
drop in total fiber intake (Vorster HH, 1999; Popkin BM, 1999). This dietary shift, in
combination with reduced physical activity due to urbanization and mechanization,is
generally considered to be the main cause for the increased global incidence of
overweight, obesity, and related comorbidities, such as cardiovascular diseases (CVDs)
and type 2 diabetes mellitus (T2DM) (Bechmann LP, 2012; Swinburn BA, 2004).
Despite advancements in prevention and treatment, CVDs remain the leading cause of
morbidity and mortality on a global scale. Cardiovascular disease is defined as any
disease that affects the cardiovascular system (heart and blood vessels). It predominantly
includes cardiac disease, vascular diseases of the brain and kidney, and peripheral
arterial disease (Bridget B. Kelly, 2010). According to the WHO (World Health
Organization), 17.3 million people died from CVD in 2008 and this number is estimated
to reach 23.6 million worldwide by 2030 (WHO-Global health risks, 2009). The majority
of CVDs are caused by risk factors that can be controlled, treated or modified, such as
diet, obesity, raised blood pressure, smoking, lack of physical activity and T2DM (WHO-
fact sheets, 2011). There are also CVD risk factors that cannot be controlled, such as
age, gender, ethnicity, and genetic background (WHO-fact sheets, 2011). Diet is one of
the keyplayers in the development of CVDs and can therefore be considered as one of the
most powerful controllable factors in battling the CVD pandemic. The classic “diet-
heart” hypothesis states that an imbalance between the adverse effects of dietary
saturated fatty acids (SFA) and cholesterol and the beneficial effects of polyunsaturated
fatty acid (PUFA) intake contributes significantly to CVD (de Lorgeril M, 1997; Kelly,
2003). Abnormal plasma lipid levels (dyslipidemia) have a strong association with the
risk of coronary artery disease, heart attack and coronary death (Sherpa LY, 2011; Sarwar
N, 2007; De Campos, 2006). In turn, abnormal lipid levels in the plasma are closely
correlated to what one consumes. A diet that is high in saturated fats is known to lead
to high levels of plasma triglycerides and cholesterol (Deji N, 2008; Kleemann R, 2010).
Therefore, reducing the intake of total saturated fat has been the main focus of national
dietary recommendations to reduce CVD risk (American Heart Association (AHA), 2000).
This chapter provides a brief general introduction on the adverse effects of unhealthy
diets on metabolic and cardiovascular function. Moreover, dietary and pharmacological
strategies that have been proposed previously to prevent these effects will be described.
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2. Diet-associated obesity and metabolic and vascular dysfunction
2.1. Obesity: Definition and Prevalence
Both obesity and overweight are characterized by the accumulation of excessive total
body fat and are classified by means of the body mass index (BMI), which represents the
total body mass divided by the square of the height. A BMI between 25 and 29.9 kg/m2, is
considered as overweight and a BMI above 30 kg/m2as obese (NIH-NHLBI, 1998). The
worldwide prevalence of obesity and overweight has increased tremendously during
the recent decades (Lagerros YT, 2013). According to the WHO, more than 1 billion
people are estimated to be overweight and more than 300 million are obese, making
obesity one of the greatest health threats today (WHO-fact sheets, 2011). Based on
recent analyses it has been predicted that in 2030 an estimated 2.16 billion adults will
be overweight and 1.12 billion will be obese worldwide (Popkin BM, 2012).
Obesity represents a major risk factor for CVD and numerous metabolic diseases,
including atherosclerosis, T2DM, dyslipidemia and hypertension (Wilson PW, 2002;
Seidell JC, 2005). It has deleterious effects on metabolic homeostasis, and negatively
affects major organ systems. For example, it promotes non-alcoholic steatohepatitis in
the liver and structural injury of the kidney through glomerulosclerosis (Abate, 2001;
Vischer and Seidell, 2001;Barton M, 2012).
2.2. Metabolic dysfunction
Obesity is a potential risk factor for metabolic and cardiovascular disease. Hypertrophy
of the adipocytes is the rapid response of adipose tissue after exposure to excess nutrients
(N. Halberg, 2008). The excessive adipose tissue that is formed is, in turn,associated
with low-grade inflammation, potentially leading to the pathophysiological conditions
preceding the development of T2DM and CVD. This link between obesity and inflammation
is evident from the finding that obesity is associated with increased levels of pro-
inflammatory cytokines (Hotamisligil, 1993). An increase in adipose tissue mass causes
production of pro-inflammatory cytokines such as Interleukin-6 (IL-6), Tumor Necrosis
Factor-alpha (TNF-α), monocyte chemo-attractant protein-1 (MCP-1), leptin and resistin,
while the production of the anti-inflammatory adipokine adiponectin, which is known
to exert beneficial effects on insulin sensitivity, inflammation and cardiovascular
function, is markedly reduced (Antuna-Puente B, 2008). Overfeeding is the starting signal
of inflammation in obesity and it affects all metabolic cells including adipocytes,
hepatocytes, and myocytes (Emanuela F, 2008). All of these metabolic cells respond to
the overfeeding insult by evoking an inflammatory response. Studies in animals have
shown that in lean and healthy animals, feeding results in a low-grade inflammatory
response, which resolves quickly. In contrast, in obese animals or under conditions of
overfeeding, the inflammatory response is more intense and resolution thereof is less
efficient (A. Aljada, 2004).
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2.3. Endothelial and vascular dysfunction
In recent decades the endothelium has gained significant interest in the etiology of CVD.
The endothelium forms the lining of the luminal side of blood vessels and functions as
a selective barrier that permits the transport of glucose, nutrients, metabolites and
hormones from blood to tissues and vice versa. Healthy endothelium plays a major role
in the maintenance of vascular tone and exerts anti-coagulatory and anti-inflammatory
functions (Pober JS, 2007). Reduced capacity of endothelium to maintain homeostasis
is called endothelial dysfunction (Esper RJ, 2006).
The endothelium acts as the “firstresponder” to stimuli such as nutrients, cytokines and
blood cells. Furthermore, it is involved in regulating insulin delivery to muscles and
adipose tissue and thereby plays a crucial role in insulin-mediated glucose
clearance(Barrett EJ, 2013). Impairment of vascular endothelial function precedes the
onset of many metabolic diseases, including atherosclerosis and T2DM, and thus
increases cardiovascular complications (Stirban A, 2010). Endothelial dysfunction is a
mutual denominator of both micro- and macro-vascular pathologies (Feletou &
Vanhoutte,  2006).
The microvasculature encompasses vessels less than 150 µm in diameter, including
arterioles, venules and capillaries (Levy BI, 2001). The macrovasculature consists of
vessels above 150 µm in diameter, including arteries and veins (Levy BI, 2001). Dietary
stress affects both small and large vessels even when there is no clear CVD outcome
(Czernichow S, 2010). Vascular (dys)function in both small and large vessels can be
assessed by means of biomarkers, which are biological factors that are directly or
indirectly involved in a series of events controlling normal or pathological state.
Endothelial activation is characterized by increased levels of various endothelial
markers, such as E-selectin, vascular cell adhesion molecule 1 (VCAM-1), intercellular
adhesion molecule 1 (ICAM-1), and von Willebrandfactor (vWF). In turn, this activation
allows recruitment of various inflammatory cells (Stehouwer CD, 1999).
Vascular dysfunction (microvascular and/or macrovascular)acts as intermediate steps
linking metabolic stress and CVD (Figure 1) (Czernichow S, 2010). To date, numerous
metabolic factors have been linked to the development of obesity and CVD. In particular,
dysregulation of lipid metabolism and development of low-grade systemic inflammation
have been extensively postulated as key predictors of CVD(Ballantyne C, 2005).
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Figure 1. Metabolic stress-associated diseases with vascular dysfunction. Diagram illustrating the
connection between consumption of high-fat and high-cholesterol diets, and CVD. Vascular dysfunction
acts as an intermediate step linking metabolic stress and obesity to CVD.
2.3.1 Macrovascular dysfunction – Atherosclerosis
Atherosclerosis, the most common underlying cause of many CVDs, is a chronic,
multistep, complex inflammatory syndrome characterized by the accumulation of fat,
macrophages and vascular smooth muscle cells (VSMCs) in the vessel wall, eventually
leading to narrowing or occlusion of the vessel lumen (Libby P, 2002). It affects the
larger and medium-sized arteries and is considered the primary cause of heart attacks
and stroke (Lusis AJ, 2000). The name “atherosclerosis” comes from the Greek words
athero (gruel or paste) and sclerosis (hardness).
The first hallmark of atherosclerosis is the formation of a fatty streak. Fatty streaks are
caused by accumulation of foam cells, i. e.,macrophages that have ingested modified
lipid particles, in the inner most layer (intima) of arterial wall beneath the endothelium.
Upon lesion development, more macrophages are recruited and activated, eventually
culminating in the formation of an atherosclerotic plaque (Stary HC, 1994). Extensive
animal studies on the course of atherogenesis have revealed that with persisting
consumption of high-fat and high-cholesterol diets, the first evident change is the
accumulation of the cholesterol/lipids in the arterial wall (Figure 2). Elevated levels of
modified LDL, in particular oxidized LDL, are the major cause of injury to vascular
endothelium, since native LDL particles will not escape the blood stream or diffuse
through the endothelial barrier (Lusis AJ, 2000). Following the activation of the
endothelium, adhesion molecules are expressedand recruit immune cells, in particular
monocytes and lymphocytes, to repair injury caused by lipid accumulation (Han J,
1997). Recruited monocytes transmigrate through the endothelium and reach the arterial
wall, where they differentiate into macrophages. These macrophages use specific
scavenger receptors to take up trapped LDL particles that have undergone progressive
Chapter 1
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oxidation and as a consequence form foam cells (Steinberg, 1997; Griendling KK, 1997).
Foam cells produce various chemokines that attract more macrophages to the site.
When foam cells eventually die, they deliver their lipid-filled contents to the necrotic
core of the atherosclerotic plaque. The ensuing fatty streaks, together with the
accumulation of proliferating VSMCs from the medial layer, form a fibrousplaque (Quinn
MT, 1987). The plaque continues to grow by the infiltration of new monocytes cells from
the blood, accompanied by cell proliferation, extracellular matrix production and the
accumulation of extracellular lipid (Lusis AJ, 2000)
Figure 2. Schematic representation of atherosclerotic plaque formation.Plaque formation involves a
series of events initiated from (1) modified/oxidized LDL particles escaped from blood stream to inner
wall of the artery;(2) Endothelial cell (EC) dysfunction and activation, leading to increased surface
expression of adhesion molecules on ECs, including ICAM-1 and VCAM-1;(3) attachment and infiltration
of lipid and inflammatory cells into the intima (4) Monocytes differentiate into macrophages, engulf
lipid to form foam cells, and release pro-inflammatory cytokines (e.g., MCP1, IL-6, IL-1β) to create an
inflammatory environment. (5) In early lesions, VSMCs proliferate/migrate and synthesize collagen
to form the fibrous cap that encloses the growing lipid core. (Adapted and edited from Wang J C, Bennett
M, Circulation Research 2012; 111:245-259).
2.3.2. Microvascular dysfunction, insulin resistance, and Type 2 diabetes
Consumption of energy-dense foods leads to an increased prevalence of obesity, which
is a major risk factor for developing insulin resistance (IR). IR is defined as the reduced
ability of cells to respond to the action of insulin. It impairs the uptake of glucose from
the bloodstream into tissues, especially into muscle and fat, the two major insulin-
sensitive tissues. Microvascular dysfunction is considered an intermediate step between
diet-induced obesity and insulin resistance (Figure 1) (De Boer MP, 2012; Houben AJ,
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2012). Under normal circumstances, insulin, secreted by the pancreatic β-cells, is
delivered into the capillaries and from there it crosses the endothelial barrier (Vincent,
2005) to bind to insulin receptors on different cell types, including skeletal myocytes
and adipocytes. Subsequently, thephosphoinositide-3 (PI-3) kinase pathway is activated,
which triggers intracellular pathways for the uptake of glucose by translocating GLUT-
4 from intracellular vesicles to the plasma membrane (Long and Zierath, 2008). In obese
humans, the diminished insulin-stimulated glucose uptake in muscle cells is associated
with reduced activation of PI-3 kinase and hence diminishesuptakeofglucose (Jonk AM,
2007) (Figure 3).
A necessary step preceding translocation of GLUT-4 is the perfusion of the
microvasculature withinthe skeletal muscle in order to deliver insulin and glucose to
the cells. One of the main reasons for the development of IR under obese conditions is
the increased production of free fatty acids (FFAs). Chronic elevation of FFAs due to high-
fat diet may contribute to increased adiposity and inappropriate fat accumulation in
various organs of the body, leading to insulin resistance (Liu Z, 2009; de Jongh RT, 2004).
Unlike in muscle or fat cells, insulin binding to its receptor on endothelial cells leads to
the production ofnitric oxide (NO) due to increased endothelial NO synthase (eNOS)
activity induced by PI3-kinase and protein kinase B (Akt) activation, and results in
vasodilatation. At the same time, insulin activates the MAP kinase pathway leading to
the production of the vasoconstrictive factor endothelin-1 (ET-1). Under normal
circumstances, the net result is NO production, which stimulates vasodilation and
trans-endothelial transport of insulin (Fig. 3) (Wang H, 2012). Studies in models of diet-
induced obesity have revealed that the development of obesity is associated with
impaired PI3-kinase signaling in endothelial cells through impaired insulin-mediated
phosphorylation of Akt and eNOS, whereas insulin-mediated ET-1 expression was
unchanged (Kubota T, 2011). Microvascular dysfunction induced by HFD is characterized
by endothelial defects that influence the balance between vasodilatation and
vasoconstriction. Thus, disturbances in endothelial insulin signaling play an important
role in the development of obesity-related insulin resistance. In addition, TNF-α produced
by adipose tissue, inhibits both insulin-mediated capillary recruitment and insulin-
mediated glucose uptake by skeletal muscle (Zhang L, 2003). Hence, microvascular
dysfunction is an intermediate step linking central obesity and insulin resistance.
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Figure3. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by the
skeletal muscle in obese subjects. In lean subjects, the insulin-mediated activation of Akt and eNOS is
induced optimally in endothelial cells after feeding, resulting in insulin-induced capillary recruitment
of insulin, increase in interstitial insulin concentrations, and increase in glucose uptake by the skeletal
muscle, by translocating GLUT-4 to cell surface. By contrast, since the insulin-mediated activation of
Akt and eNOS is inadequate in endothelial cells of obese subjects after feeding, the insulin-induced
capillary recruitment, increase or interstitial insulin concentrations, and increase in glucose uptake
by the skeletal muscle are impaired. In obesity, FFA and TNF-α inhibit insulin-mediated vasodilation
and induce vasoconstriction. (Part of it adapted and edited from Jonk AM, et al, 2007, Physiology,Aug;
22:252-60)
2.3.2.1 Renal dysfunction
It has been extensively reported that the development of T2DM is associated with
structural and functional changes in the kidney. These changes are characterized by a
decline in glomerular filtration rate and the occurrence of albuminuria, ultimately
leading to renal failure (Fu WJ, 2012). Microalbuminuria is considered a marker for
microvascular endothelial dysfunction. It reflects the transcapillary escape of albumin,
i.e.,the excessive leak thereof into the urine as a consequence of increased microvascular
permeability (Kubota T, 2011). Albuminuria is strongly associated with the risk for
cardiovascular disease (Gaede P, 2008). Thus, microvascular dysfunctionis the primary
cause for the development of both insulin resistance and kidney failure.
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In summary, continuous high-fat consumption leads to obesity, a state in which
severalcirculating adipose tissue-derived factors, including FFA and TNF-α are
increased.These adipokines are likely candidates to influence insulin signaling
pathways in endothelial cells, thereby causing both impaired insulin-mediated
vasodilatation (endothelial dysfunction) and impaired skeletalmuscle glucose uptake
(metabolic insulin resistance) (Figure. 3) (Jonk A.M, 2007). Hence, vascular dysfunction
caused by metabolic stress plays a central rolein linkingobesityand its associated CVD.
3. Dietary strategies to prevent metabolic and vascular (dys)function
As previously mentioned, obesity isthe number one risk factor for many cardiovascular
diseases and its prevalence has increased considerably over the past decades in Western
societies.The increased prevalence of obesity is primarily due to changes in eating
habits and a sedentary lifestyle (Flegal, 2010). There is generalconsensus that “prevention
is better thancure”, therefore,improving diet and lifestyle is the ideal strategy to prevent
obesity. However, when prevention fails, there are few alternatives to counteract the
metabolic stress and maintain balance.  Among these alternatives are changes in diet
composition and overall intake (calorie restriction), as well as drug interventions.
3.1. Dietary intake changes
To date there is abundant knowledge on what to eat and what not to eatin order to
reduce CVD. For example,numerous studies have shown that omega 3&6 fatty acids and
plant-derived steroids reduce cholesterol levels, thereby reducing the risk of CVD
(Jeppesen C, 2013). Furthermore, diets rich in whole grain cereals markedly lowered
rates of CHD (Coronary Heart Disease) (Truswell, 2002). Wholegrain cereals contain
vitamin E and dietary fiber that may contribute to a reduced risk of heart disease.
Similarly, fish and fish oil containing long chain n-3 PUFAs have been shown to
significantly reduce the risk of cardiovascular mortality (Calder PC, 2004).From
epidemiological studies it is evident that regular intake of plant-derived products is
inversely correlated with cardiovascular diseases (Hertog MG, 1993). In particular, the
intake of polyphenols, a subgroup of flavonoids commonly known as antioxidants, has
been linked to improved cardiovascular health (Scalbert A, 2005; Manach C, 2005; Arts
IC, 2005).Polyphenols exert their cardioprotective effects by improving endothelial
function (Corti R, 2009) Cocoa and chocolate are examples of rich sources of polyphenols.
Thus, changes in one or more food components or nutrient intake can make a marked
difference to CVD risk. However, such dietary strategies will always be more effective
when they are part of a general healthy life style.
3.2. Lifestyle changes –Calorie restriction
Prevention of a disease solely by adapting the intake of food components is difficult,
but following a healthy dietary lifestyle can contribute tocontrolling existing risk factors
for CVD (Weiss EP, 2006; Park SY, 2005; Varady KA, 2007). An effective intervention to
Chapter 1
17
improve health is a caloric restriction diet, which aims to reduce caloric intake to 15-
40% of the typical amount. This approach was found to reduce cardiovascular risk
factors and improve insulin sensitivity (Weiss EP, 2006; Park SY, 2005). Despite the
beneficial health effects of caloric restriction, most individuals find it difficult to comply
with such strict regimens because they have to restrict their food intake daily (Das SK,
2007). More recently, an alternative to the daily caloric restriction diet has been
proposed, consisting of an alternate day fasting regimen, and has shown promising
results in reducing CVD (Varady KA, 2007).Similarly, slight weight loss has been shown
to be sufficient to provide a clinically significant health benefit in terms of reducing risk
factors for CVD and diabetes (Wilson PW, 2002).
3.3. Drug interventions
Incorporating specific food components in the diet and following a healthy life style is
likely to have beneficial effects on blood lipid levels and systemic inflammation, the
latter being major risk factors for the initiation and progression of cardiovascular
disease (Ahluwalia N, 2012). In spite of a strict dietary therapy and regular physical
activity, some patients need further treatment to reduce elevated blood cholesterol
levels (AHA, 2000).
3.3.1. Statins
Increased cholesterol levels have been associated with cardiovascular diseases. An
important class of drugs that reduce plasma cholesterol levels are statins, also known
as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Kleemann,
2003). Statins are effective in lowering LDL cholesterol levels and have few immediate
short-term side effects. They function by interfering with the synthesis of cholesterol
through inhibition of the rate-limiting enzyme HMG-CoA reductase, which plays a key
role in cholesterol synthesis.
Besides hyperlipidemia, it is well known that inflammation is closely associated with
atherosclerosis and CVD outcomes. Therefore, suppression of inflammation using drug
interventions would be a possible alternative to reduce disease prevalence. Numerous
prospective epidemiological studies have clearly demonstrated that C-reactive protein
(CRP) levels independently predict future CVD (Gabay C, 1999; Libby P, 2002). The reasons
for the association between CRP and CVD are not fully understood. However, clinical
investigations have shown that adipose tissue in obese individuals release large amounts
of cytokines into the circulation, which accounts for a greater production of CRP by the
liver (Ridker PM, 2003; Bruno G, 2009). It is therefore of interest that statins can reduce
CRP levels and exert pleiotropic anti-inflammatory effects apart from their lipid-lowering
effects (Bikdeli B, 2011).
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3.3.2 Thiazolidinediones (TZDs)
Thiazolidinediones are aclass of drugs that increase the disposal of glucose in
peripheral tissues by sensitizing to insulin in animals and humans with insulin resistance
(Inzucchi, 1998). These drugs act as a ligand for a nuclear receptor, the peroxisomal
proliferator-activated receptor gamma (PPAR-γ) and enhance the action of insulin
(Lehmann, 1995).
Both statins and TZDs have been widely studied and proven to be beneficial in reducing
inflammation (Kleemann R, 2004). Strict blood glucose and cholesterol regulation using
TZDs and statins effectively reduce CRP levels and considerably decrease the risk of
developing T2D and CVD (Gierman LM, 2012; Szalai AJ, 2002).
Conclusion
In conclusion, elevated lipid levels and inflammation caused by dietary stress play a
pivotal role in the development of CVDs. Due to increased mortality rates, CVDs are
subject to huge investments by the biotechnology and pharmaceutical industries.
However, due to improved medication, lifestyle and diet changes, total CVD mortality
has significantly declined over the past few decades (Iso H, 2011; Sytkowski PA, 1990).
Furthermore, reduction in calorie intake reduces metabolic risk factors for CVD [Turk,
2009; Fontana, 2008]. Yet despite the undisputed beneficial health outcomes, people
find it difficult to follow caloric restriction diets because of the associated requirement
to restrict food intake on a daily basis.For this reason, it may be more feasiblein practice
to introduce a form of alternating dietary manipulation than daily dietary changes. In
this scenario, dietary changes could be instituted for limited time periods. Intuitively, it
seems likely that persons will find it easier to adapt to an alternating dietary regimen
than to a daily restriction of their food intake.
4. Outline of the thesis
The aim of the research described in this thesis was to investigate the effects of high-fat
and high-cholesterol diets on metabolic and micro- and macrovascular dysfunction
and to test whether alternative dietary strategies can be developed to prevent or diminish
the adverse effects of dietary stress on cardiovascular and metabolic parameters.In
Chapter 2 and Chapter 3, we hypothesized that an alternating dietary strategy, i.e.,
alternating low-fat/low-cholesterol (4 days) and high-fat/ high-cholesterol (3 days)
would be beneficial in terms of reducing CVD risk factors, when compared tocontinuous
consumption of a high-fat/ high-cholesterol diet. In ApoE3L mice, we investigated the
effects of two “alternate dietary regimens” and examined whether these were as beneficial
as compared to daily calorie restriction in terms of reduction of cardiovascular
complications. In Chapter 4, we hypothesized that dietary supplementation of chocolate
beneficially affects metabolic risk factors and disease endpoints in a setting of diet-
induced atherosclerosis. Bearing in mind that chocolate formulations differ and that
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cocoa content in particular varies greatly between chocolates, we compared two
chocolate preparations that differed in their polyphenol and fiber content. The effects
of chocolate supplementation on metabolic and cardiovascular parameters were studied
in ApoE3L mice fed a high-cholesterol atherogenic diet. In Chapter 5 we investigated
whether metabolic stress-induced inflammation caused by a high-fat diet can be
attenuated by anti-inflammatory drug interventions (statins and TZDs) and whether
these interventions lead to improved cardiovascular health. We used the human C
reactive protein (huCRP) transgenic mouse model to monitor the overall inflammatory
state during a high-fat diet challenge and studied whether suppression of high-fat diet-
induced inflammation protects huCRP transgenic mice from insulin resistance and early
diabetic nephropathy.
Similar to humans, mice fed a HFD develop hyperglycemia, hyperlipidemia, and obesity
over time and such mouse models are useful for studying the etiology and evolution of
diet-associated cardiovascular complications. However, to date, most studies have
focused on metabolic and cardiovascular changes after relatively short periods of high
fat diet feeding and there are limited data on the effects of long term high-fat dietfeeding.
In Chapter 6a pilot studyin C57Bl6j mice is presented, characterizing the effects of a
longterm high-fat diet (48 weeks) on metabolic, structural and functional renal
alterations in comparison to mice fed a regular diet. Finally, in Chapter 7, the work
described in this thesis is summarized and discussed in the context of our current
knowledge on diet induced metabolic and vascular dysfunction.
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Abstract
Background: Alternate day calorie restriction (CR) has been shown to be almost as
beneficial as daily CR. The question arises whether this concept is also applicable to
alternating dietary composition.
Objective: To seek evidence that alternating high cholesterol (HC) - cholesterol-free
(CON) Western diet can effectively diminish hepatic and renal inflammation and
cardiovascular risk factors as compared with daily HC-supplemented Western diet.
Design: Four groups of ApoE*3Leiden mice, a humanized model for atherosclerosis,
were subjected to different feeding treatments for 16 weeks. Mice were fed CON diet;
CON diet with 1% w/w cholesterol (HC); alternate (ALT) diet regimen of CON (4 days) and
HC (3 days); or CON diet supplemented with 0.43% (w/w) cholesterol (MC), with overall
dietary cholesterol intake equal to ALT. Plasma was analyzed for cardiovascular risk
factors, aorta for atherosclerotic lesion formation, and liver and kidney for inflammation.
Results: ALT diet but not MC was almost as effective as daily CON feeding in preventing
disease development. Compared to HC, the ALT group showed 62% lower hepatic nuclear
factor kappa B (NF-kB) activity (P,0.001), a reduction of the circulating inflammatory
markers E-selectin (220%; P,0.05), vascular cell adhesion molecule 1 (VCAM-1; 215%;
P,0.05) and Serum Amyloid A (SAA; 231%; P,0.05), smaller atherosclerotic lesion sizes
(251%; 46497610791 mm2 vs. 94664616470 mm2; P,0.05) and diminished renal
expression of specific inflammation and activation markers (VCAM-1, 227%; P,0.05;
monocyte chemotactic protein-1 (MCP-1); 237%; P,0.01).
Conclusion: Alternate HC-CON feeding reproduced most of the beneficial effects of
daily cholesterol-free diet, including strongly diminished hepatic, vascular and renal
activation and inflammation; also atherosclerosis was reduced by half as compared to
HC, albeit still higher compared to the CON group.
Introduction
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in
industrialized countries. A better understanding of modifiable risk factors for CVD is
critical in order to effectively prevent or retard this disease. Among the modifiable risk
factors are unhealthy diet and excessive calorie intake. It is well known that
improvements in dietary composition can strongly influence the risk of developing CVD
[Hu and Willett, 2002]. Similarly, calorie restriction reduces metabolic riskfactors for
CVD [Turk, 2009; Fontana, 2008]. However, compliance with these broad guidelines is
problematical and not acceptable to most people despite the undisputed beneficial
health outcomes. Therefore, novel approaches for dietary interventions should be
considered.
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It may be more feasible in practice to introduce a form of alternating dietary manipulation
than daily dietary changes. In this case dietary changes could be instituted for limited
time periods. Intuitively, it seems likely that persons will find it easier to adapt to this
than to restrict their intake every day. Recent findings suggest that alternate-day fasting
may indeed be a viable diet option to help obese individuals lose weight and decrease
CVD [Varady, 2009].  Here, we wish to seek evidence that alternate dietary composition
will also beneficially affect metabolic health. To this end, we evaluated the effect of
alternating high cholesterol (HC) diet and cholesterol-free control (CON) diet on liver
health and macro- and microvascular function in a humanized mouse model of CVD, the
ApoE3Leiden mouse [Zadelaar, 2007].
We previously showed that feeding ApoE3Leiden mice a Western diet supplemented
with HC (1% w/w), but not CON diet, induces CVD risk factors such as
hypercholesterolemia, systemic inflammation and endothelial dysfunction, which
precede atherosclerotic lesion formation [Kleemann, 2007]. Notably, the marked systemic
inflammatory responsewasshown to be related to liver inflammation. Here we wish to
explore whether in a similar experimental set-up an alternate HC diet (3 days) - Con diet
(4 days) could diminish hepatic inflammation and CVD risk factors and thereby decrease
atherosclerotic lesion formation as compared to continuous HC feeding. To evaluate
whether an alternate diet regimen may also be beneficial for the microvasculature, we
extended our analyses to the kidney. The alternate diet regimen was also compared to
feedingmice daily 0.43% w/w cholesterol (MC), whereby the overall cholesterol intake
of the MC group equals that of the alternate group. Our findings indicate that the principle
of alternate feeding regimens effectively diminishes metabolic and vascular risk factors
and improves the hepatic, renal, and vascular health status.
Methods
Animals
Sixty female ApoE3*Leiden mice (12-14 weeks old) were group housed (3-5 mice per
cage) with a 12 h light-dark cycle (7 a.m.-7 p.m. lights on). The mice had free access to
food and water and remained on maintenance chow (Sniff R/M diet V1530, Uden, The
Netherlands); composition specified in [Rein, 2006]) until the start of the study. At T=0,
the start of the study, the mice were divided into four groups matched for plasma
cholesterol and experimental diet treatment was started. The first group (control group;
“CON”) received an established [Kleemann, 2007] cholesterol-free Western type diet
(CON diet; rodent diet T, Hope Farms, Woerden, The Netherlands). The second group was
fed the same diet as CON but supplemented with a high dose (1.0% w/w) of cholesterol
(high cholesterol group; “HC”). The third group was subject to alternate diet feeding, i.e.
3 days feeding of HC diet followed by 4 days of cholesterol-free CON diet (alternating
cholesterol group; “ALT”). The fourth group was treated with the same diet as CON but
supplemented with 0.43% w/w of cholesterol (medium cholesterol group; “MC”) to achieve
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the same dietary cholesterol intake as with ALT. Body weight (individually) and food
intake (at cage level) were monitored over time and blood samples were taken by tail
incision after 4 h of fasting (9 a.m. – 1 p.m.) at T=0 and on day 24, 52, 80 and 108, i.e.
always at the end of a 3-days HC feeding period in the ALT group. To further analyze the
effect of alternate cholesterol feeding on predicted fluctuations of plasma cholesterol,
additional plasma was collected in the ALT group at T= 28, 56, 84 and 112 days (i.e. the
last day of the CON feeding periods) and at T=31, 59, 87, 112 days (i.e. the last day of the
HC feeding periods).
After sixteen weeks of experimental diet feeding, the mice were sacrificed by CO
2
 and
organs were isolated and weighed. Hearts and kidneys were fixed and embedded in
paraffin, livers were snap frozen in liquid N
2
 and stored at -80ºC until further use.
The experiment was approved by and is in compliance with the regulations set forward
by the Ethical Committee on Animal Care and Experimentation (Zeist, The Netherlands).
Plasma analyses
Total plasma cholesterol and triglyceride levels were measured using kits No. 11489437
and 11488872 (Roche Diagnostics, Almere, The Netherlands), respectively, and the
plasma levels of sVCAM-1 (R&D Systems), E-selectin (R&D Systems) and serum amyloid
A (SAA; Biosource) were determined by ELISA [Kleemann, 2010].
Liver inflammation
NF-kB activity in liver was determined as described [Kleemann, 2010] using TransAM
transcription factor assay kits no. 40097 (Active Motif Europe, Rixensart, Belgium).
Briefly, liver homogenates were prepared using the Nuclear Extract Kit (no. 40010,
Active Motif, Rixensart, Belgium). Equal amounts of protein (6 µg/well) of the liver
homogenates were used to determine the amount of active p65-NF-kB.
Free cholesterol and cholesterol ester in liver
To determine intrahepatic cholesterol concentrations, liver samples were homogenized.
Cholesteryl acetate (2 µg) was added to each sample as an internal standard. Lipids
were extracted according to the ‘Bligh and Dyer method’ and neutral lipids were separated
by high performance thin layer chromatography on silica-gel-60 pre-coated plates.
Quantification of the lipid amounts was performed by scanning the plates with a Hewlett
Packard Scanjet 4500c and by integrating the density areas with Tina version 2.09
software.
Atherosclerotic lesion analysis
Serial cross sections (5 µm-thick) were taken throughout the entire aortic root area for
histological analysis of atherosclerosis as described [Kooistra, 2006]. Briefly, paraffin-
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embedded aortic cross-sections were stained with hematoxylin-phloxine-saffron and
atherosclerotic lesion area was analyzed blindly in 4 cross-sections of each specimen
(at intervals of 50 µm). Cell-D software (Olympus Soft Imagine Solutions GmbH) was
used for morphometric computer-assisted quantification of lesion number, lesion area
and lesion severity according to the classification of the American Heart Association as
established [Verschuren, 2005]. MAC-3 (BD-Pharmigen, cat# 550292) antibody was used
to determine macrophage content. CON mice hardly developed atherosclerotic lesions
(0.1 ± 0.1 lesions per cross-section) and were therefore not included in further statistical
atherosclerosis analysis.
Renal RNA extraction and gene expression analysis
Total RNA was extracted from thirty 5-µm thin cryo-sections from kidney using RNeasy
Mini Plus Kit (Qiagen, Westburg, Leusden, The Netherlands) according to the
manufacturer’s instructions. Integrity of RNA was determined by Agarose gel
electrophoresis. RNA quantity (OD-260) and quality (OD-260 / OD-280) were determined
using a ND-1,000 UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE).
Total RNA was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen,
Breda, The Netherlands) and random hexamer primers (Promega, Leiden, The
Netherlands). To detect the expression of selected target genes Assays-On-Demand™
gene expression primer/probe sets (ABI Systems, Foster City, CA) were used. Endogenous
PPIA (assay ID Mm02342430_g1) was used as a housekeeping gene along with the
following probes: CD68 (assay IDMm00839636_g1), MCP-1 (assay IDMm00441242_m1),
VCAM-1 (assay IDMm00449197_m1), ICAM-1 (assay IDMm00516023_m1, P-selectin
(assay ID Mm00441295_m1), and E-selectin (assay IDMm00441278_m1). Real-time PCR
was performed in duplicate and the obtained threshold cycle (CT) values were averaged.





Renal light microscopy and immunohistochemistry
For lightmicroscopy, 3 µM paraffin sections were stained with Periodic acid-Schiff’s
(PAS). Immunohistochemical staining for macrophages and VCAM-1 was performed on
acetone-fixed 5 µm cryosections using an anti-rabbit peroxidase-based Envision®+
system (DakoCytomation, Carpinteria, CA, USA). In short, sections were incubated for 60
min with rat-anti-mouse CD68 (clone FA11, hybridoma supernatant), VCAM-1 (clone M/
K-2.7, hybridoma supernatant) or isotype control antibody (IgG2a, clone OX35,
hybridoma supernatant) followed by a 30 min incubation with 10 µg/ml unlabeled
rabbit-anti-rat secondary antibody (Vector Laboratories, Burlingame, CA, USA). After
detection of peroxidase activity with 3-amino-9-ethylcarbazole, sections were
counterstained with Mayer’s hematoxylin. Images were taken with a Leica microscope
using QwinV3 software, and the extent of macrophage infiltration was determined by
morphometry in a blinded manner using Leica Qwin V3 quips (Qwin V3 software, Leica
Chapter 2
33
Microsystems Imaging Solutions, Ltd., Cambridge, UK) and expressed as percentage of
positive area.
Statistical analysis
Data were analyzed with SPSS 17.0 for Windows. Changes over time were measure with
repeated measures ANOVA with factors treatment and time followed by least significant
difference (LSD) post-hoc analysis. Differences between groups at one specific time
point were analyzed with 1-way ANOVA followed by LSD post-hoc analysis. Data that
were not normally distributed were analyzed with a non-parametric Mann-Whitney U
test or a Kruskal-Wallis test followed by a Dunn’s test. P<0.05 was considered significant.
Results are shown as mean ± SEM.
Results
Alternate dietary regimen improves plasma lipids
Body weight and average food intake did not differ significantly between the groups
(Table 1). Starting baseline cholesterol levels at T=0 were comparable between the groups
(2.8 ± 0.1 mM). Feeding of a cholesterol-free Western type diet (CON group) resulted in
a moderate increase in plasma cholesterol averaging 7.0 ± 2.0 mM. A more pronounced
increase in plasma cholesterol was seen with high dose (1% w/w) cholesterol feeding
(HC group): after 24 days, plasma cholesterol levels had reached 17.3 ±0.6 mM, and
stabilized at this level for the remainder of the treatment period (average cholesterol
19.4 ± 0.7 mM). Plasma cholesterol in the ALT group fluctuated parallel to the alternate
HC diet-Con diet: after periods of HC diet, the plasma cholesterol levels were comparable
to those in the HC group, but levels dropped rapidly to on average 11.9 ± 0.9 mM after
periods of CON diet, pointing to a rapid adaptation to dietary cholesterol intake. Plasma
cholesterol levels in the medium dose (0.43% w/w) cholesterol (MC) group stabilized at
18.0 ± 0.8 mM, slightly lower than those in the HC group. Plasma triglycerides did not
differ between the groups and remained stable at 2.3 mM during the experimental period
(data not shown).
Alternate dietary regimen improves vascular and systemic inflammation
Plasma levels of the vascular inflammation marker E-selectin were on average 60.3 ±
1.6 ng/mL at T=0 (Figure 1B). Levels in the CON group slightly increased during the study,
reaching 78.2 ± 3.5 ng/mL at the end. HC feeding caused a more pronounced and significant
(P<0.05) increase in E-selectin with endpoint levels of 96.3 ± 6.7 ng/mL. Notably, alternate
diet feeding resulted in E-selectin levels comparable to those of the CON group (74.4 ±
2.4 ng/mL), and significantly lower than the E-selectin levels in the HC group (P<0.01) on
days 24, 80 and 108. The MC group showed E-selectin levels slightly, but significantly
higher than those in the ALT and CON groups, but lower than in the HC group. For example,
on day 24, E-selectin level was 78.5 ± 2.6 ng/mL in MC, which was significantly higher
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than the corresponding values in the ALT (70.3 ± 2.2 ng/mL; P<0.05) and CON (71.9 ± 2.1
ng/mL; P<0.05) groups.
Plasma levels of another vascular inflammation marker, VCAM-1, showed a similar
response to the differing feeding regimens as seen for E-selectin (Figure 1C). Levels in
the CON group increased from on average 1.38 ± 0.05 µg/mL at T=0 to 1.99 ± 0.06 µg/mL
at the end of the experimental period. HC diet feeding showed a significantly stronger
increase in VCAM-1 levels over time, reaching an average endpoint value of 2.41 ± 0.15
µg/mL. Similarly as seen with E-selectin, VCAM-1 levels of the ALT group did not
significantly differ from the CON group (endpoint value 2.04 ± 0.11 µg/mL; P =0.06
compared to HC), while the MC group showed VCAM-1 levels in between the CON/ALT
groups and the HC group (endpoint value for MC: 2.16 ± 0.07 µg/mL.
Figure 1D shows the effects of the different diets on the plasma levels of the systemic
inflammation marker, serum amyloid A (SAA). At T=0, average plasma SAA levels were
7.4 ± 2.5 µg/mL and remained at this level with the CON diet (endpoint value of 8.0 ± 4.5
µg/mL). Upon HC feeding, plasma SAA levels increased gradually, eventually reaching
12.7 ± 2.7 µg/mL (P<0.01). Again, the alternate diet did not enhance plasma levels (8.4 ±
2.6 µg/mL at the end of the study) and plasma SAA values in the ALT group were very
comparable to those in the CON group. Endpoint SAA levels in the MC group (9.9 ± 3.1 µg/
mL) were in between the CON/ALT groups and the HC group.
Figure 1. Effect of alternate diet regimen on plasma lipids and inflammation markers. Plasma parameters
over time for each treatment group. A) Plasma cholesterol over time, B) plasma E-selectin, C) plasma
VCAM-1, D) plasma serum amyloid A (SAA). Groups are abbreviated as: control mice fed a cholesterol-
free Western type diet (CON, n = 15); mice fed the same Western type diet but supplemented with high
dose (1% w/w) cholesterol (HC, n = 13); mice with alternate CON (4 days) and HC (3 days) diet regimen
(ALT, n = 13); mice fed Western type diet supplemented with a medium dose (0.43% w/w) cholesterol
(MC, n = 14). * P<0.05 compared to CON, # P<0.05 compared to ALT, and P<0.05 compared to MC. Values
are presented as means ± SEM.
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Alternate dietary regimen reduces liver inflammation
Since SAA is a liver-derived inflammation marker the expression of which is under
control of the inflammatory transcription factor NF-kB, we next compared hepatic NF-kB
activity between the groups using liver homogenates prepared at sacrifice. HC feeding
was associated with a marked 4-fold (P<0.05) increase in hepatic NF-kB activity
(Figure 2A) relative to CON. In contrast, alternating cholesterol feeding hardly affected
NF-kB activity and the ALT group displayed a comparable activity as the CON group. A
considerable 3-fold (P<0.05) elevation in NF-kB activity was seen with MC. Together, this
demonstrates that chronic dietary cholesterol exposure clearly is adverse to the liver
and that alternating cholesterol feeding is a suitable way to prevent such effects.
We next analyzed the hepatic concentration of free cholesterol (FC), which is a critical
determinant of liver inflammation [Li, 2005]. Indeed, FC concentrations were significantly
higher in the HC (14.7 ± 0.3µg/mg protein) and MC (14.0 ± 0.3 µg/mg protein) groups as
compared to the CON group (11.5 ± 0.4 µg/mg protein; P<0.001) or the ALT group (12.9 ±
0.3 µg/mg protein; P<0.001) (Figure 2B).
Figure 2. Effect of alternate diet regimen on NFkB activity and intrahepatic lipids. A)
Active p65-NFkB expression in liver homogenates relative to CON, B) Intrahepatic free
cholesterol concentrations. Control mice fed a cholesterol-free Western type diet (CON,
n=15); high dose (1% w/w) cholesterol diet (HC, n = 13); alternate CON (4 days) and HC (3
days) diet regimen (ALT, n = 13); medium dose (0.43% w/w) cholesterol diet (MC, n=14).
Values are presented as means ± SEM. * P<0.05, ** P<0.01, *** P<0.001.
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Similar differences between the groups were found for the concentration of hepatic
cholesterol ester (CE) (Table 1). Consistent with the plasma triglyceride data, hepatic
triglyceride concentrations were comparable between the groups (Table 1).
Table 1. Characteristics of the four treatment groups at the end of the study.Groups are abbreviated as:
control mice fed a cholesterol-free Western type diet (CON); mice fed the same Western type diet but
supplemented with high dose (1% w/ w) cholesterol (HC); mice with alternate CON (4 days) and HC (3
days) diet regimen (ALT); mice fed Western type diet supplemented with a medium dose (0.43% w/w)
cholesterol (MC). Data are expressed, as means ± SEM. Values in the same row with different superscript
letters are significantly different. P<0.05.
Alternate dietary regimen improves macrovascular function in aorta
Atherosclerosis was analyzed after 16 weeks of experimental diet treatment in the aortic
valve area of the heart (see Supplementary Figure 1 for representative photomicrographs).
HC feeding and MC feeding resulted in substantial atherosclerosis with total lesion
areas of 94664 ± 16470 ìm2 and 78670 ± 8877 µm2 per cross section, respectively (Figure
3A). The total lesion area of the ALT group (46497 ± 10791 µm2 per cross section) was
considerably smaller than that of the HC group (-51%; P<0.05) and the MC group (-41%;
P<0.05). The number of lesions in the ALT and MC groups did not significantly differ from
the HC group (on average 3.4 ± 0.3 lesions per cross section; data not shown). Notably,
the numbers of aortic segments free of lesions were significantly higher in the ALT group
(0.96 ± 0.30) than in HC (0.27 ± 0.06; P<0.05) and MC (0.11 ± 0.05; P<0.01) (Figure 3B).
Alternate dietary regimen reduces macrophage content of aortic lesions
While CON livers hardly showed MAC-3 immunoreactivity (IR; Figure 3C), HC treated
animals showed pronounced staining with a macrophage-positive area of 22753 ±
5555 ìm2. Alternate dietary regimen significantly reduced the macrophage-positive IR
(8442 ± 2115 µm2; P<0.05) relative to HC. MC treatment reduced the macrophage to a
lesser and insignificant extent (14341 ± 3124 µm2).
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Figure 3. Effect of alternate diet regimen on macrovascular atherosclerotic disease. A) Total
atherosclerotic lesion area per cross- section, B) Lesion-free aortic segments per cross section, C)
Macrophage immunostaining (MAC-3 immunoreactivity). Control mice fed a cholesterol-free Western
type diet (CON, n=14); high dose (1% w/w) cholesterol diet (HC, n = 12); alternate CON (4 days) and HC
(3 days) diet regimen (ALT, n = 12); medium dose (0.43% w/w) cholesterol diet (MC, n = 12). Values are
presented as means ±SEM.* P<0.05, ** P<0.01, *** P<0.001.
Together, the data indicate that alternate cholesterol feeding as compared to continuous
cholesterol feeding is beneficial for aortic (macrovascular) function.
To assess whether the microvasculature would also benefit from an alternate dietary
regimen, we next analyzed kidney integrity.
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Alternate dietary regimen reduces renal inflammation
Renal mRNA expression levels of various genes related to endothelial activation (VCAM-
1, ICAM-1, E-selectin, P-selectin) and inflammation (MCP-1, CD68) were significantly
upregulated with HC feeding compared to CON. Strikingly, in the ALT group, these effects
were either less pronounced (E-selectin, CD68) or even absent (VCAM-1, ICAM-1, P-
selectin, MCP-1) (Table 2). MC diet feeding also had a stimulating effect on VCAM-1,
ICAM-1 and E-selectin (moderate) but a strong upregulating effect (comparable to HC)
on P-selectin, MCP-1, CD68.
Table 2. Renal mRNA expression profiling. Renal mRNA expression of endothelial activation related
genes (VCAM-1, ICAM- 1, E-selectin, P-selectin) and inflammation related genes (MCP-1 and CD-68)
relative to expression of CON group. Groups are abbreviated as: control mice fed a cholesterol-free
Western type diet (CON); mice fed the same Western type diet but supplemented with high dose (1%
w/w) cholesterol (HC); mice with alternate CON (4 days) and HC (3 days) diet regimen (ALT); mice fed
Western type diet supplemented with a medium dose (0.43% w/w) cholesterol (MC). Data are expressed




Consistent with these gene expression findings, immunohistochemical analysis revealed
an increased VCAM-1 immunoreactivity (IR) in glomeruli of HC treated mice relative to
CON mice, which showed hardly any IR. Under ALT diet conditions, glomerular VCAM-1
expression was not stimulated and remained comparably low as in CON. By contrast,
chronic cholesterol exposure in the MC group was again associated with elevated VCAM-
IR (Figure 4).
Figure 4. Immunohistochemistry of VCAM-1 in the kidney. A) Expression and localization of VCAM-1 in
renal sections of each group. Insert shows a 2006 magnification of a representative glomerulus, which
indicated by arrow. Control mice fed a cholesterol-free Western type diet (CON); high dose (1% w/w)
cholesterol diet (HC); alternate CON (4 days) and HC (3 days) diet regimen (ALT); medium dose (0.43%
w/w) cholesterol diet (MC).
Compared to CON animals, mice fed HC or MC showed significantly increased numbers
of macrophages in glomeruli and tubulointerstitium (Figure 5A) as quantified by
morphometry (Figure 5B). Kidneys from ALT mice did not display any macrophage
accumulation and were indistinguishable from CON mice.
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Figure 5. Immunohistochemistry for macrophages (CD68) in the kidney. A) Expression
and localization of macrophages in renal sections. Inset shows a 2006magnification of
a representative glomerulus which indicated by arrow. B) Renal accumulation of
macrophages was quantified by morphometry. Data are expressed as a percentage of
positive area occupied by FA-11 stained macrophages. Control mice fed a cholesterol-
free Western type diet (CON, n = 15); high dose (1% w/w) cholesterol diet (HC, n = 13);
alternate CON (4 days) and HC (3 days) diet regimen (ALT, n = 13); medium dose (0.43% w/
w) cholesterol diet (MC, n = 14). Values are presented as means 6 SEM. ** P<0.01, ***
P<0.001.
To determine whether HC feeding would affect renal function, we measured urinary
albumin and creatinine levels in spot urine samples. In all groups, urinary albumin/
creatinine ratios were similar (data not shown) and within the normal range suggesting
that the experimental diets had not yet affected the filtration function of the kidneys and
that the present data reflect an early stage of renal disease. Consistent with this, analysis
of Periodic acid-Schiff (PAS) stained renal cross-sections by light microscopy showed
no overt renal abnormalities in all groups, except for a mild glomerular hypercellularity
in mice that had been exposed to cholesterol chronically (HC and MC) (Supplementary
Figure 3).
Discussion
In this study, we used a well-documented, humanized mouse model of atherosclerosis,
the ApoE3Leiden mouse, to provide evidence that alternating high cholesterol (HC) -
cholesterol-free (CON) diet can effectively diminish cardiovascular risk factors as
compared with daily HC diet. The alternating feeding regimen reproduced most of the
beneficial effects of daily cholesterol-free diet, including reduced atherosclerosis and
strongly diminished the occurrence of hepatic, vascular and renal activation and
inflammation. By demonstrating that the concept of dietary manipulation is not restricted
to caloric restriction, but is also applicable to alternating dietary composition, our
findings further underline the potential efficacy of the concept of alternate diet regimens.
The perception that alternate cholesterol-free feeding (this paper) and alternate-day
fasting [Varady, 2008; Varady, 2010] are almost as effective as daily cholesterol-free
diet or daily caloric restriction, respectively is of great societal importance. It may be
anticipated namely that alternating-diet regimens may allow better compliance than
would daily healthy diet regimens.
Although the efficacy of the alternate concept is intriguing, the exact molecular
mechanisms underlying its favorable effects remain to be established and are an
attractive area for further investigation. Some clues regarding the alternate HC diet
might come from a previous study that we performed on the effects of dietary cholesterol
on cardiovascular risk in ApoE3Leiden mice [Kleemann, 2007]. We showed that with
increasing dietary cholesterol intake, plasma cholesterol levels increase and the liver
switches from a resilient, adaptive state to an inflammatory, pro-atherosclerotic state,
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which is associated with an increase in endothelial dysfunction markers and early
atherosclerotic lesion formation. For example, liver-derived inflammation markers such
as serum amyloid A (SAA) and vascular activation markers such as soluble E-selectin,
VCAM, and von Willebrand factor increase rapidly (within days) after consumption of a
HC diet, and thus by far precede the onset of early aortic lesion formation. In the present
study, the effects of alternating HC-CON diet were close to daily CON diet and much more
favorable compared to daily 0.43% (w/w) cholesterol intake, despite an equal overall
dietary cholesterol intake for the two groups. The elevated hepatic free cholesterol and
NF-kB activity observed after feeding daily 1% or 0.43% dietary cholesterol (HC and MC),
was not seen in the alternate diet (ALT) or CON groups.
Similarly, we observed protective effects of ALT diet on the renal microvasculature.
Endothelial adhesion molecules, including E-selectin, P-selectin, VCAM-1 and ICAM-1
were significantly upregulated in the HC group and moderately expressed in the MC
group. In contrast, these diet-induced renal effects were markedly diminished in the ALT
group displaying similar levels of expression as CON. Moreover, enhanced expression
of MCP-1 in conjunction with significant renal macrophage infiltrates, particularly in
the glomeruli, was observed in the HC and MC groups but was absent in the ALT group.
These observations are in line with previous studies employing calorie restriction diets
showing significant reductions in glomerular VCAM expression [Wiggins, 2010], renal
monocyte/macrophage infiltration, mesangial expansion [Van Liew, 1992], and
development of proteinuria [Jiang, 2005].
Our results suggest that the daily dietary cholesterol intake of the HC and MC groups
overcharges both hepatic and renal resilience, which results in a metabolic overload.
This induces metabolic stress and inflammation [Hotamisligil, 2010] that equally affects
both the macro (atherosclerosis) and microvasculature (liver and kidney).  The ALT diet
apparently provides these organs (liver and kidney) with a certain degree of elasticity
which allows the mice to recover -during the cholesterol-free periods- from the
intermittent periods of HC feeding, and thus to cope with alternating cholesterol stress.
Together, our own findings as well as the still nascent literature suggest that the principle
of alternating dietary regimens can effectively modulate metabolic and functional risk
factors. This approach would be a potentially attractive strategy to be tested for
implementing more broadly in humans. If successful, it could provide a novel and more
acceptable strategy to protect against the adverse effects of an unhealthy diet typical
for the nutritional milieu, which modern humans have created for themselves and as
such could contribute to improve metabolic health. More work needs to be done to fully
establish the concept and to address some of the outstanding questions. It needs to be
ascertained whether the concept can also be extended to other alternating-diet regimens,
including alternating saturated/unsaturated fat, alternating high/low-fat or alternating
high/low-carbohydrate. An important issue also is whether the beneficial effects are
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Supporting Information chapter 2
Figure S1 Schematic illustration of feeding regimens.
Illustration of the feeding regimens during the experimental period. The red droplets
indicate blood sampling time points. Experimental groups include from top to bottom;
Control mice fed a cholesterol-free Western type diet (CON); high dose (1% w/w)
cholesterol diet (HC); alternate CON (4 days) and HC (3 days) diet regimen (ALT); medium
dose (0.43% w/w) cholesterol diet (MC).
Figure S2 Representative photomicrographs of aortic root. Photomicrographs after
histological staining with hematox- ylin-phloxine-saffron. Control mice fed a cholesterol-
free Western type diet (CON); high dose (1% w/w) cholesterol diet (HC); alternate CON (4
days) and HC (3 days) diet regimen (ALT); medium dose (0.43% w/w) cholesterol diet
(MC).
Figure S3 Representative photomicrographs of kidney morphology. Photomicrographs
after histological PAS staining. Control mice fed a cholesterol-free Western type diet
(CON); high dose (1% w/w) cholesterol diet (HC); alternate CON (4 days) and HC (3 days)
diet regimen (ALT); medium dose (0.43% w/w) cholesterol diet (MC).
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Abstract
Background: An Alternating high- cholesterol dietary regimen has proven to be beneficial
when compared to daily high- cholesterol feeding. In the current study we explored
whether the same strategy is applicable to a high- fat dietary regimen.
Objective: To investigate whether an alternating high- fat dietary regimen can effectively
diminish insulin resistance, hepatic and renal inflammation and renal dysfunction as
compared to a continuous high- fat diet.
Design: Four groups of male ApoE*3Leiden mice (n=15) were exposed to different diet
regimens for 20 weeks as follows: Group 1: low- fat diet (10 kcal% fat); Group 2:
intermediate- fat diet (25 kcal% fat); Group 3: high- fat diet (45 kcal% fat) and Group 4:
alternating- fat diet (10 kcal% fat for 4 days and 45 kcal% fat for 3 days in a week).
Results:  Compared to high fat diet feeding, the alternating and intermediate- fat diet
groups had reduced body weight gain and did not develop insulin resistance or
albuminuria. In addition, in the alternating and intermediate- fat diet groups, parameters
of tissue inflammation were markedly reduced compared to high fat diet fed mice.
Conclusion: Both alternating and intermediate- fat feeding were beneficial in terms of
reducing body weight gain, insulin resistance, hepatic and renal inflammation and
renal dysfunction. Thus beneficial effects of alternating feeding regimens on
cardiometabolic risk factors are not only applicable for cholesterol containing diets
but can be extended to diets high in fat content.
Introduction
In recent decades the prevalence of obesity and overweight has increased tremendously
worldwide. This is a major health issue because obesity and overweight are important
risk factors for cardiovascular disease (CVD), insulin resistance, and type 2 diabetes
mellitus (T2DM)[1, 2].
Obesity develops when an imbalance exists between calories consumed and calories
burned and is linked to increased consumption of energy dense foods high in fats and
sugars in combination with reduced physical activity [3, 4]. Strict dietary interventions
need to be implemented to reduce obesity and its related complications. An effective
dietary intervention to improve health is a caloric restriction diet, which aims to reduce
caloric intake to a level 15- 40% lower than is typical. This approach was found to
reduce cardiovascular risk factors and improve insulin sensitivity [5, 6]. More recently,
an alternative to the caloric restriction diet, an alternate day fasting regimen, also has
shown promising results [7].
Despite the beneficial health effects of caloric restriction, most individuals find it difficult
to comply with such strict regimens. Therefore, alternative forms of dietary interventions
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are desired that are easier to adapt to but have similar beneficial health effects. Recently,
we showed that alternating dietary composition could effectively modulate metabolic
and cardiovascular risk factors. In this study, we demonstrated that feeding
ApoE*3Leiden(E3L) mice with an alternating high-cholesterol (3 days/week) and a
cholesterol-free western type diet (4 days/week) for 16 weeks, strongly diminished
hepatic, vascular and renal activation and inflammation, and mimicked most of the
beneficial effects of a continuous cholesterol-free dietary regimen [8].
The above dietary cholesterol study provided evidence for the concept of alternating
dietary regimen as a strategy to diminish detrimental effects of an unhealthy diet. It is
unknown whether the same principle is applicable to dietary factors other than
cholesterol. To address this question, the current study was designed to test whether an
alternating diet strategy would also be beneficial for fat- containing diets wherein high
fat diet is alternated with low fat diet. Previously, it has been shown that feeding E3L
male mice on a western type high- fat diet leads to insulin resistance and inflammation
in both liver and adipose tissue [9, 10]. In the current study, we investigated whether an
alternating low- fat (4 days)/high- fat (3 days) dietary regimen was able to diminish the
adverse effects caused by a continuous high- fat diet in E3L mice.
Materials and Methods
Animals and Diets
Animal experiments were performed according to the criteria outlined in the “Guide for
the Care and Use of Laboratory Animals” published by the National Institutes of Health
(NIH) and were approved by the University of Groningen, ethical committee on animal
care and experimentation (DEC no: 6141 A). Male ApoE*3-Leiden transgenic (E3L) mice
(n = 60) were obtained from TNO-Metabolic Health Research, Gaubius Laboratory, Leiden,
The Netherlands. Mice (12–15 weeks old) were group housed (3–5 mice per cage) with a
12 h light-dark cycle and had access to water and diet ad libitum. Prior to their respective
fat diet treatments, all animals received a lard fat diet containing 10 kcal% from fat
(low- fat diet (LFD), (D11032101,Research Diets, NJ, USA).
Study design
A schematic representation of the study design including blood and urine collection is
depicted in Figure S1. Prior to the start of the experimental treatment period, mice were
subjected to an oral glucose tolerance test (OGTT) at t = -2 weeks. After a recovery period
of 2 weeks, animals were individually housed in metabolic cages and 24-hour urine was
collected. Animals were randomly divided into four groups of 15 animals eachand all
mice in different groups were treated similarly in terms of handling, and stress to
exposures. Technicians performing the analysis were blinded to treatment groups. Group
1 continued on the LFD until the end of the experiment. Group 2 received a lard fat diet
containing 25 kcal% from fat (Intermediate- fat (IFD), (D11032102,Research Diets, NJ,
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USA). Group 3 received a lard fat diet containing 45 kcal% from fat (High- fat diet (HFD),
(D11032103,Research Diets, NJ, USA). Group 4 was subjected to an alternating diet
regimen (Alternating- fat diet (AFD)) constituting of four days of LFD, followed by three
days of HFD in a week. The composition of the different diets used in this study is
provided in Table S1. The difference in dietary fat content was compensated with
carbohydrates while the other dietary components were similar in all diets.
Body weight (individually, every 2 weeks) and food intake (at cage level, every 8 weeks)
were monitored and blood samples were taken by orbital puncture under anesthesia
after 4 hours of fasting at t = 0 and weeks 4, 8, 12 and 16. At week 18, animals were
subjected to OGTT and monitored for glucose clearance from blood. At weeks 10 and 19,
animals were housed individually in metabolic cages to collect 24-hour urine. After
twenty weeks of the experimental diet feeding, mice were fasted for 4 hours and sacrificed
by Isofluorane/CO
2
 and organs were isolated and weighed. Adipose tissues, aortas,
livers (median lobe) and kidneys (left) were fixed and embedded in paraffin; livers
(sinister and caudate lobes) and kidneys (right) were snap frozen in liquid N
2
 and stored
at “80°C until further use. We considered week 16 as the end point for both body weight
and plasma analysis to avoid a possible influence of stress the mice may have experience
due to OGTT and 24 hour urine collection performed after 16 weeks.
Oral Glucose Tolerance Test
Glucose tolerance tests were performed after a 5h-fasting period. Mice were injected
with a bolus of glucose (2 g/kg body weight, 20% glucose in water) orally and blood
glucose levels were monitored for 120 minutes using a hand-held glucose analyzer
(LifeScan, Milpitas, CA, USA) at t = 0 min, 15 min, 30 min, 60 min, and 120 min after
glucose injection.
Analysis of Plasma Lipids
Total plasma cholesterol and triglyceride levels were measured after 4 hours of fasting;
using commercial kits (catalogue No. 11489437 and 11488872, respectively; Roche
Diagnostics, Almere, The Netherlands). The plasma levels of insulin (Alpco, Tilburg, The
Netherlands) were determined by ELISA according to the manufacturer’s instructions.
Renal and hepatic RNA extraction and gene expression analysis
Total RNA was extracted from thirty 5- µm thin cryo-sections from both kidney and liver
using RNeasy Mini plus Kit (Qiagen, Westburg, Leusden, The Netherlands) according to
the manufacturer’s instructions. Integrity of RNA was determined by Agarose gel
electrophoresis. RNA quantity (OD-260) and quality (OD-260/OD-280) were determined
using an ND-1,000 UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE).
Total RNA was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen,
Breda, The Netherlands) and random hexamer primers (Promega, Leiden, The
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Netherlands). To detect the expression of selected target genes Assays-On-Demand™
gene expression primer/probe sets (ABI Systems, Foster City, CA) were used. Endogenous
PPIA (assay ID Mm02342430_g1) and B-actin (assay Mm01205647_g1) were used as
housekeeping genes along with the following probes: CD68 (assay IDMm00839636_g1),
monocyte chemotactic protein-1 (MCP-1; assay IDMm00441242_m1), VCAM-1 (assay
IDMm00449197_m1), inter-cellular adhesion molecule 1 (ICAM-1, assay
IDMm00516023_m1), Endothelin-1 (assay IDMm00438656_m1), E-selectin (assay
IDMm00441278_m1), Desmin (assay Mm01205647_g1), Neutrophil gelatinase-
associated lipocalin (NGAL, assay ID Mm01324470_m1), Kidney Injury Molecule 1 (KIM-
1, assay IDMm00506686_m1), and PDGF-b (assay Mm00440678_m1). Real-time PCR
was performed in duplicate and the obtained threshold cycle (CT) values were averaged.
Relative mRNA levels were calculated as 2-∆CT, in which ∆CT is CT






For light microscopy, 5 µm epididymal fat tissue and 3 µm renal paraffin sections were
stained with Periodic acid-Schiff’s (PAS). In short, paraffin sections were deparaffinized
and re-hydrated in distilled water. Sections were placed in 0.5% periodic acid solution
for 5 minutes. After rinsing in distilled water, sections were incubated in Schiff’s reagent
(Sigma) for 15 minutes followed by rinsing in lukewarm water for 5 minutes. Sections
were counterstained with Mayer’s hematoxylin for 1 minute and washed in tap water.
Immunohistochemical staining for macrophages, E-selectin and VCAM-1 were performed
on acetone-fixed 5 µm cryosections using an anti-rabbit peroxidase-based Envision®+
system (DakoCytomation, Carpinteria, CA, USA). Briefly, sections were incubated for 60
min with 5 µg/ml rat-anti-mouse CD68 (clone FA11, serotech, Puchheim, Germany), 10
µg/ml rat-anti-mouse E-selectin (MES-1, kind gift from Dr.D.Brown, Celltech group (Slough,
UK)) and 10 µg/ml rat-anti-mouse VCAM-1 (Clone MK 2.7, American type Culture
Collection (Virginia, USA))followed by a 30 min incubation with 10 µg/ml unlabeled
rabbit-anti-rat secondary antibody (Vector Laboratories, Burlingame, CA, USA). After
detection of peroxidase activity with 3-amino-9-ethylcarbazole, sections were
counterstained with Mayer’s hematoxylin. Frozen sections were used for oil-red O
staining to evaluate accumulation of neutral lipids in the liver and kidney. Images were
taken with Aperio ScanScope XT (Aperio, Vista, CA, USA) using 200x magnification and
the extent of macrophage infiltration in the glomeruli and the diameter of epididymal
adipocytes were determined by morphometry in a blinded manner using aperio
imagescope IHC analysis algorithm (Aperio, Vista).
Kidney function measured by albumin/creatinine ratio
To assess renal function, the microalbumin and creatinine levels were measured in
mouse urine using commercially available kits. Mouse Albumin ELISA Quantitation set
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(Bethyl laboratories, Montgomery, Texas, USA) and creatinine clearance (Exocell,
Philadelphia, PA) according to the manufacturer’s instructions.
Statistical analysis
Data were analyzed with Graphpad prism (Graphpad software 5.0, San Diego CA, USA)
and SPSS 17.0 for Windows. Changes over time were evaluated with two-way repeated
measures ANOVA with factors treatment (between subjects) and time (within subjects)
followed by Bonferroni, post-hoc analysis. Differences between groups at one specific
time point were analyzed with 1-way ANOVA followed by LSD post-hoc analysis. P<0.05
was considered significant. Results are shown as means ± SEM, unless stated otherwise.
Results
Both alternating and intermediate- fat dietary regimens reduce body weight
gain and improve plasma lipids.
The average food intake expressed as kCal/24 hours did not differ significantly between
the groups (Figure 1a). Body weight at baseline (week 0) was 24.0± 0.2 g on average of all
groups together. Mice that consumed a HFD displayed a gradual increase in body weight
over the 16 week diet intervention period (19.0 ± 1.0 g weight gained at week 16). Compared
to HFD fed mice, the increase in body weight during the 16 week diet period was
significantly lower at all-time points in mice that consumed a LFD, IFD or AFD. (8.3± 0.7
g, 7.8± 0.6 g and 7.2± 0.7 g for LFD, IFD and AFD, respectively after 16 weeks) (Figure 1b).
Total plasma cholesterol at baseline (week 0) of all groups together was 3.93± 0.11 mM.
Mice that consumed a HFD showed a gradual increase in plasma cholesterol levels over
time. At week 16, plasma cholesterol levels in the HFD group (8.63± 0.67 mM) were
significantly higher when compared to the LFD (5.42± 0.29 mM), the IFD (5.35± 0.45 mM)
or the AFD (5.46± 0.27 mM) groups (Figure 1c).
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Figure 1. Effect of alternate high-fat dietary regimen on body weight, food intake and plasma cholesterol.
(a) Food intake, (b) body weight gain, and (c) plasma cholesterol. Groups are abbreviated as: Mice fed
low- fat diet (LFD, n=15); mice fed intermediate- fat diet (IFD, n=15); mice fed high- fat diet (HFD, n=15),
and mice fed 4 days LFD and 3 days HFD, alternating- fat diet (AFD, n=15). ***p<0.001, * p<0.05 compared




Both alternating and intermediate- fat dietary regimens decrease adipocyte
size and reduce leptin production.
Adipocyte size in the epididymal adipose tissue in the HFD group was significantly
increased when compared to the LFD, IFD and AFD groups (Figure 2a and 2b).At t= 0
plasma leptin levels were 2.5± 0.21 ng/ml on an average of all groups together. At 16
weeks, the HFD group showed a significant increase in plasma leptin levels (76.2± 5.9
ng/ml), when compared to the other three groups (LFD 14.7± 2.1 ng/ml, IFD 16.4± 3.6 ng/
ml and AFD 13.3± 2.8 ng/ml) (Figure 2c).
Figure 2. Effect of alternate high-fat dietary regimen on adipocyte size and plasma leptin production. (a)
Adipocyte morphology (200x), (b) quantification of the adipocyte size (n=6 animals/ group) and (c)
plasma leptin levels (week 16) (c). Groups are abbreviated as: Mice fed low- fat diet (LFD); mice fed
intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and mice fed 4 days LFD and 3 days HFD,
alternating- fat diet (AFD). *** p<0.001. Values are represented as means ± SEM.
Both alternating and intermediate- fat dietary regimensreduce fasting blood
glucose, plasma insulin, and glucose intolerance
54
To investigate whether the increase in body weight after high- fat diet consumption was
associated with systemic insulin resistance, we determined blood glucose (n=8/group)
and plasma insulin (n=15/group) levels and performed oral glucose tolerance tests
(n=8/group), two weeks before (week -2 baseline) the start of the dietary interventions
and two weeks prior to sacrifice (week 18). No significant differences in fasting blood
glucose (average 8.78± 0.44 mM) or plasma insulin (average 0.34± 0.02 mM) levels were
observed at baseline between the different groups. Plasma glucose levels after 18 weeks
in the HFD group (12.76± 0.90 mM) were significantly higher, when compared to the LFD
(10.19± 0.29 mM), IFD (7.98± 0.79 mM) and AFD (8.13± 1.02 mM) groups (Figure 3a).
Also, fasting plasma insulin levels in the HFD group (3.07± 0.52 ng/ml) were significantly
higher when compared to the LFD (0.91± 0.12 ng/m)l,IFD (0.91± 0.12 ng/ml) and AFD
(0.92± 0.13 ng/ml) groups (Figure 3b)
At baseline, all mice were able to clear a bolus of glucose within 120 min (Figure 3c,
dotted line). However, after 18 weeks, mice on a HFD showed glucose intolerance, whereas
mice that had consumed a LFD, IFD or AFD were still able to clear a glucose bolus in 120
min (Figure 3c). The area under curve (AUC) of the HFD group was significantly higher
compared to the other three groups (LFD, IFD, and AFD) (Figure 3d).
Figure 3. Effect of alternate high-fat dietary regimen on fasting plasma glucose, fasting plasma insulin, and
glucose intolerance after 18 weeks. (a) Fasting plasma glucose (n=8 animals/ group), (b) fasting plasma
insulin (n= 15 animals/ group), (c) glucose tolerance (n=8 animals/ group), and (d) Area under curve of
the glucose tolerance test. Groups are abbreviated as: Mice fed low- fat diet (LFD); mice fed
intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and mice fed 4 days LFD and 3 days HFD,
alternating- fat diet (AFD)). Lines with regular ticks indicate base line levels of the glucose clearance
from blood. * p<0.05, ** p<0.01, *** p<0.001. Values are represented as means ± SEM.
Both alternating and intermediate- fat dietary regimens reduce lipid accumulation and
expression of inflammatory markers in the liver.
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At sacrifice, livers were significantly heavier in the HFD group (1.75± 0.14 g), when
compared to the other three groups (LFD 1.32± 0.06 g, IFD 1.08± 0.04 g and AFD 1.15±
0.04 g) (Figure 4a). Histological analyses demonstrated marked differences in the
accumulation of lipid droplets in the liver among the four groups. In the HFD group fatty
livers were observed (hepatic steatosis) as evidenced by numerous lipid droplets in the
livers of these mice. Livers from mice of the LFD and IFD groups showed fewer lipid
droplets whereas in the AFD group only occasionally droplets were observed in the PAS
staining (Figure 4b). Consistent with these results, livers from mice of the HFD group
showed more extensive oil-red O (ORO) staining compared to the other three groups
(Figure 4c).
Figure 4. Effect of alternate high-fat dietary regimen on lipid accumulation after 20 weeks. (a) Liver weight,
(b) PAS staining of the liver, and (c) Oil Red O (ORO) staining in the liver (200x). Groups are abbreviated
as: Mice fed low- fat diet (LFD); mice fed intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and
mice fed 4 days LFD and 3 days HFD, alternating- fat diet (AFD). ** p<0.01, *** p<0.001. Values are
represented as means ± SEM.
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To investigate the effect of the diets on hepatic inflammation and endothelial activation,
we next analyzed mRNA expression levels of various markers (Table 1). Compared to the
LFD group, hepatic mRNA expression levels of endothelial activation markers VCAM-1,
ICAM-1, and endothelin-1 were significantly upregulated in livers of the HFD group in
conjunction with increased mRNA levels of the macrophage marker CD68. Compared to
continuous HFD feeding, the AFD group showed decreased expression levels of Endothelin-
1 and CD68 whereas in the IFD group no differences were observed in the expression of
VCAM-1 and CD68 (Table 1).
Table 1:Relative mRNA expression levels of proinflammatory genes.
Hepatic mRNA expression of endothelial activation (VCAM-1, ICAM-1 and endothelin-1)
and inflammation markers (CD68). Renal mRNA expression of endothelial activation
(VCAM-1, ICAM-1, E-selectin and Endothelin-1), inflammation (MCP-1 and CD68), and
fibrosis markers (Desmin and PDGF-b). Groups are abbreviated as:Mice fed low- fat diet
(LFD); mice fed intermediate- fat diet (IFD); mice fed high-fat diet (HFD) and mice fed 4
days LFD and 3 days HFD, alternating- fat diet (AFD). Superscripts without a common
letter differ significantly P<0.05.Values are represented as means ± SD.
Hepatic gene expression profiling
LFD (n=14) HFD (n=14) IFD (n=14) AFD (n=13)
VCAM-1 1.00± 0.48 a 2.06± 0.85 b 1.50± 1.20 ab 1.61± 0.55 ab
ICAM-1 1.00± 0.44 a 1.84± 0.62 b 1.28± 0.86 ac 1.50± 0.32 bc
Endothelin-1 1.00± 0.50 a 1.55± 0.49 b 1.29± 0.73 ab 1.10± 0.53 a
CD68 1.00± 0.52 a 1.35± 0.39b 1.03± 0.53 ab 0.91± 0.22 a
Renal gene expression profiling
LFD (n=14) HFD (n=14) IFD (n=14) AFD (n=13)
VCAM-1 1.00± 0.24 a 1.60± 0.88 b 1.34 ± 0.58 ab 1.43± 0.31 ab
ICAM-1 1.00± 0.27 a 1.46± 0.33 b 1.45± 0.58 ab 1.69± 0.53 b
E-selectin 1.00± 0.51 a 1.48± 0.58 ab 1.61± 1.06 ab 2.56± 1.75 b
Endothelin-1 1.00± 0.26 a 1.91± 1.01 b 0.82± 0.43 a 1.17± 0.28 a
CD68 1.00± 0.34 a 1.46± 0.76 b 1.34± 0.54 ab 0.84± 0.25 ac
MCP-1 1.00± 0.57 a 2.25± 2.12 b 1.07± 0.57 a 1.24± 0.56 a
PDGF-b 1.00± 0.20 a 1.43± 0.48 b 1.11± 0.30 a 1.31± 0.22 ab
Desmin 1.00± 0.22 a 1.45± 0.47 b 1.10± 0.42 a 1.22± 0.31 a
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Both alternating and intermediate- fat dietary regimens reduce renal
inflammation and improve renal function
At sacrifice, no significant differences were found in kidney weights between the groups
(data not shown). Light microscopic analysis revealed the development of mild renal
abnormalities in mice that had consumed a HFD chronically. This included mesangial
area expansion, thickening of Bowman’s capsule and basement membranes,
accumulation of lipid droplets in tubuli, and protein cast formation (Figure 5a).
Representative examples of Oil Red O staining of renal sections demonstrating abundant
positive staining in the kidneys of HFD treated mice compared to LFD, IFD or AFD treated
mice (Figure S2). At t= 0 albumin/creatinine levels were 292± 110 µg/mg on average for
all groups. In mice fed a chronic HFD, urinary albumin/creatinine levels gradually
increased reaching statistical significance at the end of the experimental period when
compared to the other groups; at 16 weeks: 494± 169 µg/mg in HFD, 340± 166 µg/mg in
LFD, 275± 119 µg/mg in IFD and 374± 178 µg/mg in AFD (Figure 5b).
Figure 5. Effect of alternate high-fat dietary regimen on renal morphology and function. (a) Morphology
of the kidney (PAS staining). Mesangial expansion (PAS positive area) (red arrow), thickening of the
Bowman ’s capsule (yellow arrow), thickening of tubular basement membrane (blue arrow),
vacuolarization (lipid accumulation) of the tubules (green arrow), and protein cast formation (orange
arrow) (inset- highlighted areas in HFD kidney) (200x) (b) Albumin: creatinine ratio (n= 13-15). Lines
with regular ticks indicate base line levels. (c) relative mRNA expression levels of NGAL, (d) relative
mRNA expression levels of KIM-1. Groups are abbreviated as: Mice fed low- fat diet (LFD); mice fed
intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and mice fed 4 days LFD and 3 days HFD,
alternating- fat diet (AFD). * p<0.05, ** p<0.01. Values represented as individual animal + mean.
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Renal mRNA expression levels of various markers for endothelial activation (VCAM-1,
ICAM-1, and Endothelin-1), inflammation (MCP-1 and CD68) and fibrosis (Desmin, and
PDGF-b) were significantly upregulated in the HFD group compared to the LFD group.
Interestingly, the AFD group had markedly decreased expression levels of Endothelin-1,
and MCP-1 when compared to the HFD group, and decreased levels of CD68 when
compared to the HFD and IFD groups (Table 1). Furthermore, we observed increased
mRNA expression levels of renal injury markers NGAL and KIM-1 in the HFD group
compared to other three groups (Figure 5c-d) although statistical significance was only
reached for NGAL when compared to the LFD group. Consistent with the mRNA expression
levels, immunohistochemical analysis revealed increased expression of VCAM-1,
especially in glomeruli, in the HFD group compared to other three groups (Figure S3a).
Immunohistochemistry of E-selectin showed restricted glomerular expression in all
four groups. However, both HFD and AFD groups showed slightly increased expression
compared to LFD and IFD groups (Figure S3b). Increased infiltration of FA11+ macrophages
was detected in the kidneys of HFD treated mice, which mainly accumulated in glomeruli
as quantified by morphometry (Figure 6b). Compared to the HFD group, mice fed an AFD
displayed substantially less glomerular macrophage accumulation, which was
comparable to the LFD and IFD groups (Figure 6a).
Figure 6. Effect of alternate high-fat dietary regimen on renal inflammation. (a) Immunohistochemistry
of macrophage infiltrates. Inset shows a representative glomerulus which is indicated by arrow mark
(200x), and (b) quantification of macrophage infiltrates in glomeruli (n=8 animals / group). Groups are
abbreviated as: Mice fed low- fat diet (LFD); mice fed intermediate- fat diet (IFD); mice fed high- fat diet
(HFD) and mice fed 4 days LFD and 3 days HFD, alternating- fat diet (AFD). * p<0.05, ** p<0.01. Values are




In the current study, we employed a humanized mouse model, the ApoE*3 Leiden (E3L)
male mouse, to determine whether an alternating dietary regimen of high and low fat
intake reduces metabolic and cardiovascular risk factors as compared to a continuous
high fat diet. We showed that by adapting to a diet with pulsed intake of high and low fat
diets (4 days low-fat diet and 3 days high- fat diet in a week) instead of a continuous
high- fat diet, fasting plasma glucose and insulin levels were reduced and insulin
sensitivity is improved. Furthermore, the alternating high- fat dietary regimen replicated
most of the beneficial effects instigated by daily consumption of a low- fat or intermediate-
fat diet including reducedbody weight gain and plasma cholesterol levels, improved
adipocyte physiology, reduced hepatic and renal inflammation and improved renal
function compared to continuous HFD.
Recently, we reported the beneficial effects of a similar dietary strategy with high
cholesterol containing diets (alternating high- cholesterol dietary regimen) on the
occurrence of atherosclerosis, hepatic and renal activation and inflammation [8]. This
study together with the results presented here and existing literature [7, 8]indicate that
the principle of an alternating dietary regimen (ADR) is a strong alternative for some of
the inflexible daily calorie restriction strategies available so far.
The exact molecular mechanisms underlying the beneficial effects of the alternating
dietary strategy are not yet fully understood. Based on literature and our own findings
we speculate that chronic and/ or long term exposure to excessive or inappropriate
nutrients places a heavy burden on adaptive responses that leads to a gradual loss of
metabolic homeostasis and a pattern of continuous, low-grade inflammatory and stress
responses, leading ultimately to metabolically driven pathologies [11, 12]. Recently, we
showed that feeding E3L male mice a high- fat diet chronically results in increased body
weight and plasma lipid content and induces insulin resistance in liver and adipose
tissue [9]. In addition, we showed that a high- fat diet leads to hepatic steatosis and
changes in adipose tissue physiology [9]. In the current study, we found that an alternating
high- fat dietary regimen, similar to low- fat and intermediate- fat diets, significantly
diminished these metabolic and functional risk factors as reflected by reduced body
weight gain, reduced total plasma cholesterol levels and reduced adipocyte size and
leptin production.
In the liver, accumulation of lipids, as observed in mice fed a HFD chronically, is a major
cause of oxidative stress and inflammation causing the liver to gain size and weight and
inducing hepatic steatosis [3]. Here, we found that mice exposed to an alternating high-
fat dietary regimen were protected against the increase in liver weight and the
development of hepatic steatosis when compared to daily HFD feeding. Also, AFD fed
mice displayed diminished liver inflammation as evidenced by significantly reduced
mRNA expression levels of various inflammatory markers although most of these markers
were still elevated when compared to the LFD group.
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The development of type 2 diabetes is well known to be associated with renal structural
and functional changes characterized by renal inflammation and glomerulosclerosis,
decline in glomerular filtration rate and the occurrence of proteinuria [13, 14]. Similar
to the liver, intrarenal accumulation of lipids has been proposed to play a major role in
causing diabetes associated nephropathy [10]. For example, intrarenal lipid
accumulation induces glomerular expression of MCP-1 and VCAM-1 [15, 16], which
contribute to glomerular macrophage accumulation [8, 17], eventually leading to
albuminuria [18]. In the current study, several parameters analyzed were consistent
with the development of (early) diabetic nephropathy in HFD fed mice including the
development of albuminuria and histological evidence for mesangial area expansion,
thickening of Bowman’s capsule and tubular basement membranes [19, 20], tubular
lipid accumulation and protein cast formation. These renal structural and functional
changes were associated with increased mRNA expression levels of markers for
endothelial activation (VCAM-1, ICAM-1, E-selectin and endothelin-1), inflammation
(MCP-1 and macrophage marker CD68), fibrosis (desmin and PDGF-b) [13, 19] and renal
injury markers (NGAL and KIM-1) [21], in the HFD group compared to the LFD group.
Recently, Fu WJ et al., reported an association between glomerular hyperfiltration,
elevated tubular injury markers and decline in kidney function in diabetic nephropathy
patients [21]. Interestingly, mice subjected to the AFD regimen displayed downregulated
expression levels of the endothelial dysfunction marker endothelin-1, the inflammatory
markers MCP-1 and CD68 and the fibrosis markers desmin when compared to HFD fed
mice.
In our experiments, a group of mice (IFD group) was included that received a 25%
(energy) fat diet daily to compare with the overall dietary fat intake of mice exposed to
the AFD regimen (4 days 10%, 3 days 45%). For many of the parameters analyzed, the
beneficial effects detected in the AFD group were also observed in the IFD group with
only minor differences in some parameters (e.g., CD68 mRNA expression in the liver).
These data are in line with recent studies by de Wit et al. who demonstrated that
increasing the dietary fat (palm oil) content from 10 kcal% to 20 kcal% did not significantly
increase body weight gain in C57Bl6 mice. These findings and the data presented here
suggest that the metabolic system is able to successfully cope with a certain amount of
dietary fat (buffering capacity) without considerably affecting metabolic homeostasis
and triggering inflammatory responses [22]. Overall, these results indicate that a
threshold exists for metabolic overload, beyond which the body cannot cope with
metabolic stress leading to the induction of various abnormalities. Our current study
indicates that the threshold under our experimental conditions must be in between the
25 and 45% lard fat diet.Thus, reduction in metabolic stress caused by a high fat diet
can be achieved either by giving the body time to recover from the metabolic overload
caused by high fat (alternating- fat diet strategy) or by lowering the daily fat intake
(Intermediate- fat diet strategy).
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In conclusion, this study indicates that the beneficial effects of alternating feeding
regimens on metabolic and functional risk factors for CVD are not only applicable for
cholesterol containing diets, as we have shown previously, but can be extended to high-
fat containing diets. These results provide further support for the concept of alternating
dietary regimens as a means to protect against the adverse effects of an unhealthy diet.
Additional studies are needed to examine whether the principles of alternating and
intermediate dietary regimens can also be implemented to improve existing metabolic
diseases. For example, it would be interesting to investigate whether an alternating or
intermediate diet can attenuate or reverse the negative effects caused by a long-term
HFD consumption in terms of body weight, glucose tolerance and hepatic steatosis.
Finally, the ultimate goal is to examine whether the concept of alternating feeding
regimens can be translated to humans.
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Supporting Information chapter 3
Figure S1. Schematic representation of the feeding regimens. Illustration of blood and urine collection.
The red droplets indicate blood sampling time points, green droplets indicate urine collection time
points and blue drop lets indicate blood sampling at the time of oral glucose tolerance test. Groups are
abbreviated as: Mice fed low- fat diet (LFD); mice fed intermediate- fat diet (IFD); mice fed high- fat diet
(HFD), and mice fed 4 days LFD and 3 days HFD, alternating- fat diet (AFD).
Figure S2. Effect of alternating high- fat dietary regimen on renal neutral lipid accumulation.
Oil Red O (ORO) staining in the kidney (200x). Groups are abbreviated as: Mice fed low-
fat diet (LFD); mice fed intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and mice
fed 4 days LFD and 3 days HFD, alternate- fat diet (AFD).
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Figure S3. Effect of alternate high- fat dietary regimen on expression of endothelial adhesion molecules
in kidney. (a) Expression and localization of VCAM-1 and (b) E-selectin (200x). Inset shows a 200x
magnification of a representative glomerulus which is indicated by the arrow. Groups are abbreviated
as: Mice fed low- fat diet (LFD); mice fed intermediate- fat diet (IFD); mice fed high- fat diet (HFD) and
mice fed 4 days LFD and 3 days HFD, alternate- fat diet (AFD
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Table S1. Composition of the different diets used in this study. Rodent diets with 10, 25, or 45
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Abstract
SCOPE: Dietary intake of cocoa and/or chocolate has been suggested to exhibit protective
cardiovascular effects although this is still controversial. The aim of this study was to
investigate the effects of chocolate supplementation on metabolic and cardiovascular
parameters.
METHODS AND RESULTS: Four groups of ApoE*3Leiden mice were exposed to the following
diet regimens. Group 1: cholesterol-free control diet (CO). Group 2: high-dose (1.0% w/
w) control-cholesterol (CC). Group 3: CC supplemented chocolate A (CCA) and Group 4:
CC supplemented chocolate B (CCB). Both chocolates differed in polyphenol and fiber
content,CCA had a relatively high-polyphenol and low-fiber content compared to CCB.
Mice fed a high-cholesterol diet showed increased plasma-cholesterol and developed
atherosclerosis. Both chocolate treatments, particularly CCA, further increased plasma-
cholesterol and increased atherosclerotic plaque formation. Moreover, compared to
mice fed a high-cholesterol diet, both chocolate treated groups displayed increased
liver injury. Mice on high-cholesterol diet had elevated plasma levels of sVCAM-1, sE-
selectin and SAA, which was further increased in the CCB group. Similar effects were
observed for renal inflammation markers.
CONCLUSION: The two chocolate preparations showed unfavorable, but different effects
on cardio-metabolic health in E3L mice, which dissimilarities may be related to
differences in chocolate composition. We conclude that discrepancies reported on the





Cardiovascular disease (CVD) represents the leading cause of mortality and morbidity
on a global scale and the costs associated with treatment of the growing number of CVD
patients are increasing correspondingly [1, 2].  To date, numerous metabolic factors
have been linked to the development of CVD and atherosclerosis but especially elevated
plasma lipids have been extensively postulated as key predictors [3, 4].
Most of these cardio-metabolic disorders can be averted if necessary precautions are
taken. Following a healthy dietary lifestyle can play a potent role in controlling the
existing and preventing the occurrence of impending chronic diseases [5-7]. From
epidemiological studies it is evident that regular intake of plant-derived products is
inversely correlated with cardiovascular diseases [8]. In particular, the intake of
polyphenols, a subgroup of flavonoids commonly known as antioxidants, has been
linked to improved cardiovascular health [9-11]. Cocoa and chocolate are a rich source
of polyphenols, which are known to exhibit protective cardiovascular effects by
improving endothelial function [12, 13].
However, there is conflicting data from human observational and intervention studies
with regards to the effect of chocolate on cardio-metabolic health. In some, but not all
cases beneficial effects were observed [14] and these are attributed to polyphenols that
are present in the diet [15]. Yet, it is difficult to make strong conclusions about the
beneficial effects of chocolate with human intervention studies because of discrepancies
in dietary habits and genetic and ethnic disparity. Similarly, studies in experimental
animal models suggest a potential beneficial effect of cacao on metabolic and vascular
health. A study in Kurosawa and Kusanagi-hypercholesterolemic rabbits showed that
cacao liquor polyphenols decreased atherosclerotic plaque formation and foam cell
formation upon cholesterol treatment [16]. Similarly, Loke et al., reported that specific
dietary polyphenols attenuate atherosclerosis by alleviating inflammation and
endothelial dysfunction in apolipoprotein E-knockout mice [17]. Also, Osakabe N and
Yasuda A have reported that cacao procyanidins reduced plasma cholesterol levels in
cholesterol fed rats [18, 19]. However, data on the beneficial effects of chocolate in their
natural context on metabolic and vascular health is still limited
To investigate the effects of chocolate supplementation in experimental models it is
essential that the model chosen mimic the human situation as closely as possible. The
APOE3*Leiden (E3L) is an established humanized mouse model to study CVD and
atherosclerosis because these mice develop hyperlipidemia and hypercholesterolemia
[20]. E3L mice have an attenuated clearance of apoB-containing lipoproteins and
consequently display a lipoprotein profile comparable to that of patients with
dysbetalipoproteinemia [20]. Unlike many other models of CVD, E3L mice respond
positively to lipid lowering drugs such as, statins [21, 22] and dietary compounds
including cafestol [23], fish oil [24], fenofibrates [25], and polyphenols [26].
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We previously showed that feeding E3L mice a diet supplemented with high-cholesterol
(1% w/w), induces atherosclerosis, systemic inflammation and inflammation in liver
and kidney [4]. We now used this model to investigate whether dietary supplementation
of chocolates beneficially affects metabolic risk factors and disease endpoints in a
setting of diet-induced atherosclerosis. To this end, we have compared these parameters
in mice fed a control, cholesterol rich (1% w/w) atherogenic diet with mice fed the same
diet supplemented with chocolate. Bearing in mind that the composition of commercially
available chocolates differs from one type of chocolate to another, in particular with
respect to the cocoa content [16], we used two different types of chocolates preparations
differing in polyphenol and fiber content. Chocolate A had a relatively high-polyphenol
and low-fiber content compared to chocolate B. In this study, our main goal was to
compare the effects of the two chocolates that differed in their composition and evaluate
their effects on metabolic and cardiovascular parameters in their natural context. The
bioavailability of phenolic compounds from cacao and chocolate is very complex and
several papers have dealt with this subject in recent years [27, 28]. Since the beneficial
effect of the cocoa component is attributed to the polyphenol (flavonoid) content [12,
13] and polyphenols have a variable bioavailability [29, 30], we have assessed plasma
polyphenol content, focusing on cocoa relevant polyphenols, using mass spectrometry.
2. Materials and Methods
Animals and Diets
Animal experiment was performed according to the criteria outlined in the “Guide for
the Care and Use of Laboratory Animals” published by the National Institutes of Health
(NIH) and were approved by an independent institutional ethical committee on animal
care and experimentation (DEC, Zeist, The Netherlands, DEC no: 2975). Female ApoE*3-
Leiden transgenic (E3L) mice (n= 76) were obtained from TNO-Metabolic Health Research,
Gaubius Laboratory, Leiden, The Netherlands. Mice (12–14 weeks old) were group housed
(3–5 mice per cage) with a 12 h light-dark cycle and had access to water and diet ad
libitum. Prior to their respective diet treatments, all animals remained on maintenance
chow (Sniff R/M diet V1530, Uden, The Netherlands).
Study design
At the start of the study, the mice were divided into four groups of 19 animals each,
matched for plasma cholesterol. Group 1 received a cholesterol free western type diet
(CO; rodent diet T, Hope Farms, Woerden, The Netherlands), provided as Supporting
Information Table 4. Group 2 was fed the same CO, supplemented with a high dose (1.0%
w/w) of cholesterol (CC; control cholesterol). Group 3 received a control cholesterol
diet supplemented with chocolate A (CCA; control cholesterol chocolate A; ACTICOA
chocolate; Article: CHD-Q65ACTICOA-000; Barry Callebaut, Belgium) and Group 4 received
a control cholesterol diet supplemented with chocolate B (CCB; control cholesterol
chocolate B; Article: CHD-L108018B01-000; Barry Callebaut, Belgium). The chocolate
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dosage used in this study is considered relevant for the human situation. The dosage in
mice was aligned according to a dosage applicable in humans, assuming an intake of
70 g chocolate/person/day (=0.875 g/kg/day). Because mice have a 10-fold higher
metabolic rate, i.e. 8.75 g/kg/day, the chocolate concentrations were in both cases
8.75% w/w of the diet.
Both CCA and CCB are high in polyphenol content but differ in the polyphenol
concentration and fiber content. For the CCA and CCB diets, cocoa butter was
compensated based on the chocolate content of CCA and CCB and thus comparable
between all the groups. All the major components present in both chocolates are same
and the total amount of fats in all the diets was kept constant and the diets did not
significantly differ in energy content. Both chocolate diets were prepared by
homogenously mixing liquid chocolate (chocolate melted in a water bath at 55°C for 3
hours), liquid cocoa butter (melted on a stove for approximately 1 hour), cholesterol-
free basic diet without cocoa butter, and cholesterol mixed with agar. Diets were stored
at -20°C until use. The gross energy content of the diets was determined by assessing 0.5
g of diet, in duplicate, in a bomb calorimeter (calorimeter C7000, IKA, Staufen, Germany).
The composition of chocolates used in this study is provided in supporting Information
Table 1.
Body weight (individually) and food intake (at cage level) were monitored every 4 weeks
and blood samples were taken by tail vein incision after 4 hours of fasting at t = 0 and
weeks 4, 8, 12, 16 and 20.  At sacrifice, spot urine was collected from individual animals.
After twenty weeks of the experimental diet feeding, mice were fasted for 4 hours and
sacrificed by CO2 and organs were isolated and weighed. Adipose tissues, aortas, livers
(median lobe) and kidneys (left) were formalin-fixed and embedded in paraffin; livers
(sinister and caudate lobes) and kidneys (right) were snap frozen in liquid N2 and
stored at “80°C until further use.
Analysis of Plasma Lipids, Lipoprotein profiles, and Plasma Inflammation
Markers
Total plasma cholesterol and triglyceride levels were measured after 4 hours of fasting,
using kits No. 11489437 and 11488872 (Roche Diagnostics, Almere, The Netherlands),
respectively. For lipoprotein profiles, pooled plasma was fractionated using an ÄKTA
FPLC system (Pharmacia, Roosendaal, The Netherlands)[31]. Plasma ALAT (alanine
transaminase) levels were determined spectrophotometrically using a Reflotron system
(Roche Diagnostics). The plasma levels of E-selectin, VCAM-1 (all R&D Systems Europe
Ltd., Abington, UK), insulin (Alpco, Tilburg, The Netherlands) and SAA (Biosource, Nivelles,
Belgium) at sacrifice were determined by ELISA as reported [4].
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Plasma polyphenol metabolites extraction and quantification
The extraction of the chocolate metabolites at sacrifice from serum (9 random serum
samples from the same dietary group pooled as three samples, n= 3) samples in the fed
state was carried out by using OASIS HLB µElution Plates 30 µm (Waters, Milford, USA)
following the method described by Serra et al (2011) with some modifications [32].
Firstly, the wells were sequentially conditioned by using 250 µl of methanol and 250 µl
of milliQ water:acetic acid (99.2:0.2, v/v). For the extraction of the metabolites, 600 µl of
a mixture of serum and phosphoric acid 4% containing catechol as internal standard
were loaded onto the plate. After that, the clean-up of the plates was sequentially done
with 200 µl of milliQ water and 200 µl of milliQ water:acetic acid (99.2:0.2, v/v) to
eliminate any interference that the sample might contain. Finally the elution of the
retained metabolites was done with 2x50 µl of acetone:miliQ water:acetic acid
(70:29.5:0.5, v/v/v).
Chocolate metabolites in the serum samples were quantified and identified by using an
HPLC-MS/MS system consisting of an Agilent HPLC 1200 Series (Agilent Technologies,
Palo Alto, U.S.A.). A Zorbax SB-Aq column (3.5µm, 150 mm x 2.1 mm i.d.) equipped with a
Pre-Column Zorbax SB-C18 (3.5 µm, 15mm x 2.1 mm i.d.) (Agilent Technologies, Palo
Alto, U.S.A.) were used to carry on the analysis. The HPLC was coupled to a triple
quadrupole mass spectrometer 6410 (Agilent Technologies, Palo Alto, U.S.A.). Data
acquisition was carried out using Masshunter software. Analyses of the serum
metabolites were carried out in electrospray (ESI) in the negative mode. The SRM (selected
reaction monitoring) transitions and the individual fragmentor voltage and collision
energy for each compound were evaluated by infusing 10 mg/l of each compound to
obtain the best instrumental conditions. Two transitions were acquired for each
compound, one for quantification and a second for confirmation purposes. The selected
SRM transitions and the instrumental parameters for each compound are shown in
Supporting Information Table S2a and Table S2b.
Qality parameters of the analytical method (linearity, recovery, accuracy, reproducibility,
LOD, and LOQ) were evaluated to confirm the reliability of the method. These parameters
were determined by spiking basal plasma with 14 commercially standards at known
concentrations. Results confirm the suitability of the method to study the phenolic
metabolite composition of plasma samples (data not shown).
Histological analysis of atherosclerosis
Serial cross sections (5 µm-thick) were taken throughout the entire aortic root area for
histological analysis of atherosclerosis. Briefly, paraffin-embedded aortic cross-sections
were stained with hematoxylin-phloxine-saffron and atherosclerotic lesion area was
analyzed blindly in 4 cross-sections of each specimen (at intervals of 50 µm). Cell-D
software (Olympus Soft Imagine Solutions GmbH) was used for morphometric computer-
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assisted quantification of lesion number, lesion area and lesion severity according to
the classification of the American Heart Association as established [21].
Renal RNA extraction and gene expression analysis
Total RNA was extracted from thirty 5- µm thin cryo-sections from kidney using RNeasy
Mini plus Kit (Qiagen, Westburg, Leusden, The Netherlands) according to the
manufacturer’s instructions. Integrity of RNA was determined by Agarose gel
electrophoresis. RNA quantity (OD-260) and quality (OD-260/OD-280) were determined
using an ND-1,000 UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE).
Total RNA was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen,
Breda, The Netherlands) and random hexamer primers (Promega, Leiden, The
Netherlands). To detect the expression of selected target genes Assays-On-Demand™
gene expression primer/probe sets (ABI Systems, Foster City, CA) were used. Endogenous
B-actin (assay Mm01205647_g1) was used as housekeeping gene along with the following
probes: CD68 (assay IDMm00839636_g1), monocyte chemotactic protein-1 (MCP-1; assay
IDMm00441242_m1), VCAM-1 (assay IDMm00449197_m1), and E-selectin (assay
IDMm00441278_m1). Real-time PCR was performed in duplicate and the obtained
threshold cycle (CT) values were averaged. Relative mRNA levels were calculated as 2-
∆CT, in which ∆CT is CT gene of interest – CT housekeeping gene.
Kidney function measured by albuminuria
To assess renal function, the microalbumin levels were measured in mouse urine using
a commercially available ELISA kit (Mouse Albumin ELISA Quantitation set, Bethyl
laboratories, Montgomery, Texas, USA) according to the manufacturer’s instructions.
Renal histology and Immunohistochemistry
For light microscopy, 3 µm renal paraffin sections were stained with Periodic acid-
Schiff’s (PAS) as reported [33]. Immunohistochemical staining for macrophages were
performed on acetone-fixed 5 µm cryosections using an anti-rabbit peroxidase-based
Envision®+ system (DakoCytomation, Carpinteria, CA, USA). Briefly, sections were
incubated for 60 min with 5 µg/ml rat-anti-mouse CD68 (clone FA11, serotech, Puchheim,
Germany), followed by a 30 min incubation with 10 µg/ml unlabeled rabbit-anti-rat
secondary antibody (Vector Laboratories, Burlingame, CA, USA). After detection of
peroxidase activity with 3-amino-9-ethylcarbazole, sections were counterstained with
Mayer’s hematoxylin.
Liver aconitase and citrate synthase activity
Liver was grinded in liquid nitrogen and further homogenized using a disposable pestle
in a microtube containing ice cooled 50 mM Tris-HCl, pH 7.4. All handling was done on
ice until measurement. Protein concentrations were measured using the DC Protein
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Assay (Bio-Rad, Veenendaal, The Netherlands) according to the manufacturer’s
instructions. Maximal aconitase activity was determined in 4-fold by monitoring the
formation of NADPH as described  [34]. Absorbance at 340 nm was measured during 1
hour at 37 °C in a microplate reader (BioTek, Winooski, USA) and the maximal aconitase
activity was calculated from the slope of the linear part of the curve. Citrate synthase
was measured in triplicate in a 96-wells plate using the Citrate Synthase assay kit
(Sigma-Aldrich, St. Louis, USA) according to the manufacturer’s instructions. Absorption
was measured for 1 hour at 25 °C in a  microplate reader (BioTek, Winooski, USA) and the
maximal citrate synthase activity was calculated from the slope of the linear part of the
curve.
Statistical analysis
Data were analyzed with Graphpad prism (Graphpad software 5.0, San Diego CA, USA)
and SPSS 17.0 for Windows. Differences between groups at one specific time point were
analyzed with One-way ANOVA followed by LSD post-hoc analysis.Changes over time
were statistically analyzed with One-way ANOVA (repeated measures for within subject
samples) and LSD post-hoc, unless stated otherwise. P<0.05 was considered significant.
Results are shown as means ± SEM, unless stated otherwise.
3. Results
Body weight, fat tissue masses and food intake
The average food intake expressed as kCal/24 hours did not differ significantly between
the groups (Figure 1a). Body weight at baseline (week 0) was 21.6± 1.15 g on average of
all groups together. All the groups showed a similar body weight gain throughout the
experimental period reaching 23.4± 2.2 g in CO group, 23.9± 1.1 g in CC group, 23.8± 1.6
g in CCA group and 23.5± 1.2 g in CCB group at the end of the experimental period of 20
weeks (Fig. 1b). Similarly, all the groups showed comparable visceral, gonadal and sub-
cutaneous fat tissues weights (data not shown).
Figure 1. Effect of chocolates on food intake and body weight gain. (a) Food intake and (b) Body weight
gain. Groups are abbreviated as:  Mice fed control diet without cholesterol (CO, n=19); mice fed control
diet (i.e with 1% cholesterol) (CC, n=19); mice fed control diet supplemented with choc A (CCA, n=19)
and mice fed control diet supplemented with choc B (CCB, n=19).
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Bioavailability of plasma polyphenol metabolites
The analysis of the phenolic compounds in the plasma of CO, CC, CCA and CCB treated
mice revealed the occurrence of phenolic acids such as 3,4-dihydroxyphenylacetic,
protocatechuic, hippuric, p-hydroxyphenylacetic, 3-hydroxyphenylacetic, vanillic, p-
coumaric, ferulic and benzoic acids. Besides, some flavonoids were also identified
such as catechin, epicatechin and procyanidin B2. Additionally, both chocolate (CCA
and CCB) treated groups revealed the presence of methyl and sulphate derivatives of
(epi)catechin including methyl catechin glucuronide, methyl epicatechin glucuronide,
epicatechin glucuronide, catechin sulphate, methyl epicatechin-O-sulphate, epicatechin
sulphate and 3-O-methyl epicatechin. These metabolites are specific of cocoa
consumption and therefore, were absent in both CO and CC treated groups. The SRM
transitions and the instrumental parameters for each plasma metabolite are listed in
Supporting Information Table 2. The individual concentrations of these polyphenols
and their corresponding metabolites are listed in the Supporting Information Table 3.
Comparing the concentrations of these plasma metabolites levels between the two
chocolates, values were almost ten times higher in CCA compared to CCB. The principal
difference in the phenolic fraction of the two chocolates is in the flavonoids (catechins,
epicathechins and procyanidins), which are considered to constitute the beneficial
compounds of cocao/chocolate [29, 30]. This result is consistent with the different
phenolic content of both chocolates used in the study.
Plasma lipids and atherosclerosis
Fasting plasma tri-glyceride levels did not significantly differ between the groups at all-
time points measured (Fig 2a). At the beginning of the study (t=0) total plasma cholesterol
levels were similar in all the groups (CC; 2.82± 0.39 mM, CCA; 2.80± 0.27 mM, CCB; 2.81±
0.39 mM, and CO; 2.66± 0.33 mM). Mice on CC, CCA and CCB displayed an increase in
plasma cholesterol levels over the 20-week diet intervention period. Compared to CO
fed mice (4.98± 0.63mM plasma cholesterol at week 20), the increase in plasma
cholesterol was significantly higher at all-time points measured in mice that consumed
a CC, CCA or CCB (16.56± 1.87 mM, 21.44± 2.74 mM and 20.03± 3.05 mM for CC, CCA and
CCB, respectively after 20 weeks, p<0.001) (Figure 2b). Lipoprotein profiles showed
significantly increased VLDL cholesterol levels in CCA and LDL cholesterol levels in CCB,
compared to CC at week 20 (Fig. 2c). The ratio between HDL cholesterol and LDL+VLDL
cholesterol of the (area under curve (AUC)) CC group was higher compared to both
chocolate groups (CCA and CCB) (Figure 2d). A refined morphological analysis of
atherosclerotic lesions displayed no signs of atherosclerotic lesions in CO group. Total
lesion areas of the other three groups (CC;102072± 61882 µm2, CCA; 163907± 61567 µm2
and CCB; 124372± 76837 µm2) were significantly higher compared to CO whereas lesion
area of the chocolate groups (CCA vs. CCB) did not differ significantly from each other.
Furthermore, CCA group showed a significantly increased lesion area compared to CC,
while CCB showed no difference compared to CC or CCA (Fig. 3a).
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Differences in the lesion severity in the aortic root were assessed according to the
classification of the American Heart Association. In the CCA group more severe lesions
of type IV-V (56%) were observed compared to the CC group (Fig. 3b).
Figure 2.Effect of chocolates on plasma lipids and plasma lipoprotein profiles. (a) Plasma cholesterol, (b)
Plasma tri-glycerides, (c) lipoprotein profiling at week 20 (n=1; plasma sample pooled from all the
animals of the same group as one sample) and (d) Ratio of HDL/LDL+VLDL cholesterol from lipoprotein
profile area under curve. Groups are abbreviated as:  Mice fed control diet without cholesterol (CO,
n=19); mice fed control diet (i.e with 1% cholesterol) (CC, n=19); mice fed control diet supplemented
with choc A (CCA, n=19) and mice fed control diet supplemented with choc B (CCB, n=19).  *** p<0.001
compared to Chol-free BD. Values are represented as means ± SEM.
Figure 3. Effect of chocolates on atherosclerosis at week 20. (a) Atherosclerotic plaque formation and (b)
atherosclerotic lesion severity after sacrifice. Groups are abbreviated as:  Mice fed control diet without
cholesterol (CO, n=19); mice fed control diet (i.e with 1% cholesterol) (CC, n=19); mice fed control diet
supplemented with choc A (CCA, n=19) and mice fed control diet supplemented with choc B (CCB, n=19).





Plasma levels of the vascular inflammatory markers E-selectin and VCAM-1 and of
liver-derived SAA in CC group were significantly increased compared to the CO group
after 20 weeks, p<0.01,p<0.001, p<0.001, respectively). CCB caused a more pronounced
and significant increase in all markers (E-selectin, VCAM-1 and SAA) measured, compared
to CC group, p<0.001, p<0.01, p<0.05, respectively.  Furthermore, CCB displayed
considerably higher E-selectin and VCAM-1 levels in plasma compared to CCA (p<0.05),
while CCA showed no difference compared to CC after 20 weeks (Fig 4).
Figure 4.Effect of chocolates on systemic inflammatory markers at week 20. (a) sVCAM-1 (b) sE-selectin
and (c) SAA. Groups are abbreviated as:  Mice fed control diet without cholesterol (CO, n=19); mice fed
control diet (i.e with 1% cholesterol) (CC, n=19); mice fed control diet supplemented with choc A (CCA,
n=19) and mice fed control diet supplemented with choc B (CCB, n=19). *p<0.05, **p<0.01 and ***
p<0.001. Values are represented as means ± SEM.
Liver function
At sacrifice, livers were significantly heavier in the CC group (1.40± 0.26 g), when compared
to the CO group (1.07± 0.14 g) (p<0.001). Treatment with both chocolates further increased
liver weights when compared to both CO and CC. However, when compared to CCB, liver
weights in the CCA group were significantly lower (1.62± 0.34 g vs 1.89± 0.25 g, p<0.05,
Fig 5a). Similarly, in the CC group a significant increase in alanine transaminase (ALAT)
levels in plasma when compared to CO was observed. Both chocolate treatments further
increased plasma ALAT levels compared to both CO and CC which was most pronounced
in the CCB group (Fig 5b).
Mitochondrial metabolic function in the liver was measured by determining citrate
synthase and aconitase activities. All the three cholesterol treated groups (CC, CCA and
CCB) displayed a decreased citrate synthase and aconitase activity (normalized to total
protein) compared to CO (p<0.01, P<0.001, P<0.001, respectively) (Fig 5c and 5d). No
change was observed in the aconitase activity /citrate synthase activity ratio between
any of the groups (Fig 5e).
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Figure 5.Effect of chocolates on liver function and mitochondrial function in the liver at week 20. (a) Liver
weight (b) ALAT levels in the plasma (n=1; plasma sample pooled from all the animals of the same group
as one sample) (c) liver aconitase activity  (d) Liver citrate synthase activity and (e) Liver aconitase/
citrate synthase activity. Groups are abbreviated as:  Mice fed control diet without cholesterol (CO,
n=19); mice fed control diet (i.e with 1% cholesterol) (CC, n=19); mice fed control diet supplemented
with choc A (CCA, n=19) and mice fed control diet supplemented with choc B (CCB, n=19). *p<0.05,
**p<0.01 and *** p<0.001. Values are represented as means ± SEM.
Renal inflammation, structure and function
Renal mRNA expression levels of endothelial activation (VCAM-1 and E-selectin) and
inflammation (MCP-1, CD68) markers were upregulated with CCB feeding when compared
to both CO and CC. Mice fed the CCA diet displayed increased expression of renal
inflammatory genes (MCP-1 and CD68) when compared to CO but not when compared to
CC. However, CCA showed less increase in expression of VCAM-1, E-selectin and CD68
when compared to CCB (Fig 6)
Figure 6. Effect of chocolates on renal mRNA expression levels of endothelial activation and inflammation
at week 20. (a) VCAM-1, (b) E-selectin, (c) MCP-1 and (d) CD-68. Groups are abbreviated as:  Mice fed
control diet without cholesterol (CO, n=19); mice fed control diet (i.e with 1% cholesterol) (CC, n=19);
mice fed control diet supplemented with choc A (CCA, n=19) and mice fed control diet supplemented
with choc B (CCB, n=19). *p<0.05, and *** p<0.001. Values are represented as means ± SEM.
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Kidney weight and urinary albumin levels were similar in all groups (Supporting
Information Figure 1a and 1b). Consistent with this, analysis of Periodic acid-Schiff
(PAS) stained renal sections showed no overt renal abnormalities in all groups (Supporting
Information Figure 1c).
4. Discussion
In recent decades, an increasing number of experimental and observational studies,
both in humans and animals, have suggested potential beneficial effects of chocolate
on cardiovascular and metabolic parameters [12, 35, 36].  In the current study, we
employed a humanized CVD prone mouse model, the ApoE*3 Leiden (E3L), to determine
whether chocolate supplementation is able to improve cardio-metabolic risk factors
induced by an atherogenic high-cholesterol diet. The high-cholesterol diet was
supplemented with two different types of chocolate and various parameters were analyzed
and compared including plasma cholesterol levels, atherosclerotic plaque formation,
liver and kidney function and systemic inflammatory responses. Overall, the results
from our study showed that dietary chocolate supplementation did not reduce the adverse
effects of an atherogenic high-cholesterol diet and in some cases even aggravated these
effects.
Hypercholesterolemia and oxidation of lipids are critical steps in the pathogenesis of
atherosclerosis [4, 37]. Previous studies, both in humans and animal models,
investigating chocolate or cacao powder supplementation have suggested a protective
effect on atherosclerosis development attributed to hypocholesterolemic and/or anti-
oxidative properties of chocolate components [38, 39, 17]. Our study does not
corroborate these findings since chocolate supplementation was found to increase
plasma total cholesterol levels and, in the case of CCA, aggravated atherosclerotic
plaque formation. In spontaneously hypercholesterolemic rabbits receiving cocoa liquor
extract elevated plasma cholesterol have been reported as well although the cocoa
liquor supplementation did reduce atherosclerosis development [16]. Moreover, studies
in golden Syrian hamsters have shown that the cardio-metabolic effects of cacao-powder
supplementation may be dose-dependent: a high dose cacao powder (1% Hershey’s
cocoa powder) significantly reduced plasma cholesterol levels but failed to reduce
atherosclerotic plaque formation whereas a low dose cacao powder (0.1% Hershey’s
powder) did significantly reduce atherosclerosis development [40]. In the same context,
Desch and colleagues reported possible long-term side effects of chocolate intake
including increased energy, fat, and sugar content probably leading to adverse metabolic
effects. These authors suggested determining the optimal dose of cacao or chocolate
before considering it as a treatment for cardio-vascular health [41]. This could be one
of the reasons behind the differences observed in plasma cholesterol levels and plaque
formation between the two chocolates used in our study.
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It has been reported that parameters for liver damage (elevated plasma ALAT levels) and
lack of anti-oxidative capacity are closely associated [42]. Chocolate is one of the
major sources of bioactive antioxidant compounds [38] and both chocolate and cocoa
have been reported to be associated with reduced LDL oxidation and platelet aggregation
[38]. In our study we observed that in both chocolate fed groups plasma ALAT levels were
increased compared to mice fed high-cholesterol suggesting that the possible anti-
oxidative properties of chocolate polyphenols are insufficient to prevent these adverse
effects [43, 44]. Moreover, in the liver, the ratio of aconitase activity over citrate synthase
activity, which is considered a marker for oxidative stress, was unchanged indicating
that dietary chocolate supplementation did not reduce the level of oxidative stress
upon high-cholesterol feeding.  This is in line with the current notion that chocolates
may have specific physiological effects such as amelioration of atherogenesis and
dampening systemic inflammation, rather than having a general anti-oxidant effect
[30].
Inflammation plays a crucial role in atherogenesis. Leukocyte binding to endothelial
cells and their subsequent infiltration into subendothelial spaces is mediated by various
adhesion molecules including E-selectin and vascular cell adhesion molecule-1 [45].
Previously, we have shown that elevated plasma E-selectin, VCAM-1 and SAA levels are
associated with atherosclerosis development in E3L mice [4]. In the present study, dietary
treatment with either chocolate preparation did not reduce the plasma levels of sVCAM-
1, sE-selectin and SAA levels in plasma when compared to mice fed a high-cholesterol
diet. In fact, in mice fed CCB the levels of these soluble markers were increased when
compared to mice fed the atherogenic diet alone suggesting an increased inflammatory
response.  Similar effects were observed in the kidney showing significantly upregulated
E-selectin and VCAM-1 mRNA levels in the CCB group. These diet-induced renal effects
were diminished in the CCA chocolate group, which displayed similar levels of expression
as the atherogenic CC group. In addition, enhanced expression of MCP-1 mRNA in
conjunction with increased expression of the macrophage marker CD68 was observed
in CCB chocolate treated group, while CCA displayed similar levels as CC group. This
shows that the overall components and composition of chocolate A is partially able to
reduce these adverse effects of the chocolate supplementation, whereas, chocolate B
aggravated these renal effects.
In the present study, we observed differential effects of the two chocolates on systemic
and organ-specific inflammatory parameters. Both CCA and CCB show no effect or
unfavorable effects on plasma parameters, atherosclerosis and/or kidney status when
compared with CC. These unfavorable effects cannot be easily explained because the
chocolate preparations differ in many components and we can only speculate.
Supplementation with chocolate A (CCA group) appeared to be less unfavorable than
chocolate B (CCB group) with respect to plasma and renal inflammatory parameters.
This may be related to the higher circulating polyphenol concentrations present in the
CCA group (see Supporting Information Table 3), which would be in line with reported
Chapter 4
81
anti-inflammatory effects of cocoa polyphenols [46]. However, CCA was unsuccessful in
reducing the adverse effects caused by the atherogenic diet (CC) itself and mice in this
group developed more severe atherosclerosis compared to the CC group. This may be
due to the higher plasma cholesterol levels observed in the CCA group. In contrast, the
reduced atherosclerosis development observed in the CCB group may be attributed to a
cholesterol lowering effect of fibers of which the content was higher in the CCB group.
Interestingly, in a meta-analysis, dietary fiber intake has been associated with lower
cholesterol levels [47].
In all, the present study shows that two chocolate preparations differing in the content
of polyphenols, fiber, and others, both unfavorably affected cardiovascular and
metabolic health, albeit to a different extent. Together with previous findings
demonstrating that different dietary doses of chocolates can also exert dissimilar effects
on CVD outcome [40, 41], we conclude that discrepancies reported on the effects of
chocolate on cardiometabolic health may at least partly be due to differences in chocolate
composition and quantity consumed.
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Supporting InformationFigure 1. Effect of chocolates on kidney weight, morphology and function at
week 20. (a) Kidney weight, (b) Morphology of the kidney (PAS staining) (n=8), (c) Kidney function
(albuminuria), and (d) Immunohistochemistry of macrophage infiltrates (200x) (n=5). Groups are
abbreviated as:  Mice fed control diet without cholesterol (CO, n=19); mice fed control diet (i.e with 1%
cholesterol) (CC, n=19); mice fed control diet supplemented with choc A (CCA, n=19) and mice fed control
diet supplemented with choc B (CCB, n=19).
Supporting Information Table 1. Composition of the chocolates used in this study.
Chocolate A: Article: CHD-Q65ACTICOA-000.
Typical composition: Cocoa mass 58.0 %; Sugar 32.0 %; Fat-reduced cocoa powder 5.0 %;
Anhydrous milk fat 4.0% ; Emulsifier: soya lecithin ; Natural vanilla flavoring.
Nutritional data for 100g (Calculation based on literature data)
Compound Units Compound Units
ENERGY VALUE 509 kcal VITAMIN B6 RDA 3.4 %
ENERGY VALUE 2,131 kJ VITAMIN-B12 (cobalamine) 0.0 µg
TOTAL PROTEIN 8.0 g VITAMIN B12 RDA 0.0 %
MILK PROTEIN 0.0 g VITAMIN C L-ASCORBIC ACID 0.0 mg
AVAILABLE CARBOHYDRATES 36.8 g VITAMIN C RDA 0.0 %
SUGARS(MONO+DISACCHARIDES) 32.3 g VITAMIN D CALCIFEROL 1.5 µg
POLYOLS 0.0 g VITAMIN D RDA 29.6 %
STARCH 4.6 g VITAMIN D (IU) 5.9
TOTAL FAT 36.3 g VITAMIN E (µ-TOCOPHEROL) 2.8 mg
SATURATED FAT 22.9 g VITAMIN E RDA 28.1 %
MONO UNSATURATED FAT 12.2 g VITAMIN E (IU) 1.9
POLY UNSATURATED FAT 1.3 g VITAMIN H BIOTIN 0.0 mg
TRANS FATTY ACID (TFA) TOTAL 0.3 g VITAMIN H RDA 0.0 %
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TFA (PLANT ORIGIN) 0.0 g VITAMIN M FOLIC ACID 17.4 µg
CHOLESTEROL 14.8 mg VITAMIN M RDA 8.7 %
ORGANIC ACIDS 1.00 g SODIUM 8.3 mg
DIETARY FIBRE 7.6 g PHOSPHORUS 255.7 mg
TOTAL ALKALOIDS 1.0 g PHOSPHORUS RDA 32.0 %
ALCOHOL 0.0 g IRON 16.5 mg
POLY HYDROXYPHENOLS 6.2 g IRON RDA 118.1 %
VITAMIN A RETINOL 47 µg MAGNESIUM 161.4 mg
VITAMIN A RDA 5.7 % MAGNESIUM RDA 53.8 %
VITAMIN A (IU) 158 ZINC 2.2 mg
PROVITAMIN A BETA-CAROTENE 8 µg ZINC RDA 15.0 %
VITAMIN B1 THIAMIN 0.1 mg IODINE 0 µg
VITAMIN B1 RDA 9.8 % IODINE RDA 0.0 %
VITAMIN B2 RIBOFLAVIN 0.1 mg CALCIUM 44.7 mg
VITAMIN B2 RDA 8.6 % CALCIUM RDA 5.6 %
VITAMIN-B3/PP NIACINE/NICOTIN 1.0 mg CHLORIDE 13.0 mg
VITAMIN B3 RDA 5.7 % POTASSIUM 721.1 mg
VITAMIN B5 PANTOIC ACID 0.5 mg ASH CONTENT 1.9 g
VITAMIN B5 RDA 9.1 % VITAMIN B6 PYRIDOXIN 0.1 mg
Chocolate B; Article: CHD-L108018B01-000.
Typical composition: Cocoa mass 58.0 %; Sugar 32.0 %; Fat-reduced cocoa powder 5.0 %;
Anhydrous milk fat 4.0% ; Emulsifier: soya lecithin ; Natural vanilla flavoring.
Nutritional data for 100g (Calculation based on literature data)
Compound Units Compound Units
ENERGY VALUE 514 kcal VITAMIN B6 RDA 3.4 %
ENERGY VALUE 2,150 kJ VITAMIN- B12 (cobalamine) 0.0 µg
TOTAL PROTEIN 7.8 g VITAMIN B12 RDA 0.0 %
MILK PROTEIN 0.0 g VITAMIN C L-ASCORBIC ACID 0.0 mg
AVAILABLE CARBOHYDRATES 36.7 g VITAMIN C RDA 0.0 %
SUGARS (MONO+DISACCHARIDES) 31.7 g VITAMIN D CALCIFEROL 1.5 µg
POLYOLS 0.0 g VITAMIN D RDA 29.1 %
STARCH 4.5 g VITAMIN D (IU) 5.8
TOTAL FAT 37 g VITAMIN-E ( µ-TOCOPHEROL) 2.8 mg
SATURATED FAT 22.9 g VITAMIN E RDA 27.6 %
MONO UNSATURATED FAT 12.4 g VITAMIN E (IU) 1.8
POLY UNSATURATED FAT 1.3 g VITAMIN H BIOTIN 0.0 mg
TRANS FATTY ACID (TFA) TOTAL 0.3 g VITAMIN H RDA 0.0 %
TFA (PLANT ORIGIN) 0.0 g VITAMIN M FOLIC ACID 17.1 µg
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CHOLESTEROL 14.7 mg VITAMIN M RDA 8.6 %
ORGANIC ACIDS 1.01 g SODIUM 8.2 mg
DIETARY FIBRE 11.3 g PHOSPHORUS 250.6 mg
TOTAL ALKALOIDS 1.0 g PHOSPHORUS RDA 31.3 %
ALCOHOL 0.0 g IRON 16.6 mg
POLY HYDROXYPHENOLS 2.0 g IRON RDA 118.2 %
VITAMIN A RETINOL 47 µg MAGNESIUM 158.2 mg
VITAMIN A RDA 5.6 % MAGNESIUM RDA 52.7 %
VITAMIN A (IU) 157 ZINC 2.2 mg
PROVITAMIN A BETA-CAROTENE 8 µg ZINC RDA 14.8 %
VITAMIN B1 THIAMIN 0.1 mg IODINE 0 µg
VITAMIN B1 RDA 9.8 % IODINE RDA 0.0 %
VITAMIN B2 RIBOFLAVIN 0.1 mg CALCIUM 43.8 mg
VITAMIN B2 RDA 8.6 % CALCIUM RDA 5.5 %
VITAMIN-B3/PP NIACINE/NICOTIN 1.0 mg CHLORIDE 12.7 mg
VITAMIN B3 RDA 5.6 % POTASSIUM 721.6 mg
VITAMIN B5 PANTOIC ACID 0.5 mg ASH CONTENT 2.1 g
VITAMIN B5 RDA 9.1 % VITAMIN B6 PYRIDOXIN 0.1 mg
Supporting Information Table 2a. Optimized SRM conditions for the







entor  (V) energy (eV) energy (V) entor (V) energy (V)
Galic acid 170 169 > 90 10 169 > 90 40
125 179
3,4-dihydroxyphenylacetic 168 167 > 50 10 167 > 50 30
123 95
Protocatechuic acid 154 153 > 80 10 153 > 80 40
109 65
Hippuric acid 179 178 > 80 5 178 > 80 10
134 77
p-hydroxyphenylacetic 152 151 > 60 5 151 > 60 20
107 93
Catechin 290 289 > 120 20 289 > 120 25
203 245
3-hydroxyphenylacetic 152 151 > 50 5 151 > 50 30
107 65




Procyanidin B2 578 577 > 130 10 577 > 130 30
425 407
Vanillic acid 168 167 > 80 10 167 > 80 5
152 123
Epicatechin 290 289 > 130 10 289 > 130 20
245 203
p-coumaric acid 164 163 > 80 10 163 > 80 30
119 91
Ferulic acid 194 193 > 60 5 193 > 60 5
134 59
Benzoic acid 122 121 > 60 25 121 > 60 25
 77 77
Supporting Information Table 2b. Optimized SRM conditions for the







entor  (V) energy (eV) energy (V) entor (V) energy (V)
Methyl-catechin-glucuronide 170 169 > 90 10 169 > 90 40
125 179
3,4-dihydroxyphenylacetic 168 167 > 50 10 167 > 50 30
123 95
Protocatechuic acid 154 153 > 80 10 153 > 80 40
109 65
Hippuric acid 179 178 > 80 5 178 > 80 10
134 77
p-hydroxyphenylacetic 152 151 > 60 5 151 > 60 20
107 93
Catechin 290 289 > 120 20 289 > 120 25
203 245
90
Supporting Information Table 3.  Quantification of chocolate plasma
metabolites (values expressed as nM in the plasma sample)
Compound CO CCA CCB CC
Galic acid n.d. n.d. n.d. n.d.
3,4-dihydroxyphenylacetic acid 37.5 ± 4.8a 56.7 ± 14.5 a 46.0 ± 7.4 a n.q.
Protocatechuic acid n.q. n.q. n.q. n.q.
Hippuric acid 47.4 ± 2.3 a 338.8 ± 78.6c 193.9 ± 32.1 b 78.9 ± 12.1 ab
p-hydroxyphenylacetic 809.3 ± 121.3 a 1434.1 ± 211.9 b 725.6 ± 185.0 a 672.3 ± 40.7 a
Catechin n.d. n.d. n.d. n.d.
3-hydroxyphenylacetic acid 29.2 ± 3.7 a 50.5 ± 17.8 a 38.0 ± 1.1 a 29.6 ± 6.9 a
3-hydroxybenzoic acid n.q. n.q. n.q. n.q.
Procyanidin B2 n.d. 6.1 ± 1.8 a 0.6 ± 0.2 b n.d.
Vanillic acid 23.7 ± 3.2 a 29.7 ± 2.0 ab 39.2 ± 4.6 b 23.0 ± 3.7 a
Epicatechin n.d. 33.5 ± 8.1 n.q. n.q.
p-coumaric acid 12.3 ± 0.4 a 23.7 ± 1.3 b 16.1 ± 2.2 a 11.6 ± 3.0 a
Ferulic acid 5.1 ± 0.5 ab 5.6 ± 0.4 b 4.5 ± 1.5 ab 2.5 ± 0.9 a
Benzoic acid 178.3 ± 25.1 a 214.6 ± 6.7 a 288.3 ± 28.5 b 177.4 ± 11.4 a
Methyl catechin gluc n.d. 18.1 ± 4.0a 1.6 ± 0.3b n.d.
Methyl epicatechin gluc n.d. 485.7 ± 65.5 a 57.5 ± 18.2 b n.d.
Epicatechin glucuronide n.d. 383.8 ± 54.8 a 52.2 ± 10.6 b n.d.
Catechin sulphate n.d. 28.1 ± 9.6 n.d. n.d.
Methyl epicatechin-O-sulphate n.d. 548.9 ± 29.2 a 74.1 ± 9.1 b n.d.
Epicatechin sulphate n.d. 1295.6 ± 84.7 a 125.4 ± 16.1 b n.d.
3-O-methyl epicatechin n.d. 38.6 ± 1.8 a 3.5 ± 1.0 b n.d.
*Values are expressed in nM of each compound in plasma samples
* n.d.: not detected; * n.q.: not quantified
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Supporting Information Table 4.  Dietary composition of basic
atherogenic diet without cholesterol
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Background: Metabolic stress-induced inflammation plays a major role in the
development of Insulin resistance (IR) and renal abnormalities.  In this study, we
investigated whether pharmacological interventions aimed at suppressing metabolic
stress-induced inflammation could reduce the development of IR and improve renal
function (albuminuria and renal inflammation) induced by high fat feeding.
Methods: Four groups of male hu-CRPtg mice (n= 9) mice were exposed to the following
diet regimens for 42 weeks as follows. Group 1: standard chow diet (Chow); Group 2:
high-fat diet (Lard); Group 3: lard diet containing 0.018% (w/w) rosiglitazone and Group
4: lard diet containing 0.005% (w/w) rosuvastatin. Plasma was analyzed for
cardiovascular risk factors and kidneys were analyzed for inflammation. Urine was
collected for renal function analysis.
Results:  Compared to lard fat diet feeding, rosiglitazone treatment improved insulin
resistance, reduced systemic inflammation and improved renal function. These effects
were associated with increased adiponectin levels upon rosiglitazone treatment. In
contrast, rosuvastatin treatment reduced systemic inflammation only at the early time
points (until week 4.5) but did not affect insulin resistance or renal function.
Conclusions: Lard fat diet induced albuminuria in huCRP transgenic mice is due to
metabolic stress-induced inflammation. Treatment with rosuvastatin failed to improve
IR and renal function whereas; rosiglitazone treatment suppressed the systemic
inflammatory response and protected mice from the development of insulin resistance
and albuminuria. These results indicate that drugs that reduce systemic inflammation
and in turn improve cardiovascular health could be of clinical importance.
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Introduction
The occurrence of obesity is increasing in almost all populations and age groups
worldwide, largely due to increased availability and consumption of calorie-dense
foods with a high-fat, high-sugar content and lack of physical activity [1]. The growing
prevalence of obesity is associated with an increased risk of Type 2 Diabetes Mellitus
(T2DM), a condition in which the body does not properly respond to the hormone insulin.
This insulin resistance (IR) results in hyperglycemia [2]. According to the International
Diabetes Federation, 366 million people were affected with diabetes in 2011 and this
number is anticipated to increase to 552 million by 2030 [3]. In patients suffering from
T2DM, (micro)albuminuria is a very common phenomenon. The presence of albuminuria
is not only an important risk factor for future cardiovascular events (CVD) [4-6], but is
also considered as a first sign of diabetic nephropathy. Impaired renal function augments
the inflammatory burden by increasing the production of systemic inflammatory
cytokines [7]. Also, IR is associated with increased production of cytokines as a
consequence of the reduced anti-inflammatory effect of insulin [8]. In patients with
T2DM and diabetic nephropathy, chronic inflammation is evidenced by elevated plasma
levels of various acute-phase inflammatory markers including C-Reactive Protein (CRP),
a commonly used marker for systemic inflammation in humans [7].
CRP is a p50-NFkB-regulated, prototypic acute-phase inflammatory marker, which is
secreted by the liver [9]. Prospective epidemiological studies have clearly demonstrated
that CRP levels independently predict future CVD [10,11]. The reasons for the association
between CRP and CVD are not fully understood. Recently, it has been reported that CRP is
independently associated with mortality risk in patients with T2DM [12]. Interventions
that reduce systemic inflammation and in turn prevent albuminuria and restore renal
function are attractive candidates for treatment of patients with diabetic nephropathy.
To gain more insight into the role of inflammation in metabolic stress induced
albuminuria and renal abnormalities in the context of IR, we used a human C-Reactive
Protein transgenic (huCRPtg) mouse model. The huCRPtg mice carry a 31 kb transgene
containing the human CRP gene, 17 kb of the 5’ flanking promoter region and all known
CRP gene regulatory elements [13]. These mice have been successfully employed to
monitor systemic inflammation and to determine the effects and mechanisms of drugs
like statins and fibrates in reducing the atherogenic and inflammatory process [14].
In this study, we hypothesize that high-fat diet induced insulin resistance and renal
abnormalities and renal dysfunction (albuminuria) in mice are due to metabolic stress-
induced inflammation. Even though statins and TZDs (PPAR gamma activators) have
been widely studied, the anti-inflammatory effects of these drugs are not yet fully
understood. We used the huCRPtg mouse model to monitor the overall inflammatory
state during a high-fat diet challenge. Interventions with a statin (rosuvastatin) and a
TZD (rosiglitazone) were applied to investigate whether suppression of metabolic stress-
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induced inflammation reduces the development of (IR) and improves renal function
(albuminuria and renal inflammation) under conditions of obesity.
Materials and methods
Animals
HuCRPtg mice [13,15] on a C57BL/6 background were characterized by polymerase chain
reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) for huCRP expression.
Mice were housed in groups under standard conditions with a 12 h light-dark cycle and
had free access to water and food. Experiments were approved by the institutional
Animal Care and Use Committee of TNO and were in compliance with European
Community specifications regarding the use of laboratory animals.
All sample materials and organs required for this study were obtained from TNO-
Biosciences, Leiden. Parts of the results were published previously, where indicated, but
presented here as well for clarity [16].
Diets
Male huCRPtg mice of 12 weeks of age were fed either standard lab chow (V1534 Ssniff
Spezialdiäten GmbH, Germany) or chow supplemented with 0.01% (w/w) rosuvastatin
(“Crestor®”, AstraZeneca, Zoetermeer, The Netherlands) (t=0). After 4 weeks (t=4) the diets
were changed and mice were divided in 4 groups consisting of 9 mice in each group.
Mice fed chow were randomly distributed in 3 different groups. Group 1 consisted of
control mice which remained on standard chow diet. Group 2 was switched to a high fat
diet (Lard) (D12451 23.1% fat, Ssniff Spezialdiäten GmbH, Germany) and mice in group 3
were fed a lard diet containing 0.018% (w/w) rosiglitazone (Lard+ Rosi) (Avandia, GSK,
London, United Kingdom). Group 4 consisted of mice fed with standard chow supplemented
with rosuvastatin and were switched to lard diet containing 0.005% (w/w) rosuvastatin
(Lard+ Rosuva). Reason for this decreased dose is the increased absorption of
rosuvastatin in HFD. Rosuvastatin and rosiglitazone doses were based on their anti-
inflammatory effects observed in previous studies [17,18]. Mice on chow diet (group 1),
untreated mice on lard diet (group 2) and drug-treated mice on lard diet (group 3 and 4)
remained on their respective diets until the completion of the study at 54 weeks of age
(t=42).A schematic representation of the study design is depicted in supplementary
figure 1.
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Supplementary Figure 1: Schematic representation of the experimental set up
Body weight
Body weight was monitored and blood samples were taken by tail incisions in EDTA
tubes after 4 hours of fasting (Sarstedt, Germany) at t= 0 and weeks 2, 4, 4.5, 5, 11, 34,
and 42. Tubes were centrifuged for 10 minutes at 6000 rpm and plasma was immediately
stored at -80°C until analysis. Spot urine was collected from all animals at the time of
sacrifice. After 42 weeks of the experimental diet feeding, mice were fasted for 4 hours
and sacrificed by Isofluorane/CO2, and organs were isolated and weighed. Kidneys
(left) were fixed and embedded in paraffin and, kidneys (right) were snap frozen in
liquid N2 and stored at “80°C until further use.
Plasma analysis
Hu-CRP in the plasma was quantified by established ELISA (R&D systems, Europe, Ltd.,
Abingdon, United Kingdom) at t = 0 and weeks 2, 4, 4.5, 5, 11 and 34. The plasma levels
of E-selectin (R&D Systems), Leptin (R&D systems), and  Adiponectin (R&D systems) were
quantified at t=0, weeks 2, 4, 5 and 11. The plasma insulin (week 42) (Alpco, Tilburg, The
Netherlands) was determined by ELISA according to the manufacturer’s instructions.
To characterize the inflammatory responsiveness of the mice and to verify the anti-
inflammatory effect of rosuvastatin and rosiglitazone, all groups on lard fat diet were
injected peritoneally (i.p.) with 100 µl IL-1â (Peprotech, Rocky Hill, USA) at a mild dose
(~200 ng) 2 weeks before (t=2) and 8 weeks after diet switch (t=12). The used concentration
in this study is negligible to previously used models in which IL-1 was intra-articularly
injected in the mouse knee joint [19]. Plasma samples were collected prior to and 18
hours after this challenge and used for huCRP and sE-selectin levels quantification.
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Renal RNA extraction and gene expression analysis
Total RNA was extracted from thirty five- µm thin cryo-sections from kidney using RNeasy
Mini plus Kit (Qiagen, Westburg, Leusden, The Netherlands) according to the
manufacturer’s instructions. Integrity of RNA was determined by Agarose gel
electrophoresis. RNA quantity (OD-260) and quality (OD-260/OD-280) were determined
using an ND-1,000 UV-Vis spectrophotometer (NanoDrop Technologies, Rockland, DE) as
mentioned earlier [20].
Total RNA was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen,
Breda, The Netherlands) and random hexamer primers (Promega, Leiden, The
Netherlands). To detect the expression of selected target genes Assays-On-Demand™
gene expression primer/probe sets (ABI Systems, Foster City, CA) were used. Endogenous
PPIA (assay ID Mm02342430_g1) was used as housekeeping gene along with the following
probes: CD68 (assay IDMm00839636_g1), VCAM-1 (assay IDMm00449197_m1), E-
selectin (assay IDMm00441278_m1), and Kidney Injury Molecule 1 (KIM-1, assay
IDMm00506686_m1). Real-time PCR was performed in duplicate and the obtained
threshold cycle (CT) values were averaged. Relative mRNA levels were calculated as 2-
∆CT, in which ∆CT is CT gene of interest – CT housekeeping gene.
Histology and immunohistochemistry
For light microscopy, 3 µm renal paraffin sections were stained with Periodic acid-
Schiff’s (PAS). In short, paraffin sections were deparaffinized and re-hydrated in distilled
water. Sections were placed in 0.5% periodic acid solution for 5 minutes. After rinsing in
distilled water, sections were incubated in Schiff’s reagent (Sigma) for 15 minutes
followed by rinsing in lukewarm water for 5 minutes. Sections were counterstained with
Mayer’s hematoxylin for 1 minute and washed in tap water. Images were taken with a
Leica microscope using QwinV3 software (Qwin V3 software, Leica Microsystems Imaging
Solutions, Ltd., Cambridge, UK).
Kidney function measured by albumin/creatinine ratio
To assess renal function, the albumin and creatinine levels were measured in mouse
urine using commercially available kits. Mouse Albumin ELISA Quantitation set (Bethyl
laboratories, Montgomery, Texas, USA) and creatinine clearance (Exocell, Philadelphia,
PA) according to the manufacturer’s instructions.
Statistical analysis
Data were analyzed with Graphpad prism (Graphpad software 5.0, San Diego CA, USA)
and SPSS 17.0 for Windows. Differences between groups at one specific time point were
analyzed with 1-way ANOVA followed by LSD post-hoc analysis. P<0.05 was considered
significant. Results are shown as means ± SEM, unless stated otherwise.
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Results
Body weight and fat mass distribution
Body weight at baseline (week 0) was 28.6± 2.0 g on average of all groups together. All
the lard fed groups showed a gradual increase in bodyweight throughout the experimental
period. All three lard fed groups had significantly higher average body weights at the
end of the experimental period compared to the chow group (35.1± 1.9 g). Mice treated
with rosiglitazone had the highest average body weight (57.7± 11.0 g), which was
significantly higher than the lard group (41.4± 4.7 g) and rosuvastatin treated group
(46.1± 6.2 g) (Figure 1A; this has been reported earlier by Gierman et al., 2012) [16].
All groups that were fed the lard diet had increased fat depots when compared to chow
fed mice but clear differences were observed between the groups with respect to fat
mass distribution. Rosiglitazone treatment was associated with a decrease in visceral
fat tissue mass and an increase in sub-cutaneous fat tissue mass when compared to the
lard group. (Visceral fat : 0.39± 0.16 g vs. 0.64± 0.28 g, p<0.01; subcutaneous fat: 2.92±
1.30 g vs. 0.83± 0.40 g, p<0.001). In the rosuvastatin group visceral fat tissue mass was
similar to the lard group (0.57± 0.16 g vs. 0.64± 0.28 g), whereas a significant increase
in gonadal fat tissue mass was observed when compared to both the chow group (rosuva
vs. chow, 2.01± 0.91 g vs. 0.69± 0.31 g, p<0.001) and the rosiglitazone group (rosuva vs.
rosi, 2.01± 0.91 g vs. 1.27± 0.27 g, p<0.05).
Figure 1.Effects of rosiglitazone and rosuvastatin drugs on body weight and weights of fat tissue mass in
Hu-CRP transgenic mice upon lard diet. (a) Body weight (this has been reported earlier by Gierman et
al., 2012), (b) Visceral fat tissue mass, (c) Sub-cutaneous fat tissue mass, (d) Gonadal fat tissue mass.
Groups are abbreviated as:  Mice fed control diet (chow, n=9); mice fed lard diet (lard, n=9); mice fed
lard diet supplemented with rosiglitazone drug (lard+ Rosi, n=9) and mice fed lard diet supplemented
with rosuvastatin drug (lard+ Rosuva, n=7). *** p<0.001, ** p<0.01, * p<0.05 compared to chow, ###




The obesity related adipokines leptin and adiponectin levels were measured in plasma.
At baseline (t= 0) and at weeks 2 and 5, plasma leptin levels did not differ significantly
between the experimental groups (Figure 2a). Notably, adiponectin levels were
significantly increased in the rosiglitazone group at week 5 and 11 when compared to
all the other three groups (Figure 2b).
Figure2.Effects of rosiglitazone and rosuvastatin drugs on plasma adipokines production in Hu-CRP
transgenic mice upon lard diet. (a) Plasma leptin and (b) Plamsa adiponectin. Groups are abbreviated
as: Mice fed control diet (chow, n=9); mice fed control diet supplemented with rosuvastatin (before
diet switch) (Chow+ Rosuva, n=7); mice fed lard diet (lard, n=9); mice fed lard diet supplemented with
rosiglitazone drug (lard+ Rosi, n=9) and mice fed lard diet supplemented with rosuvastatin drug (lard+
Rosuva, n=7). Dashed lines represent groups before diet switch. * p<0.05, *** p<0.001 compared to
chow, ### p<0.001 compared to lard diet, &&& p<0.001 compared to rosuvastatin. Values are the
mean± SEM.
Plasma inflammatory markers
HuCRP levels were measured during the experiment to monitor the overall inflammatory
state induced by the lard diet and the effect of interventions with rosuvastatin and
rosiglitazone. Before diet switch all mice had similar baseline huCRP levels (data not
shown).  At weeks 2 and 4, rosuvastatin significantly lowered human CRP levels compared
to the chow group. The switch to lard diet resulted in a further increase in human CRP
levels in the lard group. Although not significant at every time point analyzed,
rosiglitazone and rosuvastatin treated mice showed lower human CRP levels compared
to mice on lard diet alone. At week 4.5, rosuvastatin treated mice and at weeks, 11 and
34, rosiglitazone treated mice showed significantly lower human CRP levels compared
to mice on the lard diet (Figure 3A;this has been reported earlier by Gierman et al., 2012)
[16].
One week after the diet switch from chow to lard diet (week 5), both rosuvastatin and
rosiglitazone treated mice showed decreased sE-selectin levels, compared to the mice
on the lard diet. This effect was maintained up to week 11 for the rosiglitazone group
(Fig 3B).
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Injection of a non-metabolic inducer of inflammation, IL1-β (200 ng IL-1; i.p.) induced
elevated huCRP levels before and after diet switch. Before diet switch, rosuvastatin
treatment significantly reduced IL1-β-induced huCRP levels compared to chow, whereas,
after diet switch, rosuvastatin treatment failed to reduce huCRP levels compared to
lard. However, rosiglitazone treatment significantly reduced huCRP levels compared to
lard (Fig 3c).
Plasma levels of the vascular inflammation marker sE-selectin showed a similar
response as huCRP upon IL1-β injection. Rosuvastatin treatment failed to reduce sE-
selectin levels both before and after diet switch upon IL1-β injection, while; rosiglitazone
treatment effectively diminished sE-selectin levels compared to lard diet (Fig 3d).
Figure 3.Effects of rosiglitazone and rosuvastatin drugs on systemic inflammatory markers
in Hu-CRP transgenic mice upon lard diet. (a) Plasma CRP (this has been reported earlier
by Gierman et al., 2012), (b) sE-selectin, (c) Plasma CRP levels after IL1-β injection and
(d) sE-selectin levels after IL1-β injection. Groups are abbreviated as:  Mice fed control
diet (chow, n=9); mice fed control diet supplemented with rosuvastatin (before diet
switch) (Chow+ Rosuva, n=7); mice fed lard diet (lard, n=9); mice fed lard diet
supplemented with rosiglitazone drug (lard+ Rosi, n=9) and mice fed lard diet
supplemented with rosuvastatin drug (lard+ Rosuva, n=7). At times 2 and 4 weeks, mice
in the chow group showed significantly higher human CRP levels compared to
rosuvastatin treated mice in the chow group (*** P< 0.001). At time 4.5 weeks, untreated
mice on a lard diet showed significantly higher human CRP levels compared to
rosuvastatin mice on a lard diet (* P< 0.05). At time 11 weeks, untreated mice on a lard
diet showed significantly higher human CRP levels compared to rosiglitazone treated
mice (### P< 0.001). At week 11, mice on lard diet showed significantly higher sE-Selectin
levels compared to rosiglitazone treated mice ($ p< 0.05). Dashed lines represent groups
before diet switch. Values are the mean± SEM.
Insulin levels
At week 5,i.e. 1 week after diet switch, insulin levels were significantly suppressed in
rosiglitazone treated mice compared to mice on the lard diet (0.5± 0.2 ng/ ml vs. 0.9 ± 0.5
ng/ ml, p<0.05). Treatment with rosuvastatin did not alter insulin levels compared to
mice on the lard diet (1.1± 0.6 ng/ ml vs. 0.9 ± 0.5 ng/ ml). Similar effects were observed
at week 11 [16] and at the end of the experiment (week 42) although the differences did
not reach statistical significance (lard diet, 2.15± 0.98 ng/ml vs. rosiglitazone, 0.98±
0.14 ng/ml, p= 0.051;  lard diet vs. rosuvastatin, 2.03± 0.55 ng/ml, p= 0.31 and lard diet
vs. chow, 1.41± 0.21 ng/ml, p= 0.10) (Figure 4).
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Figure 4.Effects of rosiglitazone and rosuvastatin drugs on insulin production in Hu-CRP transgenic mice
at week 42 upon lard diet. (a) Plasma Insulin levels. Groups are abbreviated as:  Mice fed control diet
(chow, n=9); mice fed lard diet (lard, n=9); mice fed lard diet supplemented with rosiglitazone drug
(lard+ Rosi, n=9) and mice fed lard diet supplemented with rosuvastatin drug (lard+ Rosuva, n=7). Mice
on lard diet showed significantly (P= 0.051 border line significant) higher plasma insulin levels compared
to rosiglitazone group at week 42. Values are the mean± SEM.
Renal inflammation and renal function
At the end of the experimental period, mice fed lard diet showed an increase in the
urinary albumin/creatinine ratio when compared to the chow group (chow group, 150±
57 µg/mg vs. lard group, 395± 232 µg/mg, p<0.01). Rosuvastatin treated mice had similar
albumin/creatinine ratios as lard diet (rosuvastatin group, 360± 231 µg/mgvs. lard
group, 395± 232 µg/mg). However, mice treated with rosiglitazone had urinary albumin/
creatinine ratios similar to the chow fed mice and significantly lower compared to lard
diet (rosiglitazone group, 128± 19 µg/mg vs. lard group, 395± 232 µg/mg, p<0.01)
(Figure 5b).
Light microscopic analysis revealed the development of mild mesangial area expansion
(yellow arrow) and accumulation of lipid droplets in tubuli (green arrow) in mice that
had consumed the lard diet. Tubular lipid accumulation was also observed in the
rosiglitazone treated group but was absent in the rosuvastatin treated mice (Figure 5A).
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Figure 5.Effects of rosiglitazone and rosuvastatin drugs on renal structural and functional changes in Hu-
CRP transgenic mice upon lard diet. (a) Morphology of the kidney (PAS staining). Mesangial expansion
(PAS positive area, yellow arrow), vacuolarization (lipid accumulation) of the tubules (green arrow) and
(b) Kidney function (albumin/creatinine ratio) (n=9). Groups are abbreviated as:  Mice fed control diet
(chow, n=9); mice fed lard diet (lard, n=9); mice fed lard diet supplemented with rosiglitazone drug
(lard+ Rosi, n=9) and mice fed lard diet supplemented with rosuvastatin drug (lard+ Rosuva, n=7). **
p<0.01. Values are the mean± SD.
Gene expression analysis revealed that mRNA expression levels of Kidney injury marker
1 (KIM-1) were markedly upregulated in the rosuvastatin group when compared to all
other groups. In addition, CD68 mRNA expression levels, as a marker for macrophage
infiltration did not significantly differ in both drug treated groups when compared to
lard group. Renal mRNA expression levels of the endothelial activation marker E-selectin,
were significantly upregulated in both the lard and rosuvastatin groups when compared
to the chow fed group. Rosiglitazone treatment considerably downregulated E-selectin
expression when compared to the lard fed group and showed expression levels similar
to chow fed mice. In contrast, VCAM-1 mRNA expression levels in kidney were not
significantly different between the groups (Table 1).




Table 1: Effects of rosiglitazone and rosuvastatin drugs on renal mRNA expression profiling
in Hu-CRP transgenic mice upon lard diet.
Renal mRNA expression levels of endothelial activation markers (E-selectin and VCAM-
1), macrophage marker (CD68) and Kidney Injury Marker (KIM-1). Groups are abbreviated
as:  Mice fed control diet (chow, n=9); mice fed lard diet (lard, n=9); mice fed lard diet
supplemented with rosiglitazone drug (lard+ Rosi, n=9) and mice fed lard diet
supplemented with rosuvastatin drug (lard+ Rosuva, n=7). Superscripts without a common
letter differ significantly P<0.05. Values are represented as means ± SD.
Discussion
In the current study, we employed human C-reactive Protein transgenic (huCRPtg) mice
in conjunction with two pharmacological interventions, (Rosiglitazone and
Rosuvastatin) to study the role of inflammation in the development of insulin resistance
and renal dysfunction induced by a high-fat diet. The results demonstrate that
rosiglitazone treatment improves insulin resistance, reduces systemic inflammation
and improves renal function. In contrast, rosuvastatin treatment reduced systemic
inflammation only at the early time points (until week 4.5) but did not affect insulin
resistance or renal function.
T2DM is the most common cause of kidney disease and is associated with the occurrence
of albuminuria and reduced glomerular filtration rates [21]. The development of
albuminuria in T2DM not only signals renal disease but also increases the risk of CVD
[22]. Recently, we reported that development of T2DM in mice is associated with renal
structural and functional changes, including renal inflammation, glomerulosclerosis
and the occurrence of albuminuria [23]. Treatments that reduce albuminuria are
renoprotective and consequently improve CVD outcomes [22,24]. Consistent with our
previous results, we observed that mice on a lard fat diet showed mesangial expansion,
glomerulosclerosis, lipid accumulation and albuminuria. Rosiglitazone treatment
markedly diminished these diet induced renal effects and improved kidney function as
evidence by reduced urinary albumin/creatinine ratios. Moreover, rosiglitazone
treatment strikingly reduced sE-selectin levels and, similarly, reduced renal E-selecting
mRNA expression levels. Rosuvastatin treatment failed to display any beneficial effects
on markers of endothelial activation and inflammation in the kidney and did not improve
albumin/creatinine ratios. In fact, the expression levels of some markers including E-
selectin and kidney injury marker-1 (KIM-1) were increased in the kidneys of rosuvastatin
treated mice when compared to those from control and lard-fat challenged mice. Previous
studies have demonstrated that statins can inhibit tubular reabsorption of filtered
albumin [25,26]. Furthermore, this notion is supported by a recent study in hypertensive
patients demonstrating that statin treatment was independently associated with the
occurrence of microalbuminuria [27].
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T2DM is a disease characterized by hyperglycemia, hyperinsulinemia, adipokine
dysregulation and low-grade inflammation, all of which can also be involved in the
development of renal dysfunction [28]. Rosiglitazone, a thiazolidinedione, has two
distinct properties: it can improve insulin sensitivity and it exerts anti-inflammatory
properties [29]. Previously, it has been reported that in patients with T2DM, treatment
with a thiazolidinedione (pioglitazone) along with insulin therapy decreased huCRP
levels when compared to insulin treatment alone [29][30]. In the current study,
rosiglitazone treatment decreased plasma insulin levels and therefore reduced IR. In
contrast, rosuvastatin treatment failed to decrease insulin levels in the plasma. This is
in line with a recent report where rosuvastatin treatment failed to improve IR in patients
on peritoneal dialysis [31].
Rosiglitazone treatment caused a significant increase in body weight in huCRPtg mice
when compared to lard fat challenged mice. More specifically, rosiglitazone treated
mice had an increased fat mass of especially sub-cutaneous fat, when compared to the
lard fat challenged mice. Consistent with these observations, treatment with PPAR-γ
agonists has been shown to improve insulin sensitivity despite increasing body fat
mass, in particular sub-cutaneously [32]. In contrast, an increase in visceral fat has
been reported to be highly associated with IR and T2DM [33,34]. Here, we observed that
rosiglitazone treatment decreased the visceral fat mass. In contrast, in the rosuvastatin
treated mice the mass and distribution of the fat depots were similar to those observed
in untreated lard fat challenged mice.
It is well known that low-grade inflammation plays a major role in IR [35,36]. In our
study, we focused on huCRP levels as a marker for systemic inflammation. CRP is a well-
known pro-inflammatory marker and studies have indicated that it can directly activate
endothelial cells resulting in increased adhesion molecule expression [37]. Recently, it
has been reported that rosiglitazone treatment reduces plasma CRP levels in T2DM
induced rats [38]. Consistent with these findings, we observed that rosiglitazone treatment
reduced huCRP levels in high-fat challenged huCRPtg mice and reduced sE-selectin levels
in these animals indicating that rosiglitazone suppresses systemic inflammatory
responses.  A similar response was observed when mice were injected with a non-
metabolic inducer of inflammation, IL-1β. Rosiglitazone treatment reduced both huCRP
and sE-selectin levels, which indicates that rosiglitazone exerts anti-inflammatory
activities beyond its glucose lowering activity. In contrast, rosuvastatin treatment did
not reduce systemic inflammatory markers after IL-1β injection.
We also observed that mice on rosiglitazone treatment displayed increased plasma
levels of adiponectin. It is well documented now that adiponectin is a cardioprotective
adipokine, due to its anti-inflammatory and insulin sensitizing properties [39,40]. In
patients with end stage renal disease an inverse relationship between adiponectin
levels and CVD has been reported [41] and there is increasing evidence that adiponectin
plays a protective role in T2DM and IR. For example, adiponectin deficient mice are
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prone to IR and vascular damage after high-fat diet challenge [42] whereas treatment
with adiponectin inhibits renal fibrosis and albuminuria in adiponectin knock-out mice
[28]. Moreover, enhanced expression of adiponectin attenuated inflammation and
decreased diabetes development in diabetic db/db mice [43].
In conclusion, the results of our study demonstrate that lard fat diet induced albuminuria
in huCRP transgenic mice is due to metabolic stress-induced inflammation. Intervention
with rosuvastatin failed to improve IR and renal function that may have been due to a
lack of sustained anti-inflammatory effects in the model used here. However, rosiglitazone
treatment reduced lard fat diet induced insulin levels, suppressed the systemic
inflammatory response and protected mice from the development of albuminuria.
Although multiple mechanisms may be involved, rosiglitazone treatment was associated
with a marked increase in circulating adiponectin levels suggesting that the anti-
inflammatory properties of this adipokine may have contributed to these effects. Patients
with T2DM and IR associated with albuminuria are more prone to CVD, if left untreated.
Our findings suggest that drugs that reduce systemic inflammation and in turn improve
cardiovascular health could be of clinical importance.
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Introduction
During the last decades, life expectancy of the global population has increased
drastically and has resulted in a relative increase of the elderly (age >60)
population.[1,2]. In parallel to life expectancy, the incidence of chronic kidney disease
(CKD) has also increased significantly [2] and population based studies have
demonstrated that elderly are more prone to develop CKD [3]. Numerous factors
contribute to age associated renal insufficiency and among these, obesity is considered
as one of the main risk factors [4,5]. Apart from leading to renal failure,the development
of CKDhas been shown to be an independent risk factor for cardiovascular disease
(CVD) [6] and death [7]. To develop potential preventive or therapeutic strategies, a
better understanding of the pathological changes and the factors that contribute to or
accelerate age associated CKD is necessary.
 Already in 1936, Kimmelstiel and Wilson reported the presence of lipid deposits in the
kidneys of diabetic patients and suggested their potential role in the development of
renal disease [9]. Since then, many studies have demonstrated a correlation between
lipid deposits in the kidney and renal dysfunction [8][10]. For example, renal lipid
accumulation has been associated with increased accumulation of extracellular matrix
proteins resulting in glomerulosclerosis and proteinuria [11].  Moreover, there is
accumulating evidence that high-fat diet intake activates renal endothelium and
promotes accumulation of macrophages in renal tissue causing chronic
inflammation [4].
Similar to humans, mice fed a high fat diet develop hyperglycemia, hyperlipidemia, and
obesity. Moreover, previous studies have shown that HFD feeding in C57BL/6J mice induces
obesity associated renal structural and functional changes that resemble diabetic
nephropathy [5][8]. However, most of these studies have focused on renal histo-
pathological and functional changes after relatively short periods of HFD feeding [4,5,12]
and there is limited data on the effects of a long term HFD challenge. Therefore, we
performed a pilot study in C57BL/6j mice comparing metabolic and renal structural and




Animal experimentswere performed according to the criteria outlined in the “Guide for
the Care and Use of Laboratory Animals” published by the National Institutes of Health
(NIH) and were approved by theUniversity of Groningen, ethical committee on animal
care and experimentation. C57BL/6J mice were obtained from Charles River (Sulzfeld,
Germany)(n = 16) Mice were group housed (3–5 mice per cage) with a 12 h light-dark
cycle (from 7.00 PM to 7.00 AM)and had access to water and diet ad libitum.
112
Study design
Animals were randomly divided into 2 groups of 8animals eachand mice in both groups
were treated similarly in terms of handlingand stress to exposures. Group 1 receiveda
chowdiet (Chow, AB-diets, Woerder, The Netherlands) till the end of the experiment i.e.
48 weeks. Group 2 received a high-fat diet containing 60 kcal% from fat (beef-tallow)
(High- fat diet (HFD), (4031.45, AB-diets, Woerder, The Netherlands) till the end of the
experiment. The composition of the diets used in this study is provided in Table S1. After
48 weeks of the experimental diet feeding, mice were fasted for 5 hours and sacrificed
by Isofluorane/CO
2
 and organs were isolated and weighed. Kidneys (left) were fixed and
embedded in paraffin; and kidneys (right) were snap frozen in liquid N
2
 and stored at
“80°C until further use.
Plasma lipid analysis
Total plasma cholesterol,Tri-glycerides (catalogue no. 11877771, 11489232, respectively)
(Roche Diagnostics, Almere, The Netherlands), free cholesterol (catalogue no.
113609910930; DiaSys, Holzheim, Germany) and cholesteryl ester were measured after
4 hours of fasting, using commercially available kits.
Plasma cytokine profiling
Cytokine concentration in the plasma was measured with a mouse cytokine multiplex
bead kit (Invitrogen, Carlsbad, CA) and a Luminex 100 analyzer (Luminex Corporation,
Austin, Texas, USA) according to manufacturer’s instructions. For all measurements
serum samples were frozen and stored at - 80°C and were thawed immediately before the
assay. The limits of detection for each cytokine in this assay are as follows FGF (Fibroblast
Growth Factor) basic= 27,000 pg/ml; IL(Interleukin)-6= 17.300 pg/ml; IL-17= 3,900 pg/
ml; GM-CSF (granulocyte macrophage colony-stimulating factor)= 11,200 pg/ml; IFN
(Interferon)–γ= 7,100 pg/ml and TNF (Tumor Necrosis Factor)-α = 12,700 pg/ml.
Histology and immunohistochemistry
For light microscopy, 3 µm renal paraffin sections were stained with Periodic acid-
Schiff’s (PAS). In short, paraffin sections were deparaffinized and re-hydrated in distilled
water. Sections were placed in 0.5% periodic acid solution for 5 minutes. After rinsing in
distilled water, sections were incubated in Schiff’s reagent (Sigma) for 15 minutes
followed by rinsing in lukewarm water for 5 minutes. Sections were counterstained with
Mayer’s hematoxylin for 1 minute and washed in tap water. Immunohistochemical
staining for macrophageswere performed on acetone-fixed 5 µm cryosections using an
anti-rabbit peroxidase-based Envision®+ system (DakoCytomation, Carpinteria, CA, USA).
Briefly, sections were incubated for 60 min with 5 µg/ml rat-anti-mouse CD68 (clone
FA11, serotech, Puchheim, Germany), followed by a 30 min incubation with 10 µg/ml
unlabeled rabbit-anti-rat secondary antibody (Vector Laboratories, Burlingame, CA, USA).
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After detection of peroxidase activity with 3-amino-9-ethylcarbazole, sections were
counterstained with Mayer’s hematoxylin. Frozen sections were used for oil-red O
staining to evaluate accumulation of neutral lipids in the liver and kidney.
Immunohistochemical staining for α-smooth muscle actin (α-SMA) was performed on
paraffin sections. Deparaffinized and re-hydrated sections were subjected to inactivation
of endogenous peroxidases by incubation with 0.1% H2O2+ 0.3% Normal Horse Serum
in PBS for 5 minutes followed by washing in PBS for 5 minutes. Endogenous biotin and
streptavidin were blocked with Vector blocking kit avidine, streptavidin for 15 minutes
followed by washing with PBS for 5 minutes. Then, sections were incubated with primary
antibody (anti-smooth muscle actin)(DAKO M0851) in M.O.M diluent buffer for one
hour, followed by washing in PBS for 15 minutes. Then, sections were incubated with
biotinylated secondary antibodies for 30 minutes at room temperature followed by
washing in PBS for 10 minutes. Secondary antibody detection was performed using the
Vectastain ABC kit (Vector Laboratories Inc., Burlingame, CA, USA). First, each section
was covered with a 100× dilution of A and B reagent in PBS (1 µl reagent A, 1 µl reagent
B, and 98 µl PBS), followed by washing in PBS for 15 minutes and color was developed
using DAB reagent (Sigma-Aldrich). Sections were counterstained with hematoxylin-
eosine and mounted with Kaiser’s glycerine.
Images were taken with a Leica microscope using QwinV3 software (Qwin V3 software,
Leica Microsystems Imaging Solutions, Ltd., Cambridge, UK) and the extent of macrophage
infiltration in the kidneysand α-SMA expression in the kidney were determined by
morphometry in a blinded manner using aperio imagescope IHC analysis algorithm
(Aperio, Vista).
Kidney function measured by albumin/creatinine ratio
To assess renal function, albumin and creatinine levels were measured in mouse urine
using commercially available kits (Mouse Albumin ELISA Quantitation set (Bethyl
laboratories, Montgomery, Texas, USA) and creatinine companion (Exocell, Philadelphia,
PA) according to the manufacturer’s instructions.
Statistical analysis
Data were analyzed with Graphpad prism (Graphpad software 5.0, San Diego CA, USA)
and statistical analysis of the results was performed by a two-tailed unpaired Student’s
t-test, unless stated otherwise. P<0.05 was considered significant. Results are shown as
means ± SEM, unless stated otherwise.
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Results
Plasma lipids and systemic inflammatory markers
Mice on HFD showed significantly increased plasma total cholesterol, tri-glyceride,free
cholesterol and cholesteryl-ester levels, compared to the age matched control group
(figure 1).
Figure 1. Effects of HFD on plasma lipids in C57bl6 mice. (a) Total cholesterol, (b) Tri-glycerides, (c) Free
cholesterol, (d) Cholesteryl ester. Groups are abbreviated as:  Mice fed control diet (chow, n=8) and
mice fed high-fat diet (HFD, n=8). *** p<0.001, ** p<0.01. Values are the mean± SEM.
Plasma levels of the inflammation markersIL-6, IL-17, GM-CSF, TNF-α, IFN-γ and FGF-
basic levels were measured at the end of the experiment to monitor the overall
inflammatory state induced by the high-fat diet. Mice on a HFD for 48 weeks showed
significantly increased plasma IL-6, IL-17, GM-CSF and FGF basic levels compared to the
age matched control group.  Plasma TNF-α  and IFN-γ levels showed a similar trend but
this did not reach statistical significance compared to chow group (Figure 2).
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Figure2. Effects of HFD on systemic inflammatory markers in C57bl6 mice. (a) IL-6, (b) IL-17, (c)GM-CSF
(Granulocyte macrophage colony stimulating factor), (d) TNF-α, (e) IFN-γ and (f) FGF (Fibroblast growth
factor)-basic. Groups are abbreviated as:  Mice fed control diet (chow, n=8) and mice fed high-fat diet
(HFD, n=8). ** p<0.01, * p<0.05. Values are the mean± SEM.
High-fat diet increased renal inflammation and renal dysfunction
At sacrifice, weights of the kidneys were significantly heavier in the HFD group compared
to the chow group (Figure 3A). In mice fed a HFD, urinary albumin/creatinine levels were
significantly increased at the end of the experimental period when compared to the age-
matched control group, (494± 169 µg/mg in HFD vs. 340± 166 µg/mg in LFD, p=0.02)
(Figure 3B).
Figure 3. Effects of HFD on Kidney weight and kidney function in C57bl6 mice. (a) Weight of the kidneys
and (b) Albumin: creatinine ratios. Groups are abbreviated as: Mice fed control diet (chow, n=8) and
mice fed high-fat diet (HFD, n=8). (Performed one-tailed student’s t-test for albumin/creatinine ratios)**
p<0.01, * p<0.05. Values are the mean± SEM.
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Light microscopic analysis revealed that chow fed animals had developed mesangial
expansion and glomerulosclerosis; this is consistent with previous reports by Schmitt
et al., [19]. However, compared to age matched controls, mice on a HFD had developed
severe renal abnormalities. These abnormalities included mesangial area expansion,
acellular PAS positive area, tubular dilatation, loss of tubular structure, loss of
glomeruli,fibrous tissue formation, glomerulosclerosis, thickening of Bowman’s capsule
and basement membrane,protein cast formation and accumulation of lipid droplets in
both tubuli and glomeruli (Figure 4).
Figure 4. Effects of HFD on renal structural changes in C57bl6 mice. Mesangial area expansion,
glomerulosclerosis, fragmentation of glomerulus, thickening of bowman’s capsule, acellular PAS
positive area, loss of glomerulus, tubular dilatation, loss of tubular structure, thickening of basement
membrane, fibrous tissue formation, protein cast formation. Groups are abbreviated as:  Mice fed
control diet (chow, n=8) and mice fed high-fat diet (HFD, n=8).
Oil Red O staining of renal sections demonstrated abundant positive staining of neutral
lipids in both glomeruli and tubuli in the kidneys of HFD treated mice compared to chow
treated mice   (Figure 5a and 5d).Increased infiltration of FA11+ macrophages was
detected in the kidneys of HFD treated mice compared to age-matched controls (Figure
5b and 5e). Immunohistochemical analysis of α-SMA revealed increased expression of
extracellular matrix protein both in glomeruli and tubuli in the HFD group compared to
age-matched control group (Figure 5c and 5f).
Chapter 6
117
Figure 5. Effects of HFD on Renal lipid accumulation, macrophage infiltration and
extracellular matrix protein expression in C57bl6 mice. (a) ORO staining, (b)
Immunohistochemistry of macrophage infiltration, (c) α-SMA staining, (d)quantification
of renal ORO staining (e) quantification of macrophage infiltrates in kidney and (f)
quantification of α-SMA staining in kidney. Groups are abbreviated as:  Mice fed control
diet (chow, n=8) and mice fed high-fat diet (HFD, n=8). *** p<0.001, * p<0.05. Values are
the mean± SEM.
Discussion
In the present pilot study we investigated whether a high-fat diet feeding aggravatedrenal
injury in aged C57BL/6 mice. The results show thatlong term HFD feeding inC57BL/6 mice,
aggravated systemic alterations including, hypercholesterolemia, hypertriglyceridemia,
and elevated systemic inflammatory markers. Furthermore, when compared to mice
that had been fed normal chow HFD fed mice had increased urinary albumin/creatinine
ratiosindicative of renal function impairment. Morphologically, mice on a HFD for 48
weeks showed significant renal histopathological and structural changes. These changes
include, lipid accumulation, accumulation of macrophages, structural changes in
glomeruli and interstitiumand accumulation of extra-cellular matrix proteins. These
changes were associated with renal fibrosis and renal functionimpairment.
Metabolic stress induced renal injuries have been widely investigated by using
genetically modified animal models such as, db/db mice, ob/ob mice, and obese Zucker
rats [17, 18]. However, due to lack of a specific gene they may show abnormal metabolic
amendments [16]. In contrast, feeding mice with the HFD is a very simple method of
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examining physiological and metabolic alterations accompanying the development of
metabolic stress induced renal injury. In this way renal alterations can develop without
any drug intervention or gene depletion, resembling the human situation.
Tao et al., observed the first evidence of mesangial expansion at 12 months of age in
C57BL/6j miceand then there was a further age-related increase in intensity of PAS staining
[8]. Also, Schmitt et al., reported that C57BL/6j mice from Charles River had developed
nodular sclerosis of the glomeruli at 20 months of age [19] and we observed similar
structural changes in mice fed chow diet for 48 weeks. Mice on HFD showed a further
increase in PAS staining and detailedmorphological analysis revealed that these mice
displayed many additional structural alterations including dilatation of tubules and
thickening of tubular membranes, mesangial expansion, thickening of bowmans capsule,
loss of glomeruli, fragmentation and lobular formation of glomeruli, proliferation of
extracellular matrix protein andglomerulosclerosis.
Systemic lipid overload resulting in systemic inflammation has been proposed as the
underlying mechanism for obesity-related disorders [13]. In the present study, we
observed several metabolism-associated systemic alterations in mice on a HFD upon
aging. Along with systemic lipid alterations, an imbalance in renal lipid metabolism
plays an important role in renal inflammation and injury [8]. By ORO staining, mild
depositions of neutral lipids were observed in the kidneys of chow fed mice in particular
in glomeruli, which is in line with previous reports [8]. Mice fed HFD showed increased
tubular interstitial ORO staining along with increased glomerular staining. Renal lipid
accumulation and macrophage infiltration are associated with renal injury resulting in
glomerulosclerosis, interstitial fibrosis, and albuminuria and may be caused by an
imbalance between renal lipogenesis and lipolysis upon HFD feeding [10][14]. Here, we
observed macrophage infiltration and extracellular matrix protein deposition in the
kidneys of mice on HFD upon aging. Previous studies have been reported renal
macrophage infiltration and extracellular matrix protein accumulation upon high-fat
diet feeding [14][15].
In conclusion, we showed that long term HFD feeding of C57Bl6j mice instigated systemic
inflammation, elevated circulating triglycerides and changes in comparison to mice fed
a chow diet.
Further studies would be of interest to perform to investigate the effects of different
types of fats such as, saturated, mono or poly unsaturated fatty acids onrenal injuries
for a longer period of time to resemble human situation. We propose that research
employing agedC57BL/6j micecan be helpful in elucidating and developing novel dietary
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Summary and General Discussion
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Obesity is reaching epidemic proportions worldwide. The development of obesity is
closely associated with multiple metabolic disorders such as insulin resistance,
hyperlipidemia and hypertension, which increase the risk for developing type 2 diabetes
mellitus (T2DM) and cardiovascular diseases (CVD) (Grundy SM, 2004). The prevalence
of these cardio-metabolic diseases is increasing mainly because of rapid changes in
dietary intake patterns and unfavorable lifestyles (Eckel RH, 2012). The current
therapeutic strategies to treat the complications ensuing from these disorders are not
adequate. In order to prevent the occurrence of health problems associated with these
disorders, it is of utmost importance to understand the pathological mechanisms taking
place in the tissues and cells that engage in the development and progression of the
disease. The clarification of these mechanisms will provide insight that can be used as
a basis for the design and development of improved therapeutic strategies to reduce the
risk and burden of these cardio-metabolic diseases.
The main aim of this thesis was to investigate whether (dietary) strategies can be
developed and implemented to prevent or reduce the occurrence of high-fat and/or high
cholesterol-induced cardio-metabolic complications. As described in Chapter 1, the
treatment strategies studied in this thesis can be divided into three main categories: life
style changes (calorie restriction), dietary intake changes (diet enriched with
polyphenols) and, lastly, pharmacological interventions.
With respect to life style changes, one of the dietary strategies that has been proposed
is caloric restriction, which aims to reduce overall caloric intake and was indeed found
to reduce the risk for developing CVD (Fontana L, 2008). It is important to bear in mind
that despite the beneficial health effects of caloric restriction, most individuals find it
difficult to comply with such strict regimens. Therefore, alternative forms of dietary
interventions are desired that are easier to adopt to but have similar beneficial health
effects. Studies by Varady et al., suggested that an alternate-day fasting regimen might
indeed be an alternative to caloric restriction and assist obese individuals to lose
weight and decrease the risk for CVD (Varady KA et al., 2009). Based on this suggestion
we hypothesizedin Chapters 2 and 3, that an alternating diet strategy, i.e., alternating
low-fat / low-cholesterol (4 days) and high-fat / high-cholesterol (3 days), instead of
continuous consumption of a high-fat or high-cholesterol diet would be beneficial in
terms of reducing CVD risk factors (Chapter 2). In a CVD prone mouse model, the ApoE*3
Leiden (E3L), we found that the alternating high-cholesterol dietary regimen attenuated
the development of atherosclerosis and diminished the occurrence of hepatic, vascular
and renal endothelial activation and inflammation. Moreover, in Chapter 3, we showed
that the beneficial effects of an alternating feeding regimen could be extended to diets
high in fat content.  Alternating high-fat feeding in E3L mouse model reduced gain in
body weight, insulin resistance, hepatic and renal inflammation and renal dysfunction.
Based on these results, we propose that the principle of the alternating dietary regimens
could be an attractive strategy to protect against the adverse effects of an unhealthy
Chapter 7
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diet typical for the nutritional milieu, which modern humans have created for themselves
and as such, could contribute to improved metabolic health.
From epidemiological studies it is evident that regular intake of plant-derived products
is inversely correlated with cardiovascular diseases. In particular, the intake of
polyphenols, a subgroup of flavonoids commonly known as antioxidants, has been
linked to improved cardiovascular health. Cocoa and chocolate are a rich source of
polyphenols, which are known to exhibit protective cardiovascular effects by improving
endothelial function (Corti R, 2009; Fernandez-Murga L, 2011 ). In Chapter 4, we
investigated whether dietary supplementation of chocolate beneficially affects metabolic
risk factors and disease endpoints in a setting of diet-induced atherosclerosis. Bearing
in mind that not every chocolate is formulated similarly and that especially cocoa
content varies greatly between chocolates, we used two different chocolate preparations
with a similar cocoa mass that differed in their composition of polyphenols and fiber
content. One chocolate preparation contained high amounts of polyphenols and was
low in fiber content (CCA). In comparison, the second preparation contained less
polyphenols while it was higher in fiber content (CCB). Dietary supplementationof
chocolate in the E3L mouse model did not reduce the adverse effects of an atherogenic
high-cholesterol diet. In fact, the two chocolate preparations unfavorably affected
cardiovascular and metabolic health albeit to a different extent. From this study, we
suggest that discrepancies reported on the effects of chocolate on cardio-metabolic
health may at least be partly due to differences in chocolate composition and quantity
consumed.
As demonstrated in chapters 2 and 3, it is evident that metabolic stress induced by diets
high in fat or cholesterol also induces a systemic inflammatory response that can
adversely affect organ function. In Chapter 5, we investigated whether metabolic stress-
induced inflammation caused by a high-fat diet can be attenuated by anti-inflammatory
drug interventions (statins and TZDs (Thiazolidinedione) (PPAR gamma activators), and
whether this attenuation, in turn, would improve cardiovascular health. Statins function
by interfering with the synthesis of cholesterol through inhibition of the rate-limiting
enzyme HMG-CoA reductase, which plays a key role in cholesterol synthesis.
Thiazolidinediones act as a ligand for a nuclear receptor, the peroxisomal proliferator-
activated receptor gamma (PPAR-γ) and enhance the action of insulin (Lehmann, 1995).
Both statins and thiazolidinediones exert pleiotropic anti-inflammatory effects apart
from their lipid lowering and insulin sensitizing effects (Gierman LM, 2012; Szalai AJ,
2002).
In these studies, we used the hu-CRPtg (Human C-reactive protein transgenic) mouse
model to monitor the overall inflammatory state during a high-fat diet challenge. In
mice, CRP is synthesized in only trace amounts and it is not an acute phase reactant.
Consequently, hu-CRPtg mice have been developed which serve as a unique model for
studying the biological effects of CRP in vivo. Interventions with rosuvastatin and
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rosiglitazone were applied to investigate whether suppression of metabolic stress-
induced inflammation reduces the development of insulin resistance (IR) and improved
renal function under conditions of obesity. Rosiglitazone treatment protected mice from
developing IR, reduced systemic inflammatory markers including huCRP and sE-selectin
and protected mice from the development of albuminuria, whereas rosuvastatin
treatment failed to do so.
Finally, in Chapter 6, we performed a pilot study to investigate whether high-fat diet
stress further intensifies cardiovascular risk factors and especially renal injury in
mice upon ageing. We showed that high-fat diet feeding upon ageing enhanced systemic
inflammation, elevated circulating triglycerides and cholesterol levels, and aggravated
renal structural and functional changes in comparison to mice fed a chow diet.
Effects of different dietary strategies on obesity-related complications
Obesity is considered a major public health problem because it is associated with
many cardio-metabolic disorders including insulin resistance, diabetes, atherosclerosis,
hypertension, chronic kidney disease and increased cardiovascular morbidity and
mortality (Reaven G, 2004). From the large body of literature it is evident that
consumption of a high-fat diet increases the probability of obesity while this probability
is low in individuals consuming low-fat diets (Hill JO, 2000). In Chapter 3, we showed
that the likelihood of becoming obese increases with increasing consumption of high-
fat diets and decreases with low-fat diet consumption.Decreased dietary fat
consumption consistently leads to a proportional reduction in body weight gain (Bray
GA, 1998). The potential effect of a low-fat diet may reside as much in improving weight
loss as in preventing weight gain (Hill JO, 2000). As discussed in Chapter 3, reduction in
body weight caused by a high-fat diet might likely be achieved by giving the body time to
recover from the metabolic overload caused by continuous high-fat diet consumption
by introducing intermittent periods of low-fat diet in between high-fat diet periods
(alternating high-fat diet strategy). These results provide further support for the concept
that alternating dietary regimens protect against the adverse effects of an unhealthy
diet. Additional studies are needed to examine whether the principle of alternating
dietary regimens can also be implemented to improve existing metabolic diseases. For
example, it would be interesting to investigate whether an alternating diet can attenuate
or reverse the negative effects caused by long-term high-fat diet consumption. Finally,
the ultimate goal is to examine whether the concept of alternating dietary regimens can
be translated to humans.
Maintenance of a healthy amount of adipose tissue is essential because excess adipose
tissue can cause serious health problems by dysregulating the release of adipokines
(cytokines released by adipose tissue), which can lead to vascular disturbances and
inflammation (de Oliveira Leal V, 2013; Gray SL, 2007). It has been hypothesized that the
state of chronic low-grade inflammation associated with excess adipose tissue may
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explain the development of obesity-related pathologies. Increased leptin production by
excess adipose tissue facilitates the secretion of proinflammatory cytokines such as
TNF-∝, IL-1 and IL-6 (Iikuni N, 2008). In Chapter 6, we observed that high-fat diet feeding
upon aging leads to an increase in the level of inflammatory markers such as IL-6, GM-
CSF and FGF-2 (basic Fibroblast Growth factor) in the plasma. Thus, high-fat diet
consumption further adds to aging associated complications.
In Chapter 3, we showed that high-fat feeding increased plasma leptin levels whereas
an alternating high-fat dietary regimen substantially decreased plasma leptin levels
when compared to continuous high-fat feeding, providing support for the beneficial
effects of alternating dietary regimen. Next to an increase in leptin expression, an enlarged
adipose compartment also leads to increased production of the acute-phase protein
serum amyloid A (SAA). SAA is also produced by activated monocytes and macrophages
in the liver (Cantarini L, 2012). Interestingly, it has been reported that SAA could be a
possible link between type 2 diabetes, atherosclerosis and inflammation and is
potentially useful for predicting CVD risk (B.D. Johnson, 2004). In Chapter 2, we showed
that high-cholesterol feeding increased SAA plasma levels whereas an alternating high-
cholesterol dietary regimen significantly reduced these levels providing further support
for the beneficial effects of the alternating diet principle.
Adiponectin, in contrast to most other adipokines, possesses anti-inflammatory
properties (Ouchi N, 2007). Plasma levels of adiponectin are reduced in obesity and its
related cardio-metabolic disorders, including type 2 diabetes, endothelial dysfunction,
hypertension, atherosclerosis and myocardial infarction (Zhu W, 2008; Tan KC, 2004;
Chow WS, 2007). Hypoadiponectinemia is considered an independent risk factor for
these diseases (Xu A, 2012).It is well documented now that adiponectin is a
cardioprotective adipokine, due to its anti-inflammatory and insulin sensitizing
properties (Ouchi N, 2007; Pajvani UB, 2003). In patients with end stage renal disease,
an inverse relationship between adiponectin levels and CVD has been reported (Zoccali
C, 2002), and there is increasing evidence that adiponectin plays a protective role in
T2DM and insulin resistance (IR). In Chapter 5, we showed that mice receiving
rosiglitazone treatment had reduced high-fat diet-induced insulin levels, systemic
inflammation, and were protected from the development of albuminuria. Although
multiple mechanisms may be involved, rosiglitazone treatment was associated with a
marked increase in circulating adiponectin levels suggesting that the anti-inflammatory
properties of this adipokine may have contributed to these effects. In contrast, in mice
treated with rosuvastatin, adiponectin levels were unchanged and treatment did not
improve IR and renal function.
Effects of different dietary strategies on adipose tissue morphology
Continuous nutritional surplus increases serum levels of fatty acids and lipids that are
initially stored in existing fat cells in adipose tissues. When these fat cells reach a
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threshold of storage capacity they promote the proliferation and recruitment of
preadipocytes (adipogenesis) (B.G. Marques, 1998). When these fat cells are inept to do
so (i.e. proliferating and recruiting preadipocytes), a condition called adipose cell
enlargement occurs (adipocyte hypertrophy) i.e. loss of functional adipocytes, which
indicates impairment in preadipocyte differentiation (Heilbronn L, 2004; Lionetti L, 2009).
Previous studies have shown that adiponectin, an adipokine released by the adipocytes,
provides a signal for proliferation and recruitment of preadipocytes instead of
hypertrophy of existing adipocytes(Fu Y, 2005; Kim JY, 2007). As a result, excess lipids
are effectively distributed in adipose tissue. This redistribution coupled to increased
adipogenesis results in improvements in all the metabolic parameters including insulin
sensitivity (Kim JY, 2007). Experiments in animal models also support the principle of
adipogenesis. For example, overexpressing adiponectin in adipose tissue in mice leads
to a marked hypercellular obesity without adipose cell enlargement and these animals
are at least as insulin sensitive as lean wild type mice (Kim JY, 2007). Low levels of
adiponectin have been associated with adipocyte hypertrophic obesity and insulin
resistance (Fu Y, 2005). In Chapter 3, we showed that adipose tissue of mice fed an
alternating high-fat diet displayed reduced adipocyte cell size when compared to mice
fed a continuous high-fat diet. Also, in Chapter 5, we observed that in spite of having
increased body weight, animals treated with rosiglitazone had increased plasma
adiponectin levels and reduced plasma insulin levels. We propose that these effects
could be due to differentiation of preadipocytes but further experiments are necessary
to substantiate this suggestion.
Effects of dietary strategies on the development of T2DM and associated fatty
liver disease
Lipid accumulation in non-adipose tissue, also known as ectopic lipid accumulation,
has been suggested as a major link between obesity and T2DM through induction of
insulin resistance (Qatanani M, 2007). Increased fatty acid uptake is the major reason
for accumulation of lipids in these ectopic sites (Shulman GI, 2000). In the absence of
functional adipocytes due to overfeeding of a high-fat diet, increased accumulation of
hepatic lipids occurs, which is considered a major cause of oxidative stress and
inflammation. This causes the liver to gain in size and weight and induces hepatic
steatosis (Bechmann LP, 2012). Hepatic steatosis is commonly associated with obesity
in which lipids accumulate in the hepatocytes beyond their normal lipid storing
capacities, thereby negatively affecting liver function (Hamaguchi M, 2012). In Chapter
4, we showed that a high cholesterol diet with or without supplementation with chocolate
increased liver weights along with the liver damaging marker alanine aminotransferase
(ALAT). We thus propose that chocolate supplementation along with cholesterol treatment
induced liver lipid accumulation and liver damage.
Since circulating lipid levels are commonly elevated during chronic overfeeding, the fat
storage capacity of the hepatocytes in the form of lipid droplets surpasses the limit
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which in turn affects insulin signaling and results in severe insulin resistance and
diabetes (P. Tessari, 2009; Mollica MP, 2011). In Chapter 3, we showed that the alternating
high-fat diet, instead of a continuous high-fat diet, reduced lipid accumulation in the
liver, reduced fasting plasma glucose and insulin levels, and improved insulin sensitivity.
Also, alternating high-fat diet fed mice displayed diminished liver inflammation as
evidenced by significantly reduced mRNA expression levels of various inflammatory
markers. Similarly, in Chapter 2, we showed that the alternating-cholesterol dietary
regimen reduced hepatic cholesterol accumulation and liver inflammation as evidenced
by a reduction in hepatic NF-kB activity. We thus propose that both alternating dietary
regimens are beneficial in terms of reducing hepatic lipid accumulation and dampening
inflammation.
Effects of dietary strategies on the development of atherosclerosis
Atherosclerosis is a multifactorial large vessel disease with involvement of lipids and
immune cells. There is plenty of evidence suggesting that hypercholesterolemia and
hyper-triglyceridemia are independent risk factors for the development and progression
of atherosclerosis. When plasma lipid concentrations become elevated due to continuous
consumption of a high-fat diet, the vessel wall eventually becomes lipid-inflated because
it is unable to clear the large amounts of endocytosed lipids (Hajjar DP, 1997). Similarly,
in Chapters 2 & 4, and in Chapters 3 & 6, we demonstrated that plasma cholesterol levels
were significantly increased upon high-fat and high-cholesterol diet feeding respectively.
However, in Chapters 2 and 3, we have shown that alternating dietary regimens
successfully reduced plasma cholesterol levels.As shown in Chapter 2, an alternating
cholesterol dietary regimen significantly reduced atherosclerotic plaque formation and
reduced plasma cholesterol levels. Thus, both alternating dietary regimens are beneficial
in reducing plasma cholesterol levels.
In Chapter 4, mice fed a high cholesterol diet supplemented with chocolate were found
to have elevated plasma cholesterol levels when compared to mice fed high cholesterol
alone and had increased atherosclerotic plaque formation. The results of these studies
thus do not support a beneficial effect of dietary chocolate supplementation on cardio-
metabolic health. These results also indicated that the composition and amount of
chocolate consumed are critical parameters when studying the effects of chocolate
supplementation on CVD outcome. Future studies with varying dietary chocolate doses
and composition will be necessary to determine whether dietary chocolate
supplementation is beneficial or not in improving cardiovascular health.
A significant amount of research states that oxidation of low density lipoproteins (oxLDLs)
contributes to the development of atherosclerosis (Stocker R, 2004; Shi W, 2000). In
addition, antioxidants that inhibit LDL oxidation reduce the development of
atherosclerotic lesions in animal models (Stocker R, 2004; Chisolm GM, 1991).
Chemotactic factors and adhesion molecules in oxidative stress conditions mediate the
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entry of leukocytes into the arterial wall  (Li D, 2000). OxLDLs stimulate overlying
endothelial cells to produce a number of growth factors and adhesion molecules that
contribute to atherosclerosis, such as monocyte chemotactic protein-1 (MCP-1),
macrophage-colony–stimulating factor (M-CSF), vascular cell adhesion molecule-1
(VCAM-1), and endothelial selectin-1 (E-selectin-1) (Rajavashisth TB, 1990; Liao F, 1991;
Li D, 2000). In chapter 6 we showed that plasma M-CSF levels were significantly increased
upon high-fat diet treatment. In Chapter 2, we showed thatthe alternating-cholesterol
dietary regimen significantly diminished circulating levels of sVCAM-1, sE-selectin and
vWF. Also, in Chapter 5, rosiglitazone treatment successfully diminished plasma levels
of sE-selectin and of the acute phase reactant CRP. We thus propose that rosiglitazone
treatment showed anti-inflammatory properties in the huCRP mouse model.
NF-kB plays a major role in atherosclerotic plaque formation, especially by regulating
the expression of many genes involved in the initiation and progression of atherosclerotic
lesion formation such as cytokines (e.g., TNFα, IL-1, IL-6), adhesion molecules (VCAM-1,
ICAM-1, P- and E-selectin), and chemokines (e.g., MCP-1) (de Winther et al., 2005). In
chapter 2, we investigated NF-kB activity in the liver and found that the alternating
cholesterol dietary regimen considerably diminished NF-kB activity along with a
reduction in systemic inflammatory markers, which was associated with reduced
atherosclerotic plaque formation. Thus, we conclude that the alternating high-cholesterol
dietary regimen is beneficial in reducing atherosclerotic plaque formation.
Effects of various dietary strategies on the kidney
The development of both atherosclerosis and T2DM are well known to be associated
with structural and functional changes in the kidney, characterized by renal inflammation,
glomerulosclerosis, a decline in glomerular filtration rate, and the occurrence of
albuminuria (Chade AR, 2005; Gao Q, 2010; Navarro JF, 2005). The development of
albuminuria not only signals renal disease but also increases the risk of CVD (Gaede P,
2008). Similar to the liver, intra-renal accumulation of lipids has been proposed to play
a major role in causing diabetes-associated nephropathy. For example, intrarenal lipid
accumulation induces glomerular expression of MCP-1 and VCAM-1 (Hattori M, 1999;
Kodama N, 1999), which contribute to glomerular macrophage accumulation (Wen M,
2002), eventually leading to albuminuria (Jiang T, 2005). Treatments that reduce
albuminuria are renoprotective and consequently improve CVD outcomes (Gaede P,
2008; Gerstein HC, 1999). In Chapter 5, we have shown that kidneys of mice on a high-fat
diet showed mesangial expansion, glomerulosclerosis, lipid accumulation and
albuminuria. In this study, rosiglitazone treatment markedly diminished these diet-
induced renal effects and improved kidney function as evidenced by reduced urinary
albumin/creatinine ratios. Moreover, rosiglitazone treatment strikingly reduced sE-
selectin levels and, similarly, reduced renal E-selectin mRNA expression levels. Thus,




Similarly, in Chapter 3, mice subjected to the alternating high-fat dietary regimen
displayed decreased levels of albuminuria and reduced expression levels of the
endothelial dysfunction marker endothelin-1, the inflammatory markers MCP-1 and
CD68, and the fibrosis markers desmin, when compared to high-fat diet-fed mice. Thus,
based on the results from both the alternating-high fat and alternating cholesterol
studies, we propose that an alternating dietary regimen is beneficial in terms of reducing
renal inflammation and improving renal function.
Overall, the studies described in this thesis indicate how dietary stress contributes to
the development of various cardio-metabolic diseases related to CVD. Largely, excess
plasma lipids and inflammation play a major role in the development and progression
of disease. This whole process is schematically depicted in figure 1. Chronic consumption
of a high-fat diet leads to the accumulation of lipids in adipocytes and consequently
induces hypertrophy of the adipocytes. Hypertrophic adipocytes produce pro-
inflammatory cytokines, including leptin, TNF-α, IL-6, and MCP-1. These pro-inflammatory
cytokines activate the endothelium, which leads to increased expression of adhesion
molecules such as VCAM-1, ICAM-1, E-selectin and P-selectin. Activated endothelium is
susceptible for the attachment of circulating monocytes, which are recruited by
chemokines such as MCP-1. Monocytes transmigrate to the inner wall of the endothelium
and become mature macrophages. This maturation further increases the expression of
pro-inflammatory cytokines leading to the recruitment of additional macrophages, which
causes atherosclerotic plaque formation. Additionally, these changes that occur in
vascular endothelium, together with the development of insulin resistance, adversely
affect other organs in the body, such as the kidneys, as well (Figure 1).
130
Figure 1. Potential mechanisms of diet induced CVD-associated complications. The accumulation of
lipids in adipose tissue and the expansion of the fat mass lead to the initiation of an inflammatory
process. This may be initiated through the production of proinflammatory cytokines and chemokines
by the adipocytes, including TNF-α, IL-6, leptin, and MCP-1. Endothelial cells respond through the
increased expression of adhesion molecules, which along with the chemokines serve to recruit immune
cells including monocyte-derived macrophages to the adipose tissue. This will create an inflammatory
milieu that promotes systemic inflammation. Similarly, proinflammatory and proatherogenic
mediators enter the circulation that promote insulin resistance, increase the risk for developing
atherosclerosis and adversely affect other organs in the body as well. Adapted and edited from Shoelson
SE et al., Gastroenterology, 2007.
In conclusion, the studies described in this thesis have emphasized the association of
hyperlipidemia and inflammation with increased risk for CVD and suggest the use of
anti-inflammatory treatment strategies to reduce the risk for future CVD events. In this
thesis we have introduced strategies that can aid in attenuating the adverse effects of
dietary stress via implementation of alternating dietary regimens and drug interventions
that improve cardio-metabolic health. Future studies are necessary to elucidate the
exact underlying mechanisms responsible for these beneficial effects. It will also be of
interest to investigate whether implementation of such strategies can improve existing
metabolic disease. Finally, controlled studies in humans are needed to determine
whether the beneficial effects of life style changes, as proposed in this thesis, are valid
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NederlandseSamenvatting
In dit proefschriftheeft het ontwikkelen en implementeren van (dieet) strategieën die het
ontstaan van hoog-vet of hoog-cholesterol geïnduceerde cardio-metabole complicaties
kunnen voorkomen of reduceren centraal gestaan.  Zoals beschreven in Hoofdstuk 1,
kunnen deze strategieën onderverdeeld worden in drie categorieën te weten;
veranderingen in levensstijl (calorie restrictie), veranderingen in samenstelling van het
dieet (bijvoorbeeld verrijking van het dieet met polyfenolen) en ten slotte farmacologische
interventies.
Het implementeren van een voedingsinterventie waarbij het metabole systeem minder
belast wordt kan de metabole stress die veroorzaakt wordt door continue consumptie
van een dieet hoog in vet of cholesterol verminderen. Calorie restrictie is het reduceren
van de dagelijkse calorische inname tot een bepaald niveau en  is effectief gebleken in
het verlagen van cardiovasculaire risicofactoren. Echter, ondanks het positieve effect
van calorie restrictie op de gezondheid, wordt het beschouwd als een strategie die voor
veel mensen lastig is om blijvend na te leven. Om die reden is er behoefte aan alternatieve
voedings-interventies met vergelijkbare positieve effecten op de gezondheid maar welke
gemakkelijker vol te houden zijn. Recente bevindingen hebben aangetoond dat een dieet
waarbij alternerend een dag gevast wordt een haalbare strategie zou kunnen zijn in het
helpen van mensen met obesitas bij het afvallen en daarmee hun risico op
cardiovasculaire ziekten (CVZ) te verminderen. Op basis van deze bevindingen is in de
Hoofstukken 2 & 3 in een muismodel de hypothese getest  of een alternerend dieet
bestaande uit 4 dagen laag vet of laag cholesterol en 3 dagen hoog vet of hoog cholesterol
bevorderlijk zou kunnen werken op het verlagen van cardiovasculaire risicofactoren
ten opzichte van een continue consumptie van een hoog vet of hoog cholesterol dieet.
Beide alternerende voedingsstrategieën bleken bevorderlijk te zijn in het reduceren van
metabole en functionele risicofactoren voor CVZ. Deze resultaten ondersteunen het
concept van een alternerend voedingspatroon als strategie in het beschermen tegen de
negatieve effecten van een ongezond dieet. Additionele studies zijn echter nodig om te
bepalen of het principe van alternerende voedingsregimes ook toegepast kan worden in
het verbeteren van bestaande metabole aandoeningen. Daarnaast zou het interessant
zijn om te onderzoeken of een alternerend dieet de negatieve effecten veroorzaakt door
consumptie van een hoog vet dieet over een lange termijn zou kunnen afzwakken of zelfs
teniet zou kunnen doen. Ten slotte is het van groot belang om te onderzoeken of het
concept van alternerende voedingsregimes naar de menselijke situatie te vertalen is.
Epidemiologische studies hebben aangetoond dat  de inname van plantaardige producten
op regelmatige basis een inverse correlatie vertoont met CVZ. Met name polyfenolen,
een subgroep van flavonoïden beter bekend als antioxidanten, worden met regelmaat in
verband gebracht met het verbeteren van de cardiovasculaire gezondheid. Cacao en
chocolade zijn rijk aan polyfenolen die bewezen beschermende effecten hebben op het
cardiovasculaire systeem door het verbeteren van de endotheel functie. Het veranderen
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van één of meerdere voedingscomponenten of de inname van bepaalde nutriënten kan
dus een merkbaar verschil maken in het risico op CVZ. In Hoofdstuk 4 hebben we in
muizen onderzocht of het verrijken van het dieet met chocolade een gunstig effect kan
hebben op metabole risicofactoren en de ontwikkeling van cardiovasculaire
complicaties in een model van dieet-geïnduceerde atherosclerose. In gedachte houdend
dat niet elke chocolade eenzelfde samenstelling heeft en dat met name de samenstelling
van cacao sterk kan verschillen tussen verschillende types chocolade, is gebruik gemaakt
van twee verschillende chocolade producten. Beide producten hadden dezelfde cacao
massa maar verschilden in polyfenol en vezel samenstelling.  Het ene chocoladeproduct
bevatte een grote hoeveelheid polyfenolen maar was laag in vezels terwijl het andere
product minder polyfenolen bevatte maar juist een hogere hoeveelheid vezels had (CCB).
Deze studie liet zien dat het verrijken van het dieet met chocolade de schadelijke effecten
veroorzaakt door een atherogeen hoog-cholesterol dieet niet kon verminderen en in
sommige gevallen zelfs verslechterde. De resultaten uit deze studies onderschrijven dus
niet het gunstige effect van voedingsverrijking middels chocolade met betrekking tot de
cardiovasculaire gezondheid. Verder laat deze studie zien dat de samenstelling en
hoeveelheid van de geconsumeerde chocolade belangrijke prameters zijn om in acht te
nemen bij het onderzoeken van de effecten van chocolade op CVZ. Toekomstige studies
met verschillende doseringen en samenstellingen van chocolade zullen noodzakelijk
zijn om te bepalen of de toevoeging van chocolade aan het dieet een gunstig effect heeft
op de cardiovasculaire gezondheid.
Zoals aangetoond in Hoofdstuk 2 en 3 is de metabole stress veroorzaakt door diëten
hoog in vet en cholesterol ook geassocieerd met de inductie van een sytemische
inflammatoire respons welke de functie van verschillende organen negatief kan
beïnvloeden. In Hoofdstuk 5 is onderzocht of de door metabole stress geïnduceerde
ontsteking, als gevolg van een hoog vet dieet, afgezwakt dan wel voorkomen kan worden
door interventies met anti-inflammatoire medicamenten (statines en thiazolidinediones
(TZD)) en of hiermee de cardiovasculaire gezondheid verbeterd kan worden. In deze
studies is gebruik gemaakt van het humane C reactieve proteïne (CRP) transgene
muismodel om de inflammatoire respons na blootstelling aan een hoog vet dieet te
kunnen vervolgen. Humane CRP transgene muizen zijn ontwikkeld als uniek model om de
biologische effecten van CRP in vivo te kunnen bestuderen. De acute fase respons van de
hu-CRPtg muizen werd getest na toediening van endotoxine en de expressie van CRP was,
net als in de humane situatie, verhoogd. Interventies met rosuvastatine (statine) en
rosiglitazone (TZD) werden toegepast om te onderzoeken of ontsteking als gevolg van
metabole stress de ontwikkeling van insuline resistentie (IR) kan onderdrukken en om te
onderzoeken of de nierfunctie ondanks blootstelling aan obese omstandigheden
verbeterde. Interventie met rosuvastatine leidde niet tot een verbetering van IR of
nierfunctie , wat mogelijk te wijten is aan het ontbreken van een aanhoudend anti-
inflammatoir effect van rosuvastatine in het gebruikte model. De interventie met
rosiglitazone daarentegen reduceerde hoog-vet geïnduceerde insuline waarden,
onderdrukte de systemische inflammatoire respons en beschermde de muizen tegen het
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ontwikkelen van nierfunctie stoornissen (albuminurie). Hoewel verschillende
mechanismen hier mogelijk bij betrokken zijn, werd in de rosiglitazone groep een
duidelijke verhoging van de adiponectine waarden gezien. Dit doet vermoeden dat de
anti-inflammatoire eigenschappen van deze adipokine mogelijk hebben bijgedragen
aan de geobserveerde positieve effecten. Patiënten met type 2 diabetes en IR met
albuminurie hebben een verhoogd risico om CVZ te ontwikkelen indien zij niet behandeld
worden. Onze bevindingen in het muis model duiden er op dat medicijnen die de dieet
geinduceerde systemische ontstekingsrespons onderdrukken de cardiovasculaire
gezondheid kunnen verbeteren.
Ten slotte hebben we in Hoofdstuk 6 een pilot studie uitgevoerd om te onderzoeken of
veroudering de schadelijk effecten van een hoog-vet dieet met betrekking tot
cardiovasculaire risico factoren en het ontwikkelen van nierschade,  verergert. Deze
studie liet zien dat op de lange termijn een hoog-vet dieet leidt tot systemische ontsteking,
verhoogde circulerende triglyceriden en cholesterol waarden en dat de nieren van de
hoog-vet muizen structureel en functioneel verslechteren ten opzichte van de muizen op
een normaal dieet. Vervolgstudies zouden zich moeten richten op het effect van langdurige
consumptie van verschillende types vet (verzadigd, enkel of meervoudig onverzadigde
vetzuren) op de ontwikkeling van nierschade om dichter bij de humane situatie te komen.
Onderzoek gebruikmakend van verouderende muizen kan zeer behulpzaam zijn in het
ontdekken en ontwikkelen van nieuwe voedings- of therapeutische strategieën voor
nierziekten gerelateerd aan veroudering.
Samenvattend (Hoofdstuk 7) laten de resultaten beschreven in dit proefschrift de
associatie zien tussen hyperlipidemie en ontsteking, het toenemende risico op CVZ dat
hieraan gepaard gaat en de toepassing van anti-inflammatoire behandelingsstrategieën
(veranderingen in levensstijl en farmacologische interventies) in het reduceren van dit
risico op CVZ. Verder zijn in dit proefschrift alternatieve levensstijl veranderingen
geïntroduceerd die mogelijk kunnen bijdragen aan het voorkomen van dieet geïnduceerde
metabole stress. Door middel van het reduceren van plasma lipiden en
ontstekingsfactoren kunnen veranderingen in levensstijl en/of farmacologische
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